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SUMMARY 
The lungs are perhaps the most ancient route of drug delivery. As early as 1,500 
BCE, the ancient Egyptians inhaled vapors to treat a variety of diseases. 
Unfortunately, the lungs were soon forgotten as a major route of drug delivery, and 
it only in 1950s serious consideration of the lungs was resurrected with the invention 
of the first metered dose inhaler. Today, researchers have made enormous strides in 
the development of precise pulmonary drug delivery technologies, both in terms of 
inhaler design and advances in particle engineering.  
Although dated back of some years, the opportunity to selectively target a drug to 
lungs remains a fascinating option to strongly limit ubiquitous distribution of 
systemically, and often chronically, administered drugs used to treat severe 
pulmonary diseases. Indeed, a new direction in inhalation technology has begun to 
focus on severe and chronic lung diseases such as chronic obstructive pulmonary 
disease (COPD), cystic fibrosis (CF) and lung cancer. The main research focus is to 
combine the advanced, and often “nanotechnology-based”, delivery strategies with 
the pulmonary route of administration. In this scenario, a number of advanced 
devices and drug delivery strategies are under development to increase the amount 
of drug reaching the target and its persistence in situ, to reduce dose frequency and 
time required for administration, as well as to allow combined therapy.  
The use of specially designed formulations may be highly beneficial to overcome 
extracellular and cellular barriers imposed by the lung. This aspect is especially 
critical in severe lung diseases, such as CF, where submucosal glands and distal 
airways are obstructed by thick tenacious secretions, resulting in a failure of normal 
mucociliary clearance and defective air way defense mechanism against bacteria. 
Lung mucus may strongly limit the amount of drug reaching the target, such as lung 
epithelial cells, macrophages or bacterial cells. The way to the target is even more 
complicated for inhaled antimicrobial agents due to the biofilm-like mode of growth 
adopted by Pseudomonas aeruginosa, which chronically infects CF lung. Infact, the 
slow penetration and possible entrapment within the biofilm can strongly reduce 
drug availability in proximity of bacteria colonies.  
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Recent advances in materials, particle engineering techniques and inhalation devices 
make it possible to formulate inhalable nano- and micro-carriers for pulmonary 
delivery of drugs with improved ability to overcome lung barriers and potential to 
fulfill specific therapeutic needs. Although carrier-free formulations for inhalation 
are somewhat advisable due to their mild toxicological profile, biocompatible 
materials, such as approved surfactants, biodegradable polymers and lipids, may 
allow efficient protection and delivery of both antibiotics to bacteria growing in 
biofilm and gene material to airway epithelial cells. Of note, inhalable polymer 
particles can be produced through adequate combination of available particle 
technologies with helping or “functional” excipients so as to develop sustained-
release and easy-to-use dry powders for inhalation. Indeed, it is evident from the 
literature that the interest in dry powders for inhalation is growing and they 
represent the challenge of the future of local therapy of severe lung diseases. 
In this scenario, the general aim of this work is the design and development of 
advanced nano- and micro-carriers for pulmonary delivery of drugs potentially 
useful in the local treatment of CF-related chronic lung infection and inflammation. 
This objective has been pursued through the development of four different 
formulation strategies, driven by both technological and biological design rules. 
Through the adequate combination of the most appropriate materials and available 
technologies, inhalable formulations allowing repositioning of two distinct old 
drugs, namely niclosamide and flucytosine, for local therapy of lung infections have 
been successfully developed. Then, biodegradable large porous particles have been 
especially designed for combined and sustained release of two bioactive 
macromolecules, namely a decoy oligonucleotide and poly(ethylenimine) with 
antinflammatory and antimicrobial properties. Finally, novel hybrid lipid/polymer 
nanoparticles are proposed to face the current challenge of siRNA delivery on the 
human airway epithelial barrier. 
The most appropriate formulation approach was selected taking into account the 
distinct physico-chemical profile of the drug under investigation (e.g., solubility, 
stability, molecular weight) and the peculiarities of CF lung. In vitro/in vivo studies 
represented a critical step before selection of the best formulation to candidate for 
 11 
 
further development. Special attention was paid to the optimization of the lung 
deposition profile of the drug. Nevertheless, in vitro studies aimed to acquire 
knowledge on what happens after the particles have landed were considered crucial 
for formulation choice. An important challenge that has been taken in count is the 
toxicity of the selected materials to the lung cell/tissues and its biodistribution and 
persistence in the lung in vivo.  
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1.1. PULMONARY DRUG DELIVERY: PRINCIPLES AND 
TECHNOLOGICAL CHALLENGES 
The pulmonary route is, and has long been, a highly desired route for local and 
systemic administration of drugs to be used in the therapy of more or less severe 
diseases, not only local but also systemic. In fact, lungs are characterized by an 
enormous absorptive surface area (close to 100 m
2
), a small aqueous volume at the 
absorptive surface and a highly permeable and vascularized epithelium, especially in 
the alveolar region, which leads to a rapid drug absorption and therapeutic effect.
1,2
 
Furthermore, the relatively low proteolytic activity in the alveolar area and the 
absence of first-pass metabolism minimize drug enzymatic degradation as compared 
to conventional route of administration. Nevertheless, the first application of 
pulmonary drug delivery was the treatment of local diseases and it remains the most 
widely attempted. Indeed, direct delivery into the human airways may allow to 
achieve high concentrations of the drug at the site of action, with fewer systemic 
side effects as compared to conventional routes of administration (i.e. parenteral, 
oral). An idea of the tremendous improvement in lung targeting with corresponding 
low systemic concentrations afforded by pulmonary drug delivery as compared to 
systemic administration is given in Fig.1.1. 
Figure 1.1. Comparison of mean serum and bronchial secretion concentrations of amikacin 
following intravenous administration of a 500 mg dose twice daily, and inhalation 
administration of a 400mg dose of Amikacin Inhale (Bayer) twice daily to pneumonia 
patients.3  
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Despite promising, clinical efficacy of inhaled drugs is primarily determined by the 
total and regional lung deposition of the drug. This result from the complex 
interaction of several factors, that are:  
 lung anatomy and airways morphometry; 
 aerodynamic behavior of the inhaled particle; 
 breathing pattern of the patients; 
 inhalation device; 
 drug formulation. 
Of note, the maximum therapeutic effect is achieved when the drug adequately 
deposits along the airways, remains in situ as long as possible and is able to 
overcome extracellular and cellular barriers. Indeed, the structural complexity of the 
lungs, the presence of lung lining fluids and macrophage uptake may strongly 
influence drug deposition and can reduce the absorbed dose down to the 10-20% 
with respect to the administered one.
4,5
  
1.1.1. The complex structure of human lungs 
Lung airways start with oronasal passages, followed by the larynx, trachea, main 
bronchi, bronchioles, all the way down to the gas-exchange tissue, that is the alveoli. 
Moving down to the lower airways, the number of airways in humans multiply 
mostly via dichotomous branching patterns. The airways bifurcate many times (i.e., 
bronchial generations) before the alveoli and with each bifurcation the airway 
dimensions become reduced. At the same time and as one proceeds further towards 
the alveolar region, multiple bifurcation patterns cause the overall lung volume to 
increase in non-linear fashion. The most commonly used anatomical model is the 
Weibel model
6
 (Fig. 1.2). In this model, the ways of bifurcation are indicated, 
designating the trachea as the first airway (order 0) and presuming that each airway 
leads to two branches (regular dichotomy). The bronchial generations are adopted 
for the calculation of deposition fractions of inhaled aerosol particles.  
Introduction Chapter 1 
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Figure 1.2. Human lung anatomical regions and airway generation model according to the 
International Commission for Radiological Protection (ICRP)7 Tracheobronchial (generations 
0-16) and pulmonary (generations 17-23) regions are the most important target of inhaled 
drug particles.  
 
Besides the number of lung generations, the human respiratory tract can be divided 
into four anatomical regions. Nasal or oral pathways are known as extra-thoracic 
region, which serves as an important first stage filter for inhaled particles entering 
the lung. This region also contains associated lymph vessels and lymph nodes called 
bronchus-associated lymphoid tissue (BALT). Therefore, from the point of view of 
toxicology and human health, understanding the nature of airflow and particle 
transport in the human nasal-oral passages is also important. Nevertheless, the 
therapeutic effect of inhaled drugs is first dependent upon the dose of deposited drug 
and its distribution in the air conducting system within the thoracic region.  
The bronchial region is the first part of the air conducting system within the thorax 
and consists of the trachea (assigned generation 0, Fig. 1.2), the main bronchi, and 
the intrapulmonary bronchi (usually grouped around generation 8). After the 
bronchial region, there is the bronchiolar region, which consists of the bronchioles 
(comprising generations 9 to 16 in Fig. 1.2). The branches of the last generation are 
called terminal bronchioles; whereas all airways beyond the terminal bronchioles 
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carry alveoli. The alveolar-interstitial region compartment comprises the respiratory 
tract system up to the terminal bronchioles that groups together generations 16 to 26 
(Fig. 1.2) known as the respiratory bronchioles and the alveolar ducts. The gas-
exchange region is represented by the alveolar sacs, which are closed at the 
peripheral end by a group of alveoli. 
The pseudostratified epithelium of cells that constitutes the barrier to drug 
absorption at lung is markedly different and gradually thinner going from bronchial 
to the bronchiolar region (Fig. 1.3).  
 
Figure 1.3. Schematic drawing of human airway epihtelium in the different regions of the 
lung. The cells are drawn at their relative sizes. The darker orange colour in the figure is the 
liquid layer, which gets thinner in thickness as the airways become smaller in diameter with a 
final thickness <0.1 μm in the alveoli 8. 
 
The upper human airways have anatomical structures that efficiently serve as a filter 
for inhaled non-gaseous pollutants. In fact, the epithelium of the trachea primarily 
consists of ciliated cells ending with mucus-secreting goblet cells and specialized 
mucus-secreting glands that collectively form the mucociliary escalator. The 
synchronized beating patterns of cilia drives mucus and deposited foreign particles 
up to the larynx, where they are either swallowed or expectorated. The bronchioles 
are airways without cartilage and glands, where basal cells are rarely found. They 
are characterized by ciliated cells that clear secretory fluid towards the base of 
bronchial region.  
According to its function, the epithelium in the conducting airways differs 
substantially from that in the peripheral lungs, which should provide a large and thin 
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surface facilitating gas exchange. Here, the epithelium is comprised of an extremely 
thin cell monolayer composed of two major cell types: alveolar type I and alveolar 
type II cells. Although type I cells only account for 10% of the alveolar cell number, 
they cover more than 90% of the surface in the peripheral lung; this is mainly due to 
their extremely outstretched morphology with protruding nuclei which facilitate the 
exchange of oxygen and carbon dioxide. Type II cells are more compact in shape 
and mainly serve as secretory cells for alveolar surfactant.
9
  
1.1.2. Mechanisms and factors governing lung deposition 
Understanding the mechanisms and factors determining aerosol deposition is of 
outmost importance to allow drug selective administration in specific regions of the 
lungs.  
From a physical point of view, three primary mechanisms are responsible for the 
deposition of drug aerosols in the respiratory tract, that is inertial impaction, 
gravitational sedimentation and Brownian diffusion
10
. They may be supplemented 
by electrostatic attractions and particle interception (in case of elongated particles) 
and are likely affected by the turbulent air flow. Each deposition mechanism applies 
to a different particle size range and governs aerosol deposition in a peculiar region 
of the lungs. 
Deposition via inertial impaction and sedimentation by the gravitational force 
primarily depend upon the aerodynamic behaviour of the aerosol particles. Particle 
aerodynamic diameter is defined according to the equation (1) 
ae v
0
ρ
d = d  
ρ X
 (1) 
in which dv represents the volume diameter, ρ is the density of the particle, while ρo 
is a density of control (1 g/ml) and X is the dynamic shape factor, which is 1 for a 
sphere. This parameter critically influences the deposition of the inhaled formulation 
in the upper airways, rather than the conducting airways and the alveolar region of 
the lungs
10,11
 (Fig. 1.4). 
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Figure 1.4. Effect of aerodynamic particle size on their regional deposition of inhaled 
particles along the human respiratory tract. Following a slow inhalation and a 5-second breath 
hold, larger particles deposit in the airways or mouth and throat, whereas smaller particles 
mainly deposit in the alveolar region. Particles <1 μm can be exhaled, thereby reducing deep-
lung deposition12. 
 
Large particles (dae>10 µm) are mainly deposited by inertial impaction in the upper 
airways and at the bifurcations, where the airways and the airstream change 
direction (Fig 1.5). Indeed, particles become more and more inert with growing size, 
setting rate increases and their ability to follow the respiratory flow is reduced 
proportionally to the velocity of flow. If pharmaceutical aerosols penetrate the small 
conducting airways, the dominant mechanism leading to particle deposition is 
gravitational sedimentation, meaning that particles fall under gravity onto an airway 
wall (Fig.1.5). This process is again dependent upon aerodynamic particle size 
(1<dae<10 µm) and to the length of particle stay in the lungs. Both impaction and 
sedimentation result in deposition of particles larger than 3-5 µm in the smaller 
airways (i.e. bronchus, bronchioles) before reaching the alveoli. Differently, 
particles with a dae in the 1–2 µm range will likely deposit into the capillary-rich 
alveolar airspaces, which represent the target for systemic drug delivery through the 
lungs. Here, deposition is mainly influenced by Brownian diffusion, which 
dominates for particles with diameters less than 1 µm (Fig. 1.5). In particular, 
particles with an aerodynamic diameter between 0.1 and 1 μm are mostly exhaled, 
whereas ultrafine particles (lower than 100 nm) may paradoxically deposit in the 
respiratory tract taking advantage of their random Brownian motion
13
 (Fig. 1.5).  
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Figure 1.5. Mechanisms governing the deposition of inhaled particles along the different 
anatomical regions/airway generations of the human respiratory tract 12. 
 
Alveolar deposition of small particles can be enhanced by improving the patient’s 
inhalation technique. Indeed, the mode of inhalation is another critical factor 
determining lung deposition. Faster inspiratory flow rates increase inertial impaction 
of aerosols in the oropharynx and at bifurcations in the large central airways, thus 
reducing lung deposition in the peripheral airways
10
 (Fig. 1.6). Nevertheless, dry 
powder inhalers (DPIs) represent and important exception to this rule, since lung 
deposition from dry powder devices paradoxically increases as inspiratory flow 
increases. Infact, maximal patient therapeutic effort may be needed to deaggregate 
the powder and to provide a large mass of particles with sufficiently small 
aerodynamic diameter to enter the lungs.
14
 The penetration of aerosol particles into 
the lung periphery may be also enhanced by deep inhalation and breath holding 
increases time for small particles to diffuse and/or to settle by gravity and to deposit 
on the alveolar surface, resulting in improved alveolar deposition. In other words, 
the probability that a particle will be deposited in the lungs by diffusion increases 
with increasing residence time. 
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Figure 1.6. Results of the simulation with computational fluid dynamics (CFD) of particle 
behavior at different sizes (1pm, 5μm, and 50μm), which are dragged by flows of 6, 24, and 
95 l/min. The red areas indicate a high density of trapped particles. As the size of the particle 
and flow increase, more particles tend to become trapped in more central regions of the 
airway due to impaction.15 
1.1.3. Inhalation device 
The increasing research interest towards inhaled therapeutics has recently led to 
tremendous innovations in designing inhalation devices able to ensure high 
aerosolization performance, consistent therapeutic efficacy and satisfactory patient 
adherence. Vibrating-mesh and software technologies have resulted in nebulisers 
that have remarkably accurate dosing and portability. Alternatively, advanced 
particle engineering techniques have made DPIs highly favourable for delivering 
also high-dose drugs, such as antibiotics. On the other hand, innovations are still 
needed to overcome the technical constrains in drug-propellant incompatibility and 
delivering high-dose drugs with pressurised metered dose inhalers (pMDIs).
16
 
1.1.3.1 Nebulisers 
Nebulisers have a long and complex history, and were defined in the 1870s as 
“instruments for converting a liquid into a fine spray, especially for medical 
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purposes”. More than one century has passed and they are still widely employed, 
especially for pediatric and geriatric patients and for a more convenient delivery of 
high drug doses, as in case of chronic antibiotic therapies.
10
 Indeed, design changes 
over the past decade have created different nebulizer categories, with different and 
always increasing performances in human therapy.
16,17
  
The most common nebulizer type is the jet nebuliser, which generates aerosols from 
the liquid drug formulation (solution or suspension) using a source of compressed 
gas. The compressor entrains room air, compresses it to a higher pressure and emits 
the air at a given flow rate. The air enters the nebuliser chamber and passes through 
a small hole, a “venture”, beyond which the air expands rapidly creating a negative 
pressure; this draws the medication up a feeding tube where it is atomised into 
particles. Larger particles will impact on the baffle within the nebuliser chamber and 
onto the walls of the chamber and be returned back to the well of the chamber to be 
re-nebulised. Smaller particles will be continuously released from the nebuliser 
chamber during both inspiration and expiration of the patient.  
A large number of conventional compressor and nebuliser combinations are 
available and these combinations have different characteristics in terms of aerosol 
particle size, nebulisation time and mass of medication delivered. Optimisation of 
existing nebuliser technologies has focused on maximizing aerosol lung deposition 
with each breath.
16
 This is the case of breath-enhanced (e.g., PARI LC
®
 Plus) or 
breath-assisted (e.g., AeroEclipse
®
) jet nebuliser (Fig. 1.7). Breath-enhanced jet 
systems use a valve system to allow air to be drawn in during inhalation (Fig. 1.7A). 
During exhalation, the valve closes and the airflow through the chamber is 
decreased to that coming from the compressor only. This decreases the amount of 
particles released during expiration and, consequently, medication wastage. 
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Figure 1.7. Advanced designs of jet nebulisers. A) Breath-enhanced nebuliser. B) Breath-
actuated nebulizer. In each diagram, the device’s aerosol output is indicated by the striped 
area. (From: Hess DR, Myers TR, Rau JL. A guide to aerosol delivery devices. Irving TX: 
American Association for Respiratory Care; 2007. Available from 
http://www.aarc.org/education/aerosol_devices/aerosol_delivery_guide.pdf. 
 
Conventional jet nebulisation systems tend to be cheaper than the alternatives and 
are less prone to reliability or delivery problems (or both) due to poor cleaning and 
maintenance. They are, however, noisy and bulky and therefore less portable. They 
also produce variable particle sizes and have a larger residual volume as compared 
to alternative systems, so leading to more wastage of medication. These limitations 
have led to the development of a new class of nebulizers, using the principle of the 
vibrating mesh technology (VMT).  
Vibrating mesh nebulizers aerosolise medication utilising a vibrating, perforated 
mesh to generate particles. This is achieved by using a piezoelectric element which 
either vibrates a transducer horn or which is annular and encircles the mesh causing 
A. 
B. 
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it to vibrate. Both methods result in medication pumping through the perforated 
mesh, when creates homogenous particles (Fig. 1.8). 
 
 
Figure 1.8. Aerosol generation through VMT technology. The aerosol generator uses a piezo 
element to vibrate an aperture plate (lower left) containing 1000 funnel-shaped orifices 
(magnified view, upper right) to create an electronic micropump (lower right), extruding 
aerosol droplets. Particle size is dictated by the diameter of the aperture.18  
 
Advanced VMT systems are silent, portable (being small and battery powered), fast 
and produce more homogenously-sized particles as compared to conventional jet 
nebulizer systems. There are a number of currently available devices for clinical use, 
such as the Aeroneb Pro® and the Pari eFlow®, which have been especially 
designed to deliver medications more efficiently and quicker. Deposition of 
medication in CF patients, as measured by sputum levels, was found to be greater 
with VMT as compared to conventional Jet nebulizers when used over a longer 
period of time.
17
 
Addressing many of the concerns associated with previous nebulisers types, the 
newest VMT nebulisers are expected to be more and more employed in the next 
future by patients, particularly in the domiciliary setting. Nevertheless, future studies 
are needed to definitively confirm the cost-effectiveness of these devices. 
 
1.1.3.2. Dry powder inhalers (DPIs) 
For long time, pMDIs have been the most commonly used inhalers for drug 
inhalation in the treatment of asthma and COPD. Nonetheless, pMDIs require the 
use of liquid drug formulations (mainly suspensions) in polluting propellants and 
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delivery efficiency strongly depends by the actuation-breath coordination of the 
user. As a viable alternative to pMDIs, DPIs have become accepted increasingly by 
both patients and formulators. Indeed, DPIs do not contain propellants and breath-
actuated, or “passive”, DPIs have completely eliminated the problem of actuation-
breath coordination. Furthermore, lung deposition from DPIs is often higher and less 
variable than for pMDIs and novel DPIs have been especially designed to deliver 
large drug doses.
10
 
The possibilities for dry powder dispersion were first explored in the ‘50s and in 
1971 one of the first DPI, the Spinhaler®, became commercially available. Since 
then, DPIs evolved and diversified rapidly into a huge variety of different concepts 
(i.e., multi-unit, multi-dose reservoir, reusable single dose, single-use) with specific 
pros and cons for a large number of different inhaled drugs, with an increased 
awareness that DPIs may have potential for several new areas of interest for 
pulmonary administration (e.g., lung infections, vaccination, systemic diseases)
14
 
(Fig. 1.9).  
 
 
 
Figure 1.9. DPI devices: (a) Turbuhaler™/Turbohaler™ , (b) Exubera®, (c) Podhaler™, (d) 
Turbospin, (e) Staccato®, (f) Cricket™, (g) Dreamboat™, (h) 3 M Taper DPI™, (i) 
MicroDose DPI (j), Twincer™, (K) ARCUS® inhaler (l) DPI — The University Of Western 
Ontario.19 
 
DPIs are complex delivery systems which must meter a drug dose, transfer it into 
the inhaled air and, often, deaggregate the powder into respirable particles. As a 
consequence, the performance of breath-actuated DPIs strongly depends on the 
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correct balance between the inhaler device, the powder formulation and the airflow 
generated by the patient (Fig. 1.10).  
 
Figure 1.10. Desired balance for optimal DPI-based therapy between the interparticulate 
forces, the dispersion forces generated by the inhaler and the deposition forces in the 
respiratory tract during inhalation.14 
 
From a formulation point of view, the handling, processing and inhalation of excipient-
free dried drug particles are challenging. Indeed, particles in the micron size range are 
intrinsically cohesive and display poor flow properties. This makes difficult both to 
meter accurate masses of drug and to disperse them. To overcome this issue, the classical 
approach employed for dry powder formulations has been to blend micronized drug 
particles with large particles made of inert carriers. The excipient, that is lactose, and the 
drug will form an interactive and ordered mixture with improved flow properties, which 
is more easily metered and delivered from the device and deaggregate during dry powder 
inhalation.  
To reduce excipient amount in dry powder formulations, comprising often more than 
99% of the powder, novel strategies have been developed and investigated for drug 
inhalation via DPIs, including microparticles.
19
 Working on size, shape and density of 
the particles, the first microparticles for inhalation have faced the market. Advanced 
products include PulmoSphere™ particles, hollow porous tobramycin-containing 
microparticles made of a dipalmitoylphosphatidylcholine derivative, the principal 
component of endogenous lung surfactants. Technosphere™ Insulin (MannKind Corp., 
Valencia, USA), based on the intermolecular self-assembly of fumaryl diketopiperazine 
(FDKP), forming a three-dimensional highly porous sphere, is also facing the market. 
Nevertheless, the number and quantities of excipients approved for inhalation by 
Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
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is still very small. Some of them, along with those currently under investigation for 
inhalation are presented in Table 1.1. 
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Table 1.1. Summary of excipients used or with potential for use in dry powder formulations for 
pulmonary delivery. Modified from.19 
Excipient Function Status 
Amino acids (leucine, 
glycine, arginine) 
Improved aerosolization 
properties 
Coating 
Buffering agent 
Endogenous substances but no data on lung toxicity  
Proven in vitro safety in lung cell line  
Approved by FDA for injectables 
Approved DPI product: Exubera 
Ammonium carbonate Blowing agent Promising excipent 
Calcium chloride Stabilising agent Approved: TOBI® Podhaler 
Chitosan and derivativess Controlled release Biocompatible and biodegradable 
Low or non-existent toxicity in vitro and in vivo 
FDA GRAS 
Citric acid Absorption enhancer FDA GRAS 
Promising excipient 
Approved by FDA for injectables 
Dextran Particle matrix/ stabilising 
agent 
Proven lung safety in animal studies 
FDA GRAS 
FDKP (fumaryl 
diketopiperazine)  
Carrier/particles matrix Afrezza® (MannKind Corporation) under clinical trials 
Glucose Carrier Approved in Bronchodual®  
Hyaluronic acid Controlled release FDA approved for injectables, approved in Hyaneb® 
Promising excipient and biocompatible 
Hydroxypropyl-β-
cyclodestrin 
Absorption 
enhancer/stabilising agent 
Promising results 
FDA approved for injectables 
Lactose Carrier/coating Approved (several products) 
Lipids Particle matrix 
/coating/surfactant/absorption 
enhancer 
Approved in TOBI® Podhaler™ biocompatible and 
biodegradable 
Liposomal drugs in clinical trials 
Proven lung safety 
Mannitol Carrier/particle matrix/ 
stabilising agent 
Approved in Exubera® and Bronchitol® 
FDA GRASa 
Magnesium stearate Protection from moisture Approved in SkyeProtect®, Seebri Breezhaler®, 
Foradil®, Certihaler® 
Linear and branched PEG Stabilising agent Promising excipient 
FDA approved for inhalation 
PLA, PGA, and PLGA Particle matrix/stabilising 
agent 
FDA approved for injectables 
Promising excipients for sustained release 
Polaxamer Surfactant/particle matrix Good biocompatibility and proved lung safety 
Sodium citrate Buffering agent/stabilising 
agent 
Approved: Exubera®  
FDA GRASa 
Sucrose/Threalose Stabilising agent Promising excipient for peptide and protein delivery 
FDA GRASa 
 
a FDA GRAS: FDA food substance generally recognised as safe. 
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1.2. OVERCOMING BARRIERS IN SEVERE LUNG DISEASES: THE 
CASE OF CYSTIC FIBROSIS 
Acknowledging that efficient deposition of aerosol particles in the lungs is still a 
necessary condition for successful pulmonary drug delivery, it is not always 
sufficient. Indeed, there is an increasing need to understand and control what 
happens after a particle has landed. Nowadays it is clear that at the interface between 
inhaled materials and biological systems, the organic and synthetic worlds merge 
into a new science concerned with the safe and effective use of innovative inhalation 
technologies. After deposition at lung, the success of any inhalation therapy will 
strongly depend also upon: i) drug permeation through airway mucus; iii) drug 
interaction with the cell target; iv) macrophage clearance escape.
9
 In the case of 
antimicrobials, the ability of the drug to penetrate bacterial biofilm is of great 
importance, too (Fig. 1.11).
3
 
 
Figure 1.11. Anatomical/biological barriers imposed by diseases lung (i.e., chronically 
inflamed and infected) to the most widely investigated inhaled drugs. Once landed at lung, the 
intact drug should: permeate through the mucus barrier, escape macrophages, interact with the 
cell target (e.g., biofilm bacteria, airway epithelial cells). Enzyme-mediated degradation is 
also critical for labile drugs (e.g., nucleic acids). Modified from ref20. 
If the deposition and clearance of aerosol particles in the lungs has been under 
investigation for decades, the rate, the extent and the various mechanisms 
underlying the interactions between the aerosol particle and the biological 
environment (e.g., particle/mucus interactions, mucociliary clearance, uptake by 
macrophages/lung epithelial cells, translocation across the lung epithelium) are still 
unclear. A thorough understanding of the behavior of the inhaled drug in the lung 
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and its interaction with lung cellular/extracellular environment is, thus, considered 
crucial for a beneficial therapeutic outcome and should be properly taken into 
account when designing new inhalable medicines.  
1.2.1. Lung cellular and extracellular barriers  
The cellular elements of the air-blood barrier are diverse and complex. Besides 
epithelial cells, which show dramatic differences in morphology and function 
between the upper (airways) and lower (alveolar) regions of the respiratory tract, 
there are macrophages and other cells of the immune system. The non-cellular 
elements determine the diffusion, the solubility and the rate of dissolution of 
particulate matter in the lung lining fluids, as well as its agglomeration or 
disintegration, water uptake, adsorption of biomolecules. These, in turn, will likely 
affect particle interaction with the cellular elements of the lung barrier. 
1.2.1.1. Non-Cellular barriers 
The non-cellular barriers of the airways pose a major challenge for particle 
dissolution, diffusion and drug adsorption. In fact, after landing at lung, the inhaled 
particle maybe altered by surrounding environment and, in turn, this can modify its 
fate in term of diffusion, disaggregation, dissolution and clearance. However, the 
significance of such changes for particle clearance or translocation through the 
epithelium as well as the mechanisms of particle mobility and transport within the 
mucus blanket have not been fully elucidated, yet.  
Compared to oral drug delivery, it is barely known if and to what extent the 
composition and the structure of the lining fluids in the lung play a role in drug 
dissolution and absorption. The two essential elements of the lung lining fluid are 
mucus and pulmonary surfactant, which vary in volume and thickness along the 
respiratory tract. The rather small total fluid volume in the lungs may be a challenge 
for new, often poorly soluble active pharmaceutical ingredients. Thus, insoluble 
drugs can quickly reach their saturation concentration and prevent further 
dissolution. Formulating drugs as nanoparticles (e.g., nanocrystals) increases the 
surface area to volume ratio, thereby increasing solubilization and dissolution rate.
21
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Other aspects that are not clear yet are physical, chemical or metabolic changes of 
the carriers and drug materials following deposition. Concerning physical and 
chemical changes, surface properties, agglomeration status, density and water 
content are fundamental, not merely for deposition but also for translocation and 
mobility of particles in mucus. Airway mucus is one of the more investigated non-
cellular barrier affecting the fate in the lungs of any inhaled particles.
22,23
 Indeed, the 
amount, the composition and the rheological properties of the mucus, its turn-over, 
along with wash-out of fluids that line the epithelia, determine the efficiency of the 
mucociliary clearance mechanism and are the main determinants of in situ 
permanence and extent of drug absorption.
24
 In particular, the mucus layer is 
composed of highly cross-linked mucin chains, creating a dense porous structure, 
with thickness and porosity variable for lung area and pathological conditions.
12,25,26
  
Two major mechanisms may stop particles from readily diffuse through mucus gel, 
that are “size filtering” through the mucus meshes and “interaction filtering” (Fig. 
1.12).  
 
Figure.1.12. Mechanisms governing the diffusion of inhaled particles through the airway 
mucus layer.22,23 
Infact, mucin, the principal mucus component, is a negatively-charged glycoprotein, 
due to the presence of sialic acids, able to establish interactions with a broad range 
of pharmaceutical molecules via hydrophobic, electrostatic, and hydrogen bonding 
interactions.
27
 Thus, insoluble particles maybe trapped in the mucus gel layer and 
moved toward the pharynx (and ultimately to the gastrointestinal tract) by the 
upward movement of mucus generated by the cilia beating (i.e. mucociliary 
clearance).
22,23
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Just as the thickness of lung epithelium, the pulmonary fluid layer reduces in 
thickness and surface coverage, forming single droplets on top of the scarcely 
ciliated cells of the lower bronchii and an extremely thin layer of surfactant in the 
outermost branches of the lungs, that is alveoli. There, the surfactant film reduces 
the surface tension at the air–liquid interface, thus preventing alveoli collapse during 
expiration. Pulmonary surfactant is composed of approximately 90% lipids and 10% 
proteins by weight. The most represented lipid is dipalmitoylphosphatidylcholine 
(DPPC), whereas four different surfactant proteins are commonly associated with 
the lung surfactant, that are surfactant protein A, B, C and D. Upon contact with 
surfactant, larger sized particles are displaced from the airspace to the hypophase 
due to wetting forces, a phenomenon that probably also occurs with nano-sized 
particles. In the hypophase, the particles may interact with surfactant proteins or 
may be taken up by alveolar macrophages.
28
  
 
Figure 1.13. Particle-surfactant film interaction. (a) Electron micrograph of interalveolar 
septum of human lung showing aqueous hypophase (H) and surfactant (arrow). (b) Electron 
micrograph of 1-m polystyrene particles depositedon the surface of alveolar wall after 
inhalation by hamster (P: particle; A: alveolar air; ABT: air-blood tissue barrier; C: capillary 
lumen). (c) Schematic drawing of the interaction of a particle with the surfactant film at the 
air-liquid interface (internal lung surface) and the subsequent displacement of the particle by 
surface forces exerted on it by surfactant, during which the particle might be coated with a 
film of surfactant or its components (1: air; 2: solid particle: 3: liquid and forces).
29
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Nevertheless, many literature findings suggest that, depending on their composition 
and size, inhaled particles may interfere with the function of pulmonary surfactant, 
thus hindering its physiological and essential role in the lung. This issue should be 
properly taken into account when designing novel nanoparticle-based inhalable drug 
formulations
29
 (Fig. 1.13). 
 
1.2.1.2. Lung epithelial barrier 
The routes of drug absorption across the lung epithelium include passive and active 
transport mechanisms involving paracellular and transcellular transport, pore 
formation, vesicular transport, and drainage into the lymphatics depending on the 
drug and site of absorption. As described above, the composition and morphology of 
the lung epithelial cells reflect their different physiological functions and form a 
barrier that is so large as different. The drug solute will pass through a cellular 
barrier that varies from a monolayer of thick (about 60 mm) columnar cells in the 
bronchi to a monolayer of thin (0.2 mm) broad cells in the alveoli. Furthermore, the 
epithelial cells are attached to a basement membrane and below that, there is the 
lung interstitium, which contains a variety of cells, collagen, elastic fibers, 
interstitial fluid, and lymphatic vessels. If none of these tissues is considered a 
significant restrictor of the transport of drug solutes, there are also macrophages and 
other cells of the immune system, which play a role. 
There is a great interest in fully understanding the mechanism of drug uptake by 
cells after deposition. The most important evidence is that only the nanosized 
fraction of particles with a diameter of 100 nm is able to penetrate with high 
efficiency through the air-blood tissue barrier. Without taking into account the 
possible alteration of the barrier properties of the epithelium in pathological 
conditions (e.g., lung inflammation), particle translocation through lung epithelium 
follows different passive and active mechanisms. Nevertheless, the greatest number 
of studies regard alveolar cells, while much less is known on the mechanism of drug 
absorption at bronchial/bronchiolar level, where the mucus blanket is considered 
determinant. 
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To improve drug accumulation at cell level, different formulation approaches can be 
pursued. By simply using carriers with adequate surface properties (charge, 
shielding cloud), one can regulate drug interaction with cells.
30
 Along with 
facilitating cellular uptake of the macromolecule, the carrier has to promote its 
endosomal escape and release it at the final intracellular target.
31,32
 This can be 
crucial in case of emerging nucleic acid-based therapeutics (DNA, siRNA and 
oligonucleotides), which should rely on adequately-engineered nanoparticulate 
systems, comprising not only biodegradable polymers able to compact, protect and 
sustain nucleic acid delivery in situ
33
, but also a biomimetic shell containing agents 
able to facilitate endo-lysosomal escape (e.g., fusogenic peptides or lipids, 
endosome destabilizing polymers)
32,34
. Decoration of carrier surface with different 
functional motifs can be also attempted to build up actively-targeted constructs.
35
 
In this context, advanced in vitro model play an important role to design and to 
develop effective novel carriers for inhaled therapy.
36
 Well-established alveolar 
(A549) or bronchial (Calu-3, 16HBE14o-) models have been particularly useful in 
early stages of development of inhaled medicines and for toxicological studies. 
Meanwhile, advanced models may allow to better resemble what happens in vivo. 
When cultures at an air–liquid interface (ALI), cells are grown on membranes in 
Transwell supports and supplied with nutrients from the basal side. In this case, 
alveolar epithelial cells may secrete pulmonary surfactant while human bronchial 
epithelial cells may produce mucus. Furthermore, several exposure systems, such as 
the pharmaceutical aerosol deposition device on cell cultures (PADDOCC) or the 
VITROCELL®, may allow nowadays the direct aerosolization of the formulation  
on the cells, further affecting the results of transport studies (Fig. 1.14).  
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Figure 1.14. Schematic representation of different cell culture models for human airway 
epithelial cells (AC) and consequent exposure to inhaled drugs: A) AC grown at the bottom of 
well and exposed to the drug suspended/solubilized in the medium; B) AC cells grown on 
membranes at ALI and exposed to inhaled drugs applied as aerosols; C) transport of 
budesonide across filter-grown Calu-3 monolayers using the PADDOCC system (full circles) 
versus the dissolved drug using a conventional Transwell® setup (open circles). 
 
Dual- or even triple-cell co-cultures particularly facilitated the investigation of 
particle translocation and clearance, especially with respect to the interplay between 
epithelial and immune cells (Fig. 1.15).
9,37
 Although co-culture models are more 
physiologically relevant, they cannot depict all characteristics of the in vivo 
situation. Nevertheless, much progress in this area has been due to the efforts to 
improve such model systems. Potential interspecies incompatibilities in current co-
culture models should be addressed in the future.
36
 
A B 
C 
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Figure 1.15. Triple cell co-culture model of airway epithelium. A. Scanning electron 
microscopic image of alveoli in human lung, a macrophage is on top of the epithelial cells 
(yellow arrow). B. Scanning electron micrograph of the triple cell co-culture system showing 
cells from top with a macrophage (yellow arrow) on the epithelial surface. C. Distribution of 
mouse dendritic cells (red) within the epithelium (green) shown by laser scanning 
microscopy. The red arrow points to intra-epithelial processes of dendritic cells. D, D′. In the 
triple cell co-culture model dendritic cells make processes through the membrane pores 
towards the apical side of the epithelium. E. A volume rendering from top of a laser scanning 
microscopy data set, showing macrophage (yellow arrow) on top of the epithelium. E′. When 
the same data set is shown upside down a dendritic cell (red arrow) can be seen at the bottom 
side.38 
 
1.2.1.3. Macrophage-mediated clearance 
Lung macrophages fulfill a crucial function in pulmonary immune reactions and the 
host defense system, and can be considered as the first line of defense against 
foreign material that reaches the lung environment. In particular, alveolar 
macrophages comprise more than 90% of the pulmonary immune cell population 
and are crucially involved in recovering the alveolar architecture and maintaining 
sterility in the peripheral lungs.
39
 Once a particle is deposited in to the peripheral 
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lung it first contacts the alveolar lining fluid, and encounters the pulmonary 
surfactant system. Consequently, it will be displaced into the subphase where 
interaction with alveolar macrophages is most likely. If particles depositing in the 
tracheobronchial tree may be rapidly cleared by the mucociliary escalator, alveolar 
macrophages represent a unique cell population in the lung that promptly responds 
to any airborne irritant or microbe.
39
 Particle–macrophage interactions and 
subsequent uptake can be promoted or reduced by optimizing size, shape, density, 
charge and hydrophilic/lipophilic character of particulate carriers.
40
 
The size of particulate carrier systems significantly influences particle–macrophage 
interactions, as demonstrated in numerous studies. Particles with 1–5 m size are 
taken up by alveolar macrophages at a greater extent compared with particles that 
are smaller or larger than 1–5 m both in vitro41 and in an in vivo setting.42 Also the 
mechanism of particle uptake changes as a function of particle size. Inhaled particles 
in the micrometer range (1-5 m) are taken up by alveolar macrophages mainly via 
active phagocytosis (or also macropinocytosis), whereas this is unlikely for 
nanosezed particles. Infact, particles with a mean size less than 500 nm are taken up 
sporadically and by non-specific mechanisms. Depending on their size, 
nanoparticles enter alveolar macrophages by pathways other than phagocytosis: 
while nanoparticles bigger than 0.2 µm are probably internalized via pinocytosis, 
smaller particles (less than 150 nm) can be internalized via calveolae (50-100 nm) or 
clathrin-mediated (100-120 nm) uptake.  
Particle shape is another major factor affecting endocytic uptake and, thus, 
internalization of the inhaled particles by alveolar macrophages. In fact, the 
macrophage membrane undergoes structural changes in such a way that the 
membrane spreads around the particle and the progression of particle internalization 
is dependent on the contact angle between particle and macrophage membrane. It 
was successfully demonstrated that aspherical particles with aspect ratios greater 
than 20 were internalized at the greatest extent when the macrophage approached the 
particle at points with high curvature, whereas spherical particles were shown to be 
internalized from each side equally. Similarly, shape-switching PLGA elongated 
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particles were quickly engulfed by macrophages once the particles became spherical 
in shape
43
 (Fig. 1.16). 
 
Figure 1.16. Morphology-dependent phagocytosis of poly lactic-co-glycolic acid (PLGA) 
particles by macrophages. (A) PLGA particles switching shape from elongated to spherical 
ones at pH 7.4. (B) Shape-switching PLGA elongated particles initially get attached to 
macrophages surface but not get internalized. Once the particles become spherical in shape, 
they are quickly engulfed by macrophages. (C) In the absence of shape-switching ability, 
particles are not internalized by macrophages.43 
 
Besides the particle shape, the material and material properties may strongly affect 
particle uptake by alveolar macrophage. For example, increased mechanical 
robustness and overall stiffness of particles leads to increased phagocytosis. More 
importantly, the material composition of a particle can affect the adsorption of 
biomolecules with opsonin function, which is likely to influence the uptake by 
alveolar macrophages significantly. Furthermore, particle surface can be especially 
modified to enhance or avoid recognition by alveolar macrophages. For example, 
surface modification with DPPC, the major component of lung surfactant, was 
shown to reduce the macrophage uptake of PLGA microparticles by altering the 
cellular interactions occurring in the alveoli
44
 (Fig. 1.17). 
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Figure 1.17 (A) Fluorescent confocal micrographs of rat alveolar macrophages (green) 
stained with FITC-phalloidin after a one hour exposure to peroxidase-containing PLGA 
particles (arrows). (B) Rat alveolar macrophages exposed to peroxidase-containing PLGA 
particles (arrow) modified with DPPC. Bar represents 10 microns.44 
 
It should be underlined that uptake of a (nano-) particulate carrier system by AM can 
be a desired effect, especially in the case of infectious diseases such as tuberculosis, 
where the alveolar macrophage is the affected, and therefore, target cell. In this 
scenario, selective and controlled internalization of carrier systems loaded with anti-
infective drugs by alveolar macrophages is under investigation for targeted 
antimicrobial therapy.  
1.2.2. The CF lung disease 
CF is a complex multisystem disease caused by the defect in a single gene.
45
 The 
faulty gene was identified in 1989, and encodes an epithelial ion channel known as 
the CFTR, which regulates chloride ion and water movements.
46
 Since CFTR is 
expressed throughout the body, CF disease affects multiple organs (i.e., lung, 
pancreas, gastrointestinal systems). Nevertheless, pulmonary disease is still the most 
important cause of CF morbidity and mortality.  
In the lung, CFTR is detectable on the apical membrane of ciliated cells within the 
gland ducts and in the superficial epithelium of healthy individuals. The most widely 
accepted explanation for the clinical effects of CFTR deficiency in the lung is 
known as “the low volume hypothesis” (Fig. 1.18).45
-47
  
Introduction Chapter 1 
 
39 
 
 
Figure 1.18 Proposed mechanism for the development of CF lung disease. In normal airways 
(A), hydration of lung lining fluids is controlled by Na+ absorption and Cl- secretion. In CF 
airways (B), the absence of CFTR leads to unregulated Na+ absorption and associated 
dehydration of the airway surface fluid layer with consequent poor mucociliary clearance.20  
 
Since CFTR normally down-regulates ENaC in the lungs, the loss of CFTR function 
leads to ENaC over-activation. This results in depletion of airway surface liquid, 
which is essential to support ciliary stability and functioning, ciliary collapse and 
consequent decreased mucociliary transport. Retained secretions encourage bacterial 
adherence, chronic neutrophilic infection, and a vicious cycle of persistent/recurrent 
lung infection, chronic inflammation and tissue destruction. The hallmark of the 
condition is progressive and irreversible bronchiectasis and respiratory failure.  
The dominant pathogen in CF airways is Pseudomonas aeruginosa, although other 
microrganisms (e.g., Haemophilus influenza, Staphylococcus aureus, Burkholderia 
cepacia) may play an important role in the pathogenesis of lung function decline
48
. 
While H. influenza and S. aureus colonize the lung early in life, sometimes causing 
recurrent infection, P. aeruginosa chronically infects 80% of CF patients by late 
adolescence.
45,49
 P. aeruginosa possesses a large genetic diversity and a number of 
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features that contribute to its ability to persist in the environment, and to its 
pathogenicity. In the environment, it exists as a single motile bacteria, the so-called 
“non-mucoid form” of the organism. As colonization progresses, the cell density and 
the collective growth pattern of P. aeruginosa change, thus improving its capacity 
for survival.  
In the “mucoid form”, P. aeruginosa is able to form complex multicellular mucosa-
attached aggregates (i.e., bacteria biofilm), which are more resistant than single 
bacteria to destruction by the innate immune system and become persistent.
50,51
 
Indeed, the production of an extracellular polysaccharide matrix has been shown to 
inhibit unopsonic phagocytosis of bacteria by resident monocytes and neutrophils 
both in vitro and in vivo and to increase bacterial adherence to the respiratory 
epithelia, thereby increasing P. aeruginosa rate of colonization within the 
respiratory tract.
50-52
 In the aggregated biofilm mode, P. aeruginosa behaviour is 
regulated by the phenomenon of quorum sensing (QS), a cell-to-cell communication 
system involving small signaling molecules (N-acyl homoserine lactones, 
oligopeptides), which enables bacteria to express genes for different phenotypes, 
especially those responsible for their virulent behaviour.
53
 
Lung infections become persistent in the first few years of life and contribute to the 
exaggerated, sustained, and prolonged inflammatory response responsible for much 
of the CF lung disease.
54
 There is also evidence that inflammation is deregulated in 
CF airways, and may thus play a prominent role in early CF lung disease.
55
 
Although the direct relation of inflammation to the CFTR defect is still debated, 
intense neutrophil recruitment in the lung, activation of pro-inflammatory 
transcription factors and consequent production of inflammatory mediators by 
airway epithelial cells are critical determinants of chronic airway inflammation.
54
  
Several transcription factors are activated in CF airway cells. Among them, 
numerous lines of evidence suggest that nuclear factor-κB (NF-B) activation is a 
critical signal in evoking an inflammatory response in CF.
56
 Whatever is the relation 
with NF-κB activation, elevated levels of pro-inflammatory cytokines (such as TNF-
α, IL-6, IL-8, IL-1β) and reduced levels of anti-inflammatory cytokines (such as IL-
10) have been typically found in the bronchoalveolar lavage and sputum of patients 
Introduction Chapter 1 
 
41 
 
with CF lung disease.
57
 In addition, pro-inflammatory mediators contribute to the 
overproduction of mucus/mucins responsible for airway obstruction and mucociliary 
function failure.
58
 These proteins are the main determinant of the rheological 
properties of mucus secretion, representing the major barrier to exogenous 
materials/drugs deposited in the lung
26
 
1.2.3. Overbiobarriers in CF lung disease 
Administration of drugs via the inhalation route is regarded with great interest in CF. 
As outlined in 2009 by the first European consensus on inhaled drugs for CF 
patients
59
, the main advantages are generation of high drug levels in CF airways, 
limited systemic toxicity, fast onset of action, no drug inactivation before reaching 
the target organ, direct drug action on target site, and suitability for home therapy. 
Potential disadvantages include uncertainty about drug dose at the target site, local 
side effects (e.g., cough, hoarseness), variable systemic drug absorption and, last but 
not least, limited information on drug interactions in the lung. Indeed, the 
therapeutic effect of inhaled drugs in CF will dependent first upon the dose of 
deposited drug and, then, by its ability to overcome local non-cellular and cellular 
barriers, which can be completely altered in pathological conditions.  
1.2.3.1. Airway narrowing and lung deposition 
An exception to the general rules governing the deposition of any inhaled particle in 
the lungs may be caused by airway narrowing, change in lung function and mucus 
plugging typical of CF diseased lungs.
48,60
 These factors can significantly influence 
the distribution of inhaled drugs and, as a consequence, their deposition pattern. In 
particular, pulmonary functional parameters indicating obstruction in CF patients 
were significantly correlated with aerosol bolus spreading and deposition.
61
 
Compared to healthy subjects, bronchial deposition is increased in CF at the expense 
of alveolar deposition most likely because of a decreased distance and increased 
turbulence at constricted sites caused by airway narrowing, which facilitate particle 
settlement or displacement on the airway wall.
60-62
 Furthermore, also deposition 
patterns are more heterogeneous in the diseased lung than in the healthy lung. Thus, 
predicting the actual site of deposition in CF lung is difficult, since airway caliber 
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and anatomy as well as pharmacological treatments strongly differ among CF 
population as a function of disease stage and complications. 
1.2.3.2. CF mucus  
In case of severe lung diseases, such as CF, the overproduction of a viscous and 
highly complex mucus may further limit the amount of drug reaching the 
target.
34,63,64
 CF sputum is characterized by a reduced amount of water (around 90% 
versus 95% typical of healthy individuals) and intact mucins (less than 20 g/L), with 
a contemporary increase of DNA and actin.
34,65
 These high molecular weight 
biopolymers can cross-link, thereby forming DNA or actin gels, which drastically 
increase the viscoelasticity of CF mucus, creating a dense porous structure, likely 
acting as a sieve toward inhaled macromolecular drugs and colloidal drug carriers.
26
 
Additionally, mucus may establish adhesive interactions with drugs or particulate 
carriers hydrophobic, electrostatic, and hydrogen bonding interactions.
66
 Since 
mucous plugs in CF patients are mainly composed of negatively charged mucins and 
DNA, positively charged aminoglycosides, such as tobramycin, may be bound to 
these compounds.
67,68
 On the other hand, electrostatic repulsion can be envisaged in 
case of negatively-charged nucleic acid therapeutics.
34
 Indeed, biopolymers in CF 
sputum form a network of bundled fibers with 100-1000 nm meshes, which can 
allow an easy diffusion of most nanosized gene carriers.
34,69
 
In the light of these observations, to penetrate CF mucus, inhaled drug particles 
should be in theory small enough to avoid steric obstruction (i.e., “nano” is better 
than “micro”) and have a hydrophilic/neutral surface to avoid mucus 
interactions.
23,66
 
1.2.3.3. Biofilm-forming bacteria 
The main challenge of CF chronic infections remains the biofilm-like mode of 
growth adopted by P. aeruginosa, forming complex multicellular mucosa-attached 
aggregates (biofilm), characterized by massive production of alginates and other 
extracellular polysaccharides (EPS).
50,51
 Bacteria growing in biofilm display high 
resistance levels to antimicrobials, due both to reduced penetration of the antibiotic 
molecules through the EPS layer and to modification in biofilm cell physiology.
52,70
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Indeed, the slow penetration and possible entrapment within the biofilm due to 
electrostatic interactions with the negatively-charged alginate matrix can strongly 
reduce drug availability in proximity of bacteria colonies (Fig. 1.19).  
The efficacy of inhalable tobramycin is to date severely impaired by drug binding in 
CF airways, likely due to tobramycin/biofilm electrostatic interactions.
71,72
 As a 
matter of fact, 300 mg of tobramycin inhalable solution (i.e., Tobi®, Bramitob®) or 
112 mg of tobramycin DPI (i.e., Tobi® Podhaler™) twice a day are currently 
needed to achieve therapeutically active concentrations at the lung target.  
Particulate carriers with adequate size and surface properties may hide chemical 
properties of the free molecule (e.g., charge, degree of lipophilicity) and reduce its 
non-specific interactions with biofilm surrounding bacteria.
73-75
 Furthermore, the 
increasing knowledge on a number of protein components/receptors which have 
been identified within biofilm
76
 could be useful, at least in principle, to increase drug 
carrier selectivity through surface decoration. 
 
Figure 1.19. The five stages of P. aeruginosa biofilm development (A) and consequent 
resistance to antimicrobials (B). Treatment of biofilms with antibiotics often results in 
incomplete killing allowing unaffected bacteria to act as a nucleus for the spread of infection 
following the withdrawal of antibiotic therapy77 
 
A 
B 
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1.2.3.4. CF Airway epithelial cells 
Although there is no literature evidence supporting their use in CF, surface exposure 
of a ligand (proteins, antibodies or immunoglobulin fragments) recognizing a 
receptor over-expressed in CF airway epithelial cells or in bacterial cells may further 
increase carrier selectivity by activating receptor-mediated transport mechanisms. 
For example, an increased expression of toll-like receptors 2 and 5 has been found at 
the apical surface of CF lung epithelium.
78
 On the other hand, a potential target for 
inhalable gene carriers can be intercellular adhesion molecule-1 (ICAM-1, CD54), 
which is up-regulated in chronically inflamed airway epithelium
79
, where CFTR is 
expressed predominantly. This hypothesis has been confirmed by very recent in vivo 
studies with receptor-targeted lipoplexes comprising a peptide motif (SERSMNF) 
displaying close similarity to the receptor binding proteins of two intracellular 
pathogens, rhinovirus and Listeria monocytogenes.
80
 
1.2.3.5. Defective phagocytosis 
Numerous evidences suggest a dysfunctional phagocytosis in CF patients, likely 
ascribed to an inherent defect in both airway neutrophils and macrophages.
81
 
Reduced expression of cell surface recognition receptors has been suggested as one 
mechanism for these observations. Recent studies have shown that macrophages 
from sputum of CF patients express reduced levels of the Macrophage Receptor with 
Collagenous structure (MARCO) and mannose receptors responsible of binding 
bacteria.
82
 Efferocytosis -that is the “burying of dead cells” - by alveolar 
macrophages
83
, seems also impaired in CF and is associated by the cleavage, 
mediated by neutrophil elastase, of the cell surface receptor for phosphatidylserine 
(one of the most important “eat me” signal of apoptotic cells).84
,85
 
Whatever the mechanism is, new insights into the failure of phagocytes to clear 
pathogens, and likely inhaled materials, could provide a new tool for a proper design 
of the inhaled drug formulations, paving the way to more efficient therapeutic 
options for CF.  
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1.3. EMERGING PULMONARY DELIVERY STRATEGIES TO 
OVERCOME LUNG BARRIERS IN SEVERE LUNG DISEASES 
As highlighted above, the number of excipients currently available (i.e., generally 
regarded as safe – GRAS – by FDA) for improving the technological properties of 
inhalable formulations is very limited.
86
 
Although calling in question safety issues, which should be adequately addressed, 
the specific use of especially engineered lipid-based and polymer-based carriers may 
further help in reducing daily drug doses and number of administrations and 
overcoming extracellular and cellular barriers imposed by lung. Both micron-sized 
or nano-sized carriers can be selected on the basis of the specific goal. (Fig. 1.18).  
 
 
Figure 1.18. Inhalable engineered for overcoming anatomical and biological barriers imposed 
by diseased lung. The peculiar advantages of microparticulate and nanoparticulate systems are 
highlighted.20 
1.3.1 Drug nanocrystals  
Several new drug candidates emerging from drug discovery programmes are water 
insoluble and, therefore, poorly bioavailable. Estimates state that 40% of the drugs 
in the pipelines have solubility problems. There are many ways to solubilize poorly 
soluble drugs but often these methods are limited to drugs with certain properties in 
regard to their chemistry (e.g., solubility in certain organic media) or to their 
molecular size or conformation (e.g., molecules to be incorporated into the 
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cyclodextrin ring structure. Apart from that, the use of surfactants or co-solvents is 
also possible, but sometimes leads to increased side effects (eg, Cremophor EL 
(BASF, Ludwigshafen, Germany) and other disadvantages (eg, organic solvent 
residues). The micronization of drug powders to sizes between 1 and 10 μm has 
been also attempted to increase the surface area, and thus the dissolution velocity, 
but is not always sufficient to overcome drug bioavailability issues.  
A consequent and recent step to improve the dissolution profile of poorly soluble 
drugs was to move from drug micronization to “nanonization”, producing so-called 
drug nanocrystals.
21
 Drug nanocrystals are particles made of 100% drug which can 
be used in form of colloidal dispersion, i.e. the nanocrystals are dispersed in a 
stabilizer-containing aqueous medium, producing a nanosuspension (NS). Although 
this approach has exploded recently, nanocrystals were invented in the 1990s when 
Elan Nanosystems (San Francisco, CA, USA) to enhance drug oral bioavailability. 
The first product came into the market in the 2000s (Emend®).
87
  
The main advantages of drug nanocrystals are reported in figure 1.19. The smartness 
of nanocrystal technologies is that it can be universally applied to pratically any 
drug. The nanocrystal can be performed by two basic approaches: Bottom-up 
technologies building particles up from the molecular state (e.g. precipitation) or 
top-down technologies by breaking larger non micron-sized particles down (e.g. wet 
milling, high pressure homogenization). Top-down technologies are more widely 
used than bottom-up technologies because of the yield, good control over the 
processing parameters and avoidance of the organic solvent removal typical in 
precipitation processes. 
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Figure 1.19 Main features of nanocrystals: increased saturation solubility due to increased 
dissolution pressure of strongly curved small nanocrystals (upper), increased dissolution 
velocity due to increased surface area (middle), and increased adhesiveness of nanomaterial 
due to increased contact area of small versus large particles (at identical total particle mass).21 
NS are a valid alterative to dry powders to deliver poorly soluble drugs at lung level. 
Infact, their pulmonary administration can be simply performed by aerosolizing the 
aqueous NS by the most appropriate nebulizer.
88
 When the aerosol droplets deposit 
in the lung, as fine particles, nanocrystals are expected to spread more evenly on the 
lung surface, especially when stabilized with appropriate surfactants.
89-91
 
Despite their advantages, the stability of NSs is a critical aspect that defines the 
safety and efficacy of the drug product. Nanosizing results in the creation of 
additional surface area and/or interfaces that lead to a change in free energy and 
become thermodynamically unstable while tending to minimize the free energy.
92
 In 
addition to physical stability, chemical stability of the active content in suspension is 
affected in some cases by hydrolysis of the compound. The last important concern is 
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the biological stability, especially in case of pulmonary delivery. Surfactants are 
commonly used to minimize the free energy, therefore selection of appropriate 
stabilizer for NS is a challenging task.
88
 Nevertheless, the correct choice of 
surfactant does not completely solve the biological and chemical stability issues.  
Conversion of the NS to a solid form becomes essential if stable NS is unatainable, 
solid dosage form are convinient also with renard to the market. Methods that are 
commonly used for conversion of NS include spray drying and freeze drying 
(lyophilization) pelletization and granulation. Spray drying and lyophilization are 
the most common processes and in particolar spray dryng is preferred by the 
pharmaceutical industry becouse it is faster and consumes less energy. In conclusion 
the method depends on the effectiveness in preserving particle size after processing.  
1.3.2 Lipid-based carriers 
The urgent need to increase concentration of the drug at the lung target in 
antimicrobial respiratory therapies and the promising results obtained by DSPC 
microparticles (i.e., PulmoSphere™) have prompted researchers and pharmaceutical 
industries to investigate the potential of lipid particles for the delivery of different 
antibiotic molecules. Indeed, the most commonly employed lipid materials in drug 
carriers development, such as phospholipids and cholesterol, are well tolerated since 
they constitute a significant portion of the naturally occurring pulmonary surfactant 
pool.
93,94
 Furthermore, the hydrophobic nature of lipids, especially of neutral lipids, 
reduces the absorption of the ubiquitous vapour onto particles during inhalation, 
limiting aggregation and adhesion phenomena.
86
 
Among lipid-based carriers of interest in inhalation therapy, both research and 
industry attention has been focused on novel liposome-based formulations for 
antibiotic and combined therapies and lipoplexes as non-viral vectors for gene 
therapy. More recent is the history of solid lipid particles both micro and nano 
particles, which are still in early development for pulmonary delivery (Fig. 1.20). 
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Figure 1.20. Schemmatic respresentation of some of the most investigated lipid carriers for 
pulmonary delivery: A) liposomes; B) cationic lipid-based carriers (lipoplexes); C) solid lipid 
particles (both microparticles and nanoparticles).  
 
Liposome-encapsulated drugs represent very promising drug delivery systems for 
lung targeting.
93-95
 In case of extracellular pathogens, such as P. aeruginosa in CF, 
the major advantages of liposomal antibiotics are: i) overcoming bacterial drug 
resistance ii) protection of the drug from antibiotic-inactivating enzymes (like -
lactamases) iii) tuning interactions between antibiotic and lung lining fluids (mucus 
and biofilm).
20,94
  
From a technological standpoint, liposomes have a great design versatility since 
single lipid blocks can be assembled, resulting in tuned physicochemical properties 
and, consequently, adequate interactions with mucus, biofilm matrix and bacterial 
cell surface.
95,96
 Of course, attention should be paid to the effect of liposome 
composition on carrier stability, drug entrapment efficiency and release. Indeed, the 
use of inhaled liposomal antibiotics as therapeutic agents is still challenged by their 
well-established physical and chemical instability in aqueous dispersions for long-
term storage, often causing vesicle aggregation, drug leakage, phospholipid 
hydrolysis and/or oxidation.
95-97
 Nevertheless, advanced clinical studies are ongoing 
on two neutral liposomal formulations for antibiotic inhalation, that are Arikace™ 
and Lipoquin™ (ARD-3100). Furthermore, many methods available for stabilization 
of liposomes and, possibly, achievement of DPI liposomal formulations (e.g., 
lyophilization, spray-drying and supercritical fluid technology) are currently being 
investigated.
97-99
  
Introduction Chapter 1 
 
50 
 
As compared to bare liposomes, lipid cationic nanocarriers (or lipoplexes) are 
mostly investigated to condense and deliver intracellularly negatively charged DNA 
and short nucleic acid derivatives.
100,101
 They are commonly composed of cationic 
lipids, such as 1,2-Dioleoyl-3-trimethylammoniumpropane (DOTAP). Although 
direct delivery at lung should limit systemic side effects of lipoplexes, the toxicity of 
the carrier, usually dose-related, appears still critical for in vivo translation of 
cationic lipid-based particles.
101,102
 Indeed, the major issue related to their use is the 
potential for inducing dose-dependent cellular toxicity and, when complexed with 
DNA, triggering undesired macrophage-mediated pro-inflammatory cytokine 
production. 
Solid lipid nanoparticles (SLNs) are also being explored as a viable alternative to 
liposomes for drug and gene delivery to the lung SLNs have evolved in solid lipid 
particles, known as Nanostructured Lipid Carriers (NLCs), made of a blend of a 
solid lipid and an oil consisting in a semi-crystal structure with more flexibility and 
able to better accommodate drugs.
103
 NLCs have the same advantages of SLNs, that 
is controlled drug release, improved chemical stability of encapsulated drug 
molecules and simple and non-expensive production, also on a large scale, as 
compared to liposomes.  
1.3.3 Polymer-based carriers 
Although it can be dated back to 90’s42, the concept of using polymer particles for 
pulmonary delivery has evolved during time and is experiencing growing research 
interest in recent years, also for CF.
20,104,105
 A fundamental feature of polymer 
systems, which is only partly shared by liposomal carriers, relies on their ability to 
exert a prolonged drug release. This is crucial to reduce the number of 
administrations and increase patient adherence to complex therapeutic regimens 
required by chronic lung diseases, such as CF
106
. Polymer particles have also the 
potential: i) to increase drug stability in the bottle and in vivo; ii) to co-deliver 
different molecules with complementary functionalities; iii) to promote cell uptake 
of delivered drug cargo. Indeed, various systemic and cellular barriers imposed to 
nucleic acid therapeutics, including nucleases, cell membrane, endosomal 
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compartment and nuclear membrane, maybe successfully circumvented by 
adequately designed polymer carriers. Nevertheless, to be successful, design of 
inhalable NPs should take into account well-defined rules to overcome limitations 
associated to pulmonary route of administration, providing adequate composition, 
size, and surface modification along with respirability (Fig. 1.21). 
 
 
 
Figure 1.21 Overview of the main design rules dictating the development of efficient 
polymeric particles for inhalation. 
 
Among polymers currently under investigation, synthetic biodegradable polymers 
represent the most promising class of materials for pulmonary delivery, as evidenced 
by increasing literature data, fulfilling also important safety concerns. Amid them, 
poly(lactic-co-glycolic acid) copolymers (PLGA) have generated tremendous 
research interest due to their excellent biocompatibility as well as the possibility to 
tailor their biodegradability by varying monomer composition (lactide/glycolide 
ratio), molecular weight and chemical structure (i.e. capped and uncapped end-
groups).
104
 PLGAs characterized by very different in vivo life-times, ranging from 3 
weeks to over a year, are available and approved for human use. Among all 
commercially available PLGA types, those characterized by a rapid in vitro 
degradation are undoubtedly preferred for inhalation and have shown no toxicity on 
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both healthy
107-109
 and CF human airway epithelial cells.
110,111
 Drug encapsulation 
within PLGA copolymers is regarded also as a powerful mean to achieve its 
sustained release for long time-frames and, in the case of labile drugs, effectively 
protect the molecule from in vivo degradation occurring at the administration site.
112
 
To increase the availability of the delivered drug at the lung target, engineered 
inhalable PLGA particles have been developed through the addition of specific.
104
At 
nanosize level, particle surface modification with helper hydrophilic polymers (e.g., 
PEG, poloxamer, chitosan, polyvinyl alcohol) has been found useful to modulate 
carrier interactions with lung cellular and extracellular barriers.
66,109,113
 
Excipients playing a dual role in the formulation can be preferred in the production 
of PLGA microparticles, especially if one of their effects is to widen and/or enhance 
the biological activity of the inhaled drug. Poly(ethylenimine) (PEI), used as non-
viral gene transfer agent since 90’s, could represent an interesting polymer candidate 
for inhaled drugs in CF due to its proved synergic antimicrobial properties with 
several antibiotics directed against P. Aeruginosa.
114
  
Amongst the parameters that can be adjusted to achieve inhalable microparticles, 
mass density and size have drawn researchers’ attention to limit loss of drug due to 
particle aggregation in the inhaler and macrophage-mediated clearance of the 
particles from the lungs.
8
 The idea is that conventional polymer particles achieved 
by micronization (i.e., 1–3 μm) are poorly flowable, prone to aggregation and can be 
rapidly phagocytosed in the deep lung by alveolar macrophages. On the contrary, 
large porous particles (LPP) with low mass density (<0.4 g/cm
3
) and high geometric 
diameter (>5 m) can be used to enhance both particle aerosolization behaviour and 
residence time in the lung.
42
  
In the attempt to find out novel anti-inflammatory therapies for CF, the first example 
of dry powders for oligonucleotide inhalation, consisting in biodegradable LPP 
based on PLGA for prolonged delivery of a decoy oligonucleotide to nuclear factor-
B (dec-ODN), have been recently developed (Fig. 1.22).110
,111,115
 Of note, 
intratracheal insufflation of dec-ODN LPP by means of a low-scale DPI in rats 
challenged with LPS from P. Aeruginosa resulted in the inhibition of 
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bronchoalveolar neutrophil infiltration as well as the reduction of IL-8 and MUC2 
mRNA levels induced by LPS as compared to naked dec-ODN.
115
 
 
 
Figure 1.22. Bulk, aerodynamic and release properties of PLGA LPP for prolonged delivery 
of a decoy oligonucleotide to nuclear factor-B in the lung.115 
 
In the current era of nanotechnology, increasing research efforts have been devoted 
also to engineer PLGA nanoparticles (NPs) for pulmonary drug delivery.
105
 
Actually, nanoparticulate systems can be considered of choice for drug targeting to 
specific airway tissues/cells as well as to overcome lung extracellular barriers.  
While polymer particles with a mean size around 500 nm may be blocked by the 
mucus layer, NPs smaller than 200 nm are expected to diffuse more easily through 
mucus.  
To tune NP interaction with the lung microenvironment, hydrophilic polymers, both 
mucoadhesive (e.g., chitosan, hyaluronic acid) and mucoinert (PEG) have been 
employed to impart the desired surface properties.
109,116
 Despite promising, the 
effect of hydrophilic polymers in modulating PLGA NP/mucus interactions is still 
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unclear and debated. It has been recently observed that PLGA NPs of 200–500 nm 
modified at surface with non-adhesive PEG, the so-called MPP, may deeply 
penetrate human mucus secretions.
116
 In case of CF lung disease, the use of non-
adhesive PEGylated PLGA NPs could represent also a promising approach to avoid 
interactions, responsible of the loss in activity, between the drug and the biofilm 
produced by bacteria, such as P. Aeruginosa, in chronic lung infections.
74
 
Nevertheless, surface modifications of PLGA NPs may have also a significant 
impact on their interaction with the target cell. For example, the uptake of PLGA 
NPs into macrophages may be significantly reduced upon PEGylation.
40
 
Overcoming cell membrane to reach intracellular targets is also mandatory, in case 
of emerging nucleic-acid therapeutics (i.e., oligonucleotides, siRNA, DNA).
32
  
One particular strategy to modulate the surface of PLGA NPs, and hence also 
influence their behavior at the nano–bio interface, is by depositing a stabilized 
phospholipid layer onto the hydrophobic NP core. As for liposomes, this lipid layer 
can be also employed to anchor amphiphilic PEGylated lipids to the surface of the 
particles and/or conjugate targeting moieties
117
 (Fig. 1.23). 
 
Figure 1.23. Schematic illustration of a ipid-polymer hybrid NP comprising bare and 
PEGylated phospholipids (A) and corresponding morphology observed by transmission 
electron microscopy (TEM).118 
 
Lipid–PLGA hybrid nanoparticles with core–shell morphology have been especially 
designed for siRNA delivery.
117
 In particular, siRNA was efficiently entrapped in 
PLGA NPs with the aid of a positively charged lipid, that is DOTAP. The gene 
knock-down level in vitro was positively correlated to the weight ratio of DOTAP in 
the NPs, which were successfully transformed in dry powders for inhalation by 
spray-drying in mannitol.
108,119
 Nevertheless, toxicity may be an issue when using 
non-natural lipids. Fostered by these limitations, a growing interest exists in the 
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implementation of bio-inspired and bio-mimetic materials. In particular, recent 
progresses in nanotechnologies and emerging knowledge on the properties of the 
nano-bio interface have paved the way toward core–shell lipid–polymer hybrid NPs, 
where the synthetic polymeric core is surrounded with a phospholipid bilayer of 
natural origin.
120
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ABSTRACT 
 
Inhaled anti-virulence drugs are currently considered a promising therapeutic option 
to treat Pseudomonas aeruginosa lung infections in cystic fibrosis (CF). We have 
recently shown that the anthelmintic drug niclosamide (NCL) has strong quorum 
sensing (QS) inhibiting activity against P. aeruginosa and could be repurposed as an 
anti-virulence drug. In this work, we developed dry powders containing NCL 
nanoparticles that can be reconstituted in saline solution to produce inhalable 
nanosuspensions. NCL nanoparticles were produced by high-pressure 
homogenization (HPH) using polysorbate 20 or polysorbate 80 as stabilizers. After 
20 cycles of HPH, all formulations showed similar properties in the form of needle-
shape nanocrystals with a hydrodynamic diameter of approximately 450 nm and a 
zeta potential of -20 mV. Nanosuspensions stabilized with polysorbate 80 at 10% 
w/w to NCL (T80_10) showed an optimal solubility profile in simulated interstitial 
lung fluid. T80_10 was successfully dried into mannitol-based dry powder by spray 
drying. Dry powder (T80_10 DP) was reconstituted in saline solution and showed 
optimal in vitro aerosol performance. Both T80_10 and T80_10 DP were able to 
inhibit P. aeruginosa QS at NCL concentrations of 2.5-10 µM. NCL, and these 
formulations did not significantly affect the viability of CF bronchial epithelial cells 
in vitro at microbiologically active concentrations (i.e., ≤10 µM). In vivo acute 
toxicity studies in rats confirmed the no observable toxicity of the NCL T80_10 DP 
formulation upon intra-tracheal administration at a concentration 100-fold higher 
than the anti-QS activity concentration. These preliminary results suggest that NCL 
repurposed in the form of inhalable nanosuspensions has great potential for the local 
treatment of P. aeruginosa lung infections as in the case of CF patients. 
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2.1 INTRODUCTION 
Cystic fibrosis (CF) is an autosomal disease caused by a defect in a single gene 
encoding the CF transmembrane conductance regulator (CFTR).
1
 This condition 
predisposes CF patients to recurrent/persistent bacterial lung infections, which are 
the primary cause of bronchiectasis, respiratory failure and consequent death in CF 
patients.
1-3
 The dominant pathogen in CF airways is Pseudomonas aeruginosa, 
though other microorganisms may play a role in lung function decline.
4
 Although 
lung infections can be controlled to some extent by early, aggressive antibiotic 
treatments, 60–70% of CF patients become chronically infected by P. aeruginosa by 
the age of 20. Current treatment involves life-long daily inhaled antibiotic therapies.
5
 
Anti-virulence drugs, i.e., agents that inhibit the production of disease-causing 
virulence factors but are neither bacteriostatic nor bactericidal, are considered 
promising therapeutic options for the treatment of P. aeruginosa infections in CF, 
either alone or in combination with antibiotics. These drugs are expected to prevent 
the establishment of the chronic infection and to reduce its severity by inhibiting 
bacterial processes essential for virulence and pathogenicity, rather than targeting 
bacterial growth. The main advantages of anti-virulence drugs over conventional 
antibiotics are that they are unlikely to drive the spread of resistant strains and that 
they have a reduced impact on the resident microbiota.
6,7
 
The pathogenic potential of P. aeruginosa relies on the coordinated expression of a 
large array of virulence factors
8
, the majority of which are positively controlled by 
an intercellular communication process called quorum sensing (QS). P. aeruginosa 
QS is based on the production, secretion and perception of different signal 
molecules; N-3-oxo-dodecanoyl-homoserine lactone (3OC12-HSL) is considered the 
major QS signal produced by P. aeruginosa.
9
 When the 3OC12-HSL signal molecule 
reaches a threshold concentration, it binds to the LasR transcriptional regulator, 
triggering the expression of hundreds of genes, including genes for the production of 
a large number of virulence factors and for biofilm formation.
9
 Numerous studies 
support the role of QS in P. aeruginosa infection and highlight its importance as a 
candidate for novel virulence-targeted drugs (reviewed in
10
). Therefore, the search 
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for QS inhibitors to be used as lead compounds for the development of “non-
antibiotic” drugs against P. aeruginosa has become a field of intensive research.11
,12
  
Despite the huge efforts made to date in the field of anti-QS research, clinical 
applications remain out of reach, mainly due to the unfavorable pharmacological 
properties of the majority of the QS inhibitors identified so far.
12
 A potential 
shortcut is the use of a drug repurposing approach for the identification of QS 
inhibitory compounds with low toxicity and already approved for use in humans. 
This strategy recently led to the identification of the anthelmintic drug niclosamide 
(NCL) as a strong inhibitor of the 3OC12-HSL-dependent QS system in P. 
aeruginosa. Preliminary experiments suggested that NCL interferes with the LasR-
dependent signaling pathway rather than with the synthesis of 3OC12-HSL. As a 
consequence of LasR-dependent signaling inhibition, NCL strongly reduced 
virulence factor production, impaired biofilm development, and attenuated P. 
aeruginosa pathogenicity in the Galleria mellonella model of acute infection.
13
 
The potential therapeutic value of NCL has been clearly demonstrated, and thus, an 
adequate inhalable formulation for the proposed clinical application is needed. 
Pulmonary administration represents an ideal route to treat respiratory infections 
typical of CF lung disease.
14,15
 Important determinants of the clinical outcomes of 
the inhaled drug are the lung dose as well as the ability of the drug to overcome 
extracellular and cellular barriers.
16
 From a technological point of view, the major 
obstacles related to the pulmonary administration of NCL are the achievement of 
appropriate particle size distribution and the potential poor dissolution properties in 
lung lining fluids
17
 due to its low aqueous solubility.  
Among the available formulation options for reducing the particle size of poorly 
soluble active molecules, pulmonary delivery of “nanosuspensions” can be 
considered. Nanosuspensions are colloidal dispersions of drug nanocrystals 
stabilized by surfactants,
18
 which can also increase drug interactions with biological 
substrates.
19,20
 An aqueous nanosuspension can be delivered through commercially 
available nebulizers to generate an aerosol with a 1-5 µm droplet size suitable to 
achieve the desired distribution in the lung.
21-23
 A number of smart, efficient and 
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portable nebulizers, such as adaptive aerosol delivery nebulizers with vibrating mesh 
technology (VMT), are available to CF patients.
24
  
The aim of this work was to develop inhalable NCL formulations for anti-virulence 
therapy against P. aeruginosa lung infections. To this end, different NCL 
nanosuspensions have been produced, and optimized formulations have been 
selected on the basis of morphology, size, zeta potential, and solubility profile in 
different media. A strategy to improve long-term stability of the formulations is 
proposed. In vitro aerosol performance, QS inhibitory activity and cytotoxicity in 
CF human airway epithelial cells of optimized NCL formulations have been 
investigated. Finally, the in vivo acute lung toxicity of the most promising NCL 
formulation was tested in rats following intra-tracheal administration 
.  
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2.2 EXPERIMENTAL METHODS 
2.2.1 Materials 
NCL, polysorbates (Tween® 80 and Tween® 20), diethylenetriaminepentaacetic 
acid (DTPA), dimethyl sulfoxide (DMSO), 3-(N-morpholino)propanesulfonic acid 
(MOPS), N-3-oxo-dodecanoyl-homoserine lactone (3OC12-HSL), egg yolk 
emulsion, RPMI amino acid solution, type II mucin from porcine stomach, calcium 
chloride dihydrate, magnesium chloride, potassium chloride, potassium phosphate 
dibasic, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate 
dehydrate, sodium phosphate dibasic, sodium sulfate, and 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) were obtained from Sigma-Aldrich 
(Italy). Mannitol (Pearlitol®C160) was a kind gift of Roquette Italia S.p.a. (Italy). 
Tryptone and yeast extract were obtained from Acumedia (Neogen Corporation, MI, 
USA). Analytical grade methanol was supplied by Carlo Erba (Italy). Distilled water 
filtered through 0.22 m cellulose filters (Phenex® RC, Phenomenex, USA) was 
employed throughout the study.  
2.2.2 Niclosamide quantitation 
The amount of NCL in solution was determined by UV-vis spectrophotometry using 
a Shimadzu 1204 spectrophotometer (Shimadzu, Italy) fitted out with a 0.1-cm 
quartz cell (Hellma® Italia, Italy). The absorbance (ABS) of NCL samples was 
measured at 331 nm. A calibration curve was obtained by plotting ABS versus the 
concentration of NCL standard solutions in methanol. The linearity of the response 
was verified over a concentration range of 0.2–20 μg/mL (r2= 0.999). The limit of 
detection (LOD) (estimated as 3 times the background noise) was 0.22 μg/L. The 
limit of quantitation (LOQ) (estimated as 10 times the background noise) was 0.53 
μg/L. In each case, the presence in the samples of interfering substances that could 
affect the UV-vis spectrum of NCL was accounted for with the appropriate blank. 
All blank media had negligible absorption at 331 nm. 
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2.2.3 Development of niclosamide nanosuspensions 
2.2.3.1 Production of NCL nanosuspensions 
NCL nanosuspensions were prepared by high-pressure homogenization (HPH) using 
two different polysorbates as stabilizers (i.e., Tween 20 and Tween 80). Four 
nanosuspensions were developed: T20_10 and T20_20, which contained Tween 20 
at 10% or 20% w/w NCL, respectively, and T80_10 and T80_20, which contained 
Tween 80 at 10% or 20% w/w NCL, respectively (Table 2.1).  
Table 2.1. Composition of NCL nanosuspensions. 
 
 
NCL 
(w/v ) 
Polysorbate 80 
(w/w  to NCL) 
Polysorbate 20 
(w/w  to NCL) 
T80_10 1% 10% - 
T80_20 1% 20% - 
T20_10 1% - 10% 
T20_20 1% - 20% 
 
Before processing, NCL raw material (mean volume diameter approximately 18 m) 
was pre-milled for 10 min in a colloid mill (Model IG/.W2/E, Giuliani, Italia) 
equipped with a 20 mL agate jar and balls. After milling, an appropriate amount of 
micronized NCL (Micro NCL) (1% w/v) was dispersed in 100 mL of a stabilizer 
solution in water. The dispersion was pre-mixed using a high-speed homogenizer 
(Ystral, Heidolph, Germany) operating at 19000 rpm (tool 10F) for 15 minutes and 
then subjected to a predetermined number of HPH cycles (10, 15 and 20 cycles) at 
1800 bar in a PandaPlus 2000 high-pressure homogenizer from NiroSoavi (Parma, 
Italy). To optimize process parameters, the size of NCL crystals was 
monitoredthroughout the HPH process by laser light scattering (Coulter LS 100Q, 
USA) upon dilution of the samples in water to a suitable scattering intensity. 
The amount of NCL solubilized was determined just after production. Briefly, the 
nanosuspension was centrifuged at 11000 g for 30 min at 25°C (Hettich Zentrifugen, 
Universal 16R). After centrifugation, the supernatant was withdrawn, filtered 
Inhalable niclosamide nanosuspensions Chapter 2 
 
73 
 
through 0.45 µm cellulose filters (Phenex® RC, Phenomenex, USA) and analyzed 
for NCL content.  
2.2.3.2 Size and morphology of NCL nanocrystals 
To select the process parameters, the size of the NCL nanocrystals was determined 
just after processing by laser light scattering (Coulter LS 100Q, USA) upon dilution 
of the samples in water to a suitable scattering intensity. The size of NCL raw 
material and Micro NCL was determined for comparison. Results are expressed as 
volume diameter (d10, d50 and d90) ± standard deviation (SD) of values collected 
from three different batches (n=6). 
The hydrodynamic diameter (HD), the polydispersity index (PI) and the zeta 
potential of the final nanosuspensions were determined by photon correlation 
spectroscopy (PCS) with a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). 
Results are expressed as mean value±standard deviation (SD) of triplicate 
measurements on different batches (n =6). Particle shape and external morphology 
were analyzed by Scanning Electron Microscopy (SEM) (Leica S440, Germany) 
upon air drying 10 µL of nanosuspensions on paper filters for 24 hours. Dried 
samples were stuck on a metal stub and coated with gold under vacuum for 120 s.  
2.2.3.3 Stability of NCL nanosuspensions 
After production, nanosuspensions were stored in BD Falcon™ polypropylene 
conical tubes at 4°C (up to 3 months) and 25°C (for 1 month) in the dark. The 
stability over time was assessed in terms of morphology (SEM), size and PI (PCS). 
The change in NCL content over time was also assessed upon storage in BD 
Falcon™ polypropylene conical tubes at 4°C and 25°C for 1 month in the dark. 
Experiments were run in triplicate for each time point, and the results were reported 
as NCL content (µg/mL) ± standard deviation.  
2.2.3.4 In vitro dissolution studies 
Dissolution profiles of NCL nanosuspensions were determined in simulated 
interstitial lung fluid (SILF) by the USP paddle method using a Sotax (ModelAT7, 
Switzerland) dissolution system at 37°C. SILF was prepared following the 
preparation instructions dictated by Marques et al. 
25
  Briefly, 1 L of SILF contains 
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0.095 g magnesium chloride, 6.019 g of sodium chloride, 0.298 g of potassium 
chloride, 0.126 g of sodium phosphate dibasic, 0.063 g of sodium sulfate, 0.368 g 
calcium chloride dihydrate, 0.574 g of sodium acetate, 2.604 g of sodium 
bicarbonate and 0.097 g of sodium citrate dihydrate.  
For the experiment, 1 mL of nanosuspension was added to 500 mL of SILF in the 
dissolution vessel and stirred at 100 rpm. At predetermined time intervals, 2 mL of 
the dissolution medium was withdrawn, and the same volume of fresh SILF was 
added. NCL concentration was measured by spectrophotometric analysis as 
described above. The dissolution profile of Micro NCL was evaluated as a control. 
2.2.4 Development of nanocrystal-embedded dry powders 
Dry powders containing nanosuspensions stabilized with polysorbate 80 at 10% w/w 
to NCL (T80_10 DP) were produced either by lyophilization or spray drying for 
processing into a solid dosage form with long-term stability. Freeze-drying was first 
attempted  the nanosuspension was pre-frozen at either -20°C or -80 °C. To improve 
dry powder properties, mannitol at different NCL/mannitol ratios by weight was 
added as cryoprotectant to the nanosuspension before freeze-drying. Samples were 
then dried for 24 hours by a Modulyo freeze-drier (Edwards, UK) operating at 0.01 
atm and -60°C.  
 Briefly, nanosuspensions were processed in a Mini Spray Dryer Büchi 190 (Flawil, 
Switzerland) equipped with a high-performance cyclone for the recovery of small 
powder amounts. Formulations at different NCL/mannitol ratios (1:2; 1:5; 1:10 w/w) 
were individually spray-dried with the following process parameters: feed rate 3 
mL/min; aspirator setting 20; spray-flow 600 mL/h; inlet temperature 140°C 
(resulting outlet temperature = 70°C). A 0.5 mm nozzle was used throughout the 
experiments. Powders were collected and stored at 22°C in a glass vacuum 
desiccators until use.  
The mean geometric diameter and size distribution of spray-dried powders were 
determined by laser light scattering (Coulter LS 100Q, USA) of a powder 
suspension in methanol. Size is expressed as volume mean diameter± SD of values 
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collected from three batches. SEM analysis of dried samples was performed as 
described for NCL nanosuspensions.  
To evaluate the redispersibility of NCL nanosuspensions after the solidification 
process (after lyophilization and spraydrying), particle size analysis of the 
reconstituted liquid dispersion was performed through both laser light scattering 
(Coulter LS 100Q, USA) and PCS (Zetasizer Nano ZS, Malvern Instruments, UK) 
analysis. Results are reported as the redispersibility index (RDI), defined as 
   
 
where D0 represents the size of the nanosuspension prior to drying, and D represents 
the corresponding value post-rehydration of the dried sample in water. 
Thermoanalytical tests were carried out to study the melting behavior of NCL within 
the spray-dried powders by differential scanning calorimetry (DSC). The DSC 
instrument (Q20, TA Instruments, U.S.A.) was calibrated with a pure indium 
standard. The samples (approximately 5 mg) were placed in hermetically sealed 
aluminum pans, equilibrated at 25°C and heated to 300°C at 10°C/min. 
Measurements were carried out under an inert nitrogen atmosphere, purged at a flow 
rate of 50 mL/min. The melting temperatures (Tm, °C) were obtained from the 
corresponding thermograms by peak integration. 
2.2.5 In vitro dissolution in simulated CF mucus 
To better recapitulate in vivo conditions, the release of NCL from artificial CF 
mucus to SILF from T80_10 nanosuspension and the corresponding dry powder 
T80_10 DP was followed in vitro by membrane dialysis. For comparison, the release 
kinetics of Micro NCL in the same conditions were analyzed. Briefly, the artificial 
mucus was prepared by adding 250 μL of sterile egg yolk emulsion, 250 mg of 
mucin, 0.295 mg DTPA, 250 mg NaCl, 110 mg KCl and 1 mL of RPMI to 50 mL of 
water. The dispersion was stirred until a homogenous mixture was obtained.  
T80_10 nanosuspension (0.1 mL) or a corresponding amount of T80_10 DP was 
added to 0.3 mL of donor medium (artificial mucus or PBS) and placed in a dialysis 
0
D
RDI=
D
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membrane bag (MWCO: 5000 Da, Spectra/Por®). The sample was placed into 5 mL 
of external medium and kept at 37°C. At scheduled time intervals, 1 mL of the 
external medium was withdrawn and analyzed for NCL content by 
spectrophotometric analysis as described above. The medium was replaced by the 
same amount of fresh medium. At the end of each release experiment, the amount of 
residual NCL in the dialysis bag was assessed upon dissolution in methanol. 
Experiments were run in triplicate for each time point of release kinetics. 
2.2.6 In vitro aerosol performance 
The aerosolization properties of NCL nanosuspensions were tested in vitro after 
delivery from different commercial nebulizers. The deposition pattern of the T80_10 
formulation was investigated using a Next Generation Impactor (NGI) (Copley 
Scientific, UK) according to the Comité Européen de Normalization (CEN) standard 
methodology for nebulizer systems
26
, with sampling at 15 L/min and insertion of a 
filter in micro-orifice collector (MOC). 
For each test, 2 mL of fresh T80_10 nanosuspension or reconstituted T80_10DP 
spray-dried powder was transferred to the reservoir of the nebulizer, which was 
connected to the induction port of the NGI. The nebulizer was operated at 15 L/min, 
and the aerosol was drawn through the impactor until dryness. The amount of NCL 
deposited on the seven NGI collection cups was quantitatively recovered by 
dissolution in 2 mL of methanol. The amount of NCL deposited in the induction port 
and remaining inside the nebulizer chamber was also determined by washing with an 
appropriate amount of methanol. The results achieved with different nebulizer 
systems were compared; the tested systems were PARI TurboBOY
®
(PARI GmbH, 
Germany), eFlow
®
rapid (PARI GmbH, Germany) and Aeroneb
®
 Go (Aerogen, 
Ireland). Three determinations were made for each nebulizer. 
The emitted dose (ED) was measured as the difference between the total amount of 
NCL initially placed and the amount remaining in the nebulizer chamber. Upon 
emission, the experimental mass median aerodynamic diameter (MMAD) and the 
geometric standard deviation (GSD) were calculated according to the European 
Pharmacopeia deriving a plot of cumulative mass of particle retained in each 
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collection cup (expressed as percent of total mass recovered in the impactor) versus 
the cut-off diameter of the respective stage. The MMAD of the particles was 
determined from the same graph as the particle size at which the line crosses the 
50% mark, and the GSD was defined as  
GSD = (Size X/Size Y)
1/2
 
where size X was the particle size at which the line crosses the 84% mark and size Y 
the size at which it crosses the 16% mark. 
The fine particle fraction (FPF) was calculated taking into account the actual amount 
of NCL deposited on stage 3 through 7 (MMAD < 5.39 μm) compared to the initial 
amount loaded into the nebulizer chamber; that is the nominal dose of NCL, 
according to the following equation: 
NCL amount on cup 3 through 7
FPF  x 100
NCL amount loaded into the device
  
The respirable fraction (RF) was defined as: 
NCL amount on cup 3 through 7
RF  x 100
NCL total amount deposited in the NGI 
  
 
2.2.7 Measurements of QS inhibitory activity in P. aeruginosa 
The QS inhibitory activity of the formulations T80_10, T80_10 DP and raw NCL 
dissolved in DMSO was compared by using the whole cell biosensor PA14-R3
27
 in 
the presence of 3 M synthetic 3OC12-HSL, as previously described
13
. The 
biosensor PA14-R3 was routinely grown in Luria-Bertani broth (LB; 10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl). 
T80_10 and T80_10 DP were diluted/resuspended in sterile distilled water to obtain 
stock nanosuspensions containing NCL at 15 mM. Raw NCL was dissolved in 
DMSO to obtain a 10 mM stock solution.
13
 As negative controls, DMSO and stock 
solutions containing T80 alone or in combination with mannitol dissolved in water 
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were used. Serial dilutions of NCL in DMSO, T80_10, and T80_10 DP and negative 
controls were prepared in sterile distilled water and incubated at 37°C for 16 hours. 
The assay was initiated by mixing 100 µL of each NCL dilution and an equal 
volume of the biosensor mix in microtiter wells. The biosensor mix contained the 
biosensor strain PA14-R3, LB (2-fold concentrated), 100 mM MOPS (pH 7.0) and 6 
M 3OC12-HSL. The starting ABS at 600 nanometers (A600) of the biosensor mix 
was 0.09. 
After incubation of the microtiter plates for 6 h at 37°C, A600 and light counts per 
second (LCPS) were measured in a Wallac 1420 Victor3V multilabel plate reader 
(PerkinElmer). 
2.2.8 Cytotoxicity assay 
The CF bronchial epithelial cell line CFBE41o (F508del/F508del)
28
 was maintained 
in MEM with 20 mM L-glutamine, 100 units/mL penicillin, 100 μg/mL 
streptomycin and 10% fetal bovine serum (FBS). When confluent, CFBE41o cells 
were trypsinized and seeded in 96-well microtiter plates at 30000 cells per well (in 
200 µL final volume). Twenty-four hours after seeding, cells were washed three 
times with culture medium without any additive (FBS or antibiotics), and 200 µL of 
culture medium with or without different amounts of NCL formulations or their 
corresponding controls were added to each well. After 3 h of incubation at 37°C, the 
cell culture medium was discarded, and each well was washed with 200 µL of 
Hank’s balanced buffer solution (HBSS). Cells were then incubated for 3 h at 37°C 
in the presence of 200 µL of 0.5 mg/mL MTT in HBSS. The MTT solution was then 
discarded, 100 µL of DMSO was added to each well, and ABS at 570 nm (A570) was 
read using an ELISA microtiter plate reader.
29
 
2.2.9 In vivo acute lung toxicity 
2.2.9.1 Animals and treatment 
Male Wistar rats (weighing between 200 to 220 g; Charles River, Lecco, Italy) were 
kept at a temperature of 23±2°C, relative humidity range 40-70% and 12 h light/dark 
cycles. Standard chow and drinking water were provided ad libitum. A period of 7 
days was allowed for the acclimatization of the rats before any experimental 
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manipulation. Experimental procedure was performed following the specific 
guidelines of the Italian (N. 116/1992) and the European Council law 
(N.86/609/CEE) for animal care. All the procedures were also approved by the 
Animal Ethics Committee of the University of Naples “Federico II” (Italy).  
Rats were anesthetized using ketamine (100 mg/kg, i.p.) and xylazine (5 mg/kg, 
i.p.), and the depth of anesthesia was continuously controlled. Rats were then placed 
ventral side up on a surgical table provided with a temperature-controlled pad to 
maintain physiological temperature. To avoid breathing problems, rats were placed 
on a slanted board (30° from the vertical). Rats were divided into different groups 
and treated with PBS (50 µL, SHAM group) or NCL T80_10 DP (10, 30 and 100 
µg/50 µL/rat). All the solutions were intra-tracheally administered by a 
MicroSprayer® (model IA-1B, PennCentury, USA). The cannula of the tracheal 
dispositive was inserted directly into the trachea through the mouth.
30
 Twenty-four 
hours after in vivo administration, the rats were anesthetized by urethane (25% i.p; 
10 ml/kg), and after euthanization, bronchoalveolar lavage (BAL) and the lungs 
were obtained for cell counts, BAL fluid (BALF) protein evaluation and western 
blot analysis.  
2.2.9.2 Cell count in bronchoalveolar lavage 
The trachea was cannulated with a polyethylene tube (1 mm inner diameter) to 
perform BAL as previously reported
30
. Briefly, the lungs were sequentially washed 
by flushing with 4 mL of sterile, ice-cold PBS three times for each animal. The first 
PBS recovery was immediately placed on ice and then centrifuged at 500 g for 10 
min at 4°C. The resulting cell pellets (BALC) were pooled with the other two and 
re-suspended in 1 mL of PBS. BALC suspensions (100 µL) were stained with Turk 
solution (0.1% w/v crystal violet in 3% v/v glacial acetic acid) causing hemolysis of 
the red blood cells and staining of the nuclei of white blood cells. Neutrophil and 
macrophage cell count was determined microscopically using a Neubauer 
hemacytometer chamber, according to standard morphology criteria. The first BALF 
recovered after centrifugation was stored and used for total protein evaluation. The 
total volume of BALF recovered from each animal was also evaluated.  
Inhalable niclosamide nanosuspensions Chapter 2 
 
80 
 
2.2.9.3 Protein evaluation in BALF 
Total protein concentration in BALF was determined by Bio-Rad Protein assay and 
calculated against a calibration curve of bovine serum albumin (BSA) (0.05-0.5 
mg/mL) (Sigma-Aldrich, USA). Briefly, 10 µL of each standard and sample solution 
plus 200 µL of Dye Reagent (1:4) were dispensed into a single well using a 96-well 
plate. The optical absorbance of the solution at 595 nm was measured.  
2.2.9.4 Lung Western blot analysis 
Western blots were performed as previously described
31
. Briefly, frozen lung was 
homogenized in modified RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM EDTA, 1% Igepal, 
1× inhibitor) (Roche Applied Science, Italy) and protease inhibitor cocktail (Sigma-
Aldrich, USA). Protein concentration was determined by the Bradford assay using 
BSA as a standard (Sigma-Aldrich, USA). Denatured proteins (50 µg) were 
separated on 10% sodium dodecyl sulfate polyacrylamide gels and transferred to a 
polyvinylidene fluoride membrane. The membranes were blocked by incubation in 
PBS containing 0.1% v/v Tween 20 and 5% non-fat dried milk for 1 h at room 
temperature and then incubated overnight at 4°C with mouse monoclonal antibody 
for cyclooxygenase-2 (COX-2, 1:2000; BD Bioscience, Erembodegem, Belgium) or 
rabbit polyclonal antibody for inducible nitric oxide synthase (iNOS, 1:500; Novus 
Biologicals Europe, Cambridge, UK). Membranes were extensively washed in PBS 
containing 0.1% v/v Tween-20 prior to incubation with horseradish peroxidase-
conjugated secondary antibody for 2 h at room temperature. Following incubation, 
membranes were washed and developed using an ImageQuant-400 (GE Healthcare, 
USA). The target protein band intensity was normalized over the intensity of the 
housekeeping GADPH (1:5000, Sigma-Aldrich, Milan, Italy). 
2.2.9.5 Statistical analysis 
The significance of differences was determined with the software GraphPad InStat, 
using One-Way Analysis of Variance (ANOVA) followed by the Tukey-Kramer 
multiple comparison test. In vivo data were analyzed by One-Way ANOVA 
followed by Bonferroni post hoc test. A p value <0.05 was considered significant. 
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2.3. RESULTS 
2.3.1. Development of niclosamide nanosuspensions 
Formulation development studies were carried out to select the most appropriate 
stabilizer and homogenization parameters for nanosuspensions. Two different 
surfactants, polysorbate 20 and polysorbate 80, were chosen as stabilizers and used 
at different ratios by weight to NCL (Table 1). In each case, NCL raw material was 
micronized through a colloid mill (Micro NCL) before dispersion in polysorbate to 
prevent blocking of the homogenizer gap during HPH. After 2 cycles of milling for 
10 minutes, the mean volume diameter of Micro NCL powders was 8.78 ± 0.92 µm. 
The particle size distribution after a different number of homogenization cycles was 
evaluated by laser light scattering, and volume diameter values (i.e., d10, d50 and d90) 
decreased significantly with increasing HPH cycle. (Fig. 2.1).  
 
Figure 2.1. Effect of the number of homogenization cycles (0, 10, 15, 20) on the size 
distribution of NCL nanosuspensions. 
As apparent from the error bars, highly variable values were achieved just upon 
dispersion of Micro NCL in polysorbate aqueous solution. On the contrary, a fine 
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and stable nanosuspension that was unaltered in terms of size, PI and zeta potential 
upon dilution in isotonic saline was obtained after 20 cycles of HPH (Fig. 2.2).  
 
Figure 2.2. Visual appearance of (A) dispersion of micronized NCL in polysorbate 80; (B) 
T80_10 nanosuspension; (C) T80_10 nanosuspension upon 1:20 dilution in isotonic saline. 
No significant differences were observed in the values of d10, d50 and d90, which fell 
within the range of 0.5-3.0 µm (Table 2.2).  
Table 2.2. Overall properties of NCL nanosuspensions. 
 
Volume diameter*  
(m ± SD) HD** 
(nm ± SD) 
Polydispersity 
index  
(PI ± SD) 
-
potential 
(mV ± 
SD) 
NCL 
content 
(g/mL ± 
SD) d10 d50 d90 
T80_10 
0.490 
±0.038 
0.951 
±0.292 
2.835 
±0.958 
417.8  
± 66.4 
0.360  
± 0.054 
-23.1  
± 6.08 
10.2 
± 0.17 
T80_20 
0.514 
±0.051 
1.058 
±0.303 
3.059 
±1.241 
427.8  
± 27.2 
0.337  
± 0.041 
-22.8 
± 3.60 
18.4 
± 0.068 
T20_10 
0.482 
±0.031 
0.920 
±0.246 
2.760 
±0.918 
483.2  
± 57.9 
0.367  
± 0.031 
-19.2 
± 2.60 
4.53 
± 0.11 
T20_20 
0.486 
±0.051 
0.914 
±0.343 
2.652 
±1.103 
428.2  
± 75.7 
0.346  
± 0.065 
-20.4 
± 2.50 
7.03 
± 0.051 
*Volume diameter as determined by laser light scattering. 
**Hydrodynamic diameter evaluated by PCS analysis. 
 
Bulk analysis of the particle morphology performed through SEM revealed 
significant differences in the morphologies of the raw material, Micro NCL and 
NCL nanosuspensions (Fig. 2.3). The raw NCL sample comprised coarse and large 
particles with a limited amount of needle-like NCL crystals. The size of NCL raw 
material was reduced after colloid milling (Micro NCL in Fig. 2.3), although the 
sample appeared to still contain differently sized and shaped particles. A 
Inhalable niclosamide nanosuspensions Chapter 2 
 
83 
 
homogeneous population of needle-like particles was observed in the case of 
polysorbate-stabilized NCL nanosuspensions with some aggregates in the case of 
T20_10 and T20_20. 
 
Figure 2.3. SEM images of NCL nanosuspensions just after production (magnification 
8000/15000x). SEM micrographs of raw and milled NCL at 850x magnification are reported 
for comparison. Field is representative of the sample. 
Complementary TEM analysis were performed on 10 l of nanosuspensions, which 
were applied to a carbon-coated copper grid, air dried and stained with 
phosphotungstic acid (2%, w/v). As can be seen in Fig. 2.4, all formulations showed 
typical needle-shape nanocrystals and no surfactant-based micelles were apparent in 
the background. 
Raw NCL Micro NCL
T80_10 T80_20
T20_10 T20_20
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Figure 
2.4. TEM photographs of NCL nanosuspensions just after production. Field is representative 
of the sample. 
The mean HD, PI and -potential of the nanocrystals are reported in Table 2.2. As 
determined by PCS analysis, HD was always approximately 450 nm with an 
approximate PI value of 0.35, which may help the diffusion of the nanosized NCL 
through the network of bundled fibers with 100-1000 nm meshes characteristic of 
CF sputum
16
. On the other hand, a negative -potential around -20 mV was achieved 
in each case, which may promote electrostatic repulsions between the particles and 
negatively charged airway mucus and/or biofilm bacteria in the lung.
16
 
The dissolution profiles of NCL formulations in SILF are reported in Fig. 2.5. 
Figure 2.5. In vitro dissolution profile of NCL nanosuspensions in SILF at 37°C. The 
dissolution profile of NCL after colloid milling (Micro NCL) is reported for comparison. 
 
Micro NCL exhibited the lowest dissolution rate and an incomplete dissolution 
profile, with only 50% of NCL dissolved in 24 hours. The same percent amount was 
dissolved from NCL nanosuspensions after only 5 hours, with T80_10 and T80_20 
allowing the dissolution of almost 100% of the initial NCL amount in 24 hours. 
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2.3.2. Stability of nanosuspensions upon storage 
Nanosuspensions were stored at room temperature and 4°C for the stability over 
time studies (Fig. 2.6). 
 
Figure 2.6. Physical stability of NCL nanosuspensions at room temperature (25 ± 2°C) and 
4°C over time: (A) Percent increase of hydrodynamic diameter; (B) percent decrease of NCL 
content in supernatant; (C) SEM images of NCL nanosuspensions after storage for 30 days at 
room temperature; (D) SEM images of NCL nanosuspensions after storage for 90 days at 4 °C 
(field is representative of the sample). 
In each case, a 25% increase in the particle hydrodynamic diameter compared to the 
original value was observed after 1 month of storage at room temperature (Fig. 
2.6A). Apart from the T80_10 and T20_20 formulations, the increase in size was not 
always related to an increase of the PI value (Fig. 2.7) 
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.  
Figure 2.7. PI values of NCL nanosuspensions upon storage at room temperature (25 ± 2°C) 
and 4°. 
Nevertheless, the occurrence of nanocrystal aggregation upon storage at room 
temperature was evident from SEM analysis of T80_20 and T20_10 formulations 
(Fig. 2.6C). Upon storage at 4°C for 1 month, a 13-14% increase of size was 
observed for T80_10 and T20_10 formulations, whereas it was slightly higher for 
T80_20 (22.6%) and T20_20 (16.2%) nanosuspensions (Fig. 2.6A). The size of 
nanocrystals was less stable after 3 months of storage (Fig. 2.6A), and a great 
increase in nanocrystal length was evident from SEM analysis of the stored samples 
(Fig. 2.6A). Again, the variations in particle size were not related to a variation in 
the PI value, which was almost constant at 4°C for up to 3 months (Fig. 2.7). 
Nevertheless, a progressive decrease in the amount of solubilized NCL was 
observed up to 1 month, both at 25°C and 4°C (Fig. 2.6B). 
2.3.3. Development of nanocrystal-embedded dry powders  
To improve the long-term stability of the optimized T80_10 nanosuspension, 
nanocrystal-embedded dry powders were produced through either lyophilization or 
spray drying using mannitol as a stabilizer. When the nanocrystals underwent the 
lyophilization process, massive particle aggregation was observed, independently of 
the freezing procedure or the presence of mannitol as a cryoprotectant (Fig. 2.8). 
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Figure 2.8. SEM photographs of T80_10 nanosuspensions upon freeze-drying without 
cryoprotectant at different magnifications. Field is representative of the sample. 
 
To overcome this issue, dry powders containing different amounts of mannitol were 
produced by spray drying. The RDI of the spray-dried powder was decreased by 
increasing the amount of stabilizer in the nanosuspension up to a minimum value of 
1.35 when the NCL/mannitol ratio by weight was 1:10. At this NCL/mannitol ratio, 
a homogeneous population of mannitol-based spherical particles, named T80_10 
DP, was achieved (Fig.2.9). 
 
Figure 2.9. Nanocrystal-embedded dry powders produced by spray drying: A) RDI of spray-
dried powders prepared at different NCL/mannitol ratios by weight (optimal value at 1:10 
w/w); B) SEM images of optimized powders (T80_10 DP) at different magnifications (fields 
are representative of the sample). 
The presence of some NCL nanocrystals on the particle surface was evident by SEM 
and confirmed by DSC studies (Fig. 2.10). 
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Figure 2.10. DSC thermograms and corresponding values of NCL melting temperature (Tm) 
and heat of fusion (Hf): A) raw NCL; B) T80_10 DP. Thermograms of mannitol (C) and 
mannitol/raw NCL physical mixture (D) are reported as control.  
 
DSC thermograms of raw NCL displayed a dehydration endothermic peak at 
approximately 100°C and a sharp endothermic melting peak at approximately 
230°C, typical of the NCL monohydrate crystal forms
32
. The corresponding Hf was 
153 ± 2 J/g. T80_10 DP exhibited two endothermic peaks at 168°C and 224°C, 
ascribable to the melting of mannitol and NCL crystals, respectively, in the T80_10 
DP powders. Upon peak integration, Hf  associated to NCL melting was 7.3 ± 0.1 
J/g, a value comparable to that calculated from the simple physical mixture of 
mannitol and NCL at the same ratio by weight (i.e., 8.3± 0.2 J/g). In both cases, a 
shift of the endothermic peak to a lower value (from 230°C to 224°C) and a 
corresponding reduction of Hf  was observed compared to the NCL raw material, 
indicating a partial interaction with mannitol and consequent amorphization of NCL. 
Results of in vitro release studies of NCL performed by membrane dialysis from 
simulated CF mucus to SILF are reported in Figure 2.10 as the percentage of NCL 
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diffused over time. No pronounced difference in the percentage of NCL diffused 
after 8 h was observed between T80_10 DP (58.1 ± 6.5%) and T80_10 (63.3 ± 
8.0%). In contrast, the diffusion rate of Micro NCL slowed down significantly, and 
after 8 h, only 22.9 ± 1.3% of the amount of NCL initially dispersed in mucus was 
found in the external medium. 
 
Figure 2.10. In vitro release profile of NCL from T80_10 and T80_10 DP from artificial CF 
mucus to SILF at 37°C. Data are presented as mean ± standard deviation (n=3). 
2.3.4 In vitro aerosol performance of optimized formulations 
In vitro aerosol performance of the T80_10 nanosuspension before and after spray 
drying (T80_10 DP) was assessed through NGI. According to the new regulatory 
guidelines, both USP and Ph.Eur. recognize the suitability of the NGI for nebulizer 
characterization when used at 15 L/min, excluding the pre-separator and placing an 
internal filter below the MOC
26
. 
In this configuration, the seven NGI stages produce cutoff diameters in the range of 
14.1-0.98 m, while the last five stages have cutoff diameters between 5.39 and 0.98 
m. Figure 2.11A and Figure 2.12A describe the cumulative droplet size distribution 
of the emitted dose of T80_10 nanosuspension and T80_10 DP after reconstitution 
in saline, respectively, from PARI TurboBOY®, eFlow®rapid and Aeroneb® Go.  
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Figure 2.11. In vitro aerosol performance of T80_10 nanosuspensions: A. Cumulative mass recovered as 
a function of the cut-off diameter; B. NGI deposition pattern. The formulation was delivered through 
PARI TurboBOY® (PARI GmbH, Germany), eFlow® rapid (PARI GmbH, Germany) and Aeroneb® Go 
(Aerogen, Ireland) nebulizers. Data are presented as mean ± standard deviation (n=3). 
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Figure 2.12. In vitro aerosol performance of T80_10 DP dry powders for inhalation suspension: A. 
Cumulative mass recovered as a function of the cut-off diameter; B. NGI deposition pattern. The 
formulation was delivered through PARI TurboBOY® (PARI GmbH, Germany), eFlow® rapid (PARI 
GmbH, Germany) and Aeroneb® Go (Aerogen, Ireland) after reconstitution in an appropriate amount of 
isotonic saline. Data are presented as mean ± standard deviation (n=3). 
In each case, the best fit line was from logarithmic linear regression (r
2
 = 0.96). The 
calculated values of MMAD are reported in Table 2.3. T80_10 showed an 
experimental MMAD of approximately 3 m, independent of the nebulizer 
employed, whereas an increase of MMAD up to 5 m was observed for the T80_10 
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DP dry powder for inhalation solution upon delivery from the eFlow® rapid system. 
Of note, the GSD of the lognormal distribution was always higher than 1 with values 
falling within the range of 2.34-2.68 and 2.18-2.49 for T80_10 and T80_10 DP, 
respectively (Table 2.3). 
Table 2.3. Fine particle characteristics of the aerosol clouds generated upon delivery of 
T80_10 liquid nanosuspension and T80_10 DP powder for inhalation solution through 
different nebulizer systems. 
 
PARI® TurboBOY™ Aeroneb® Pro eFlow® rapid 
T80_10 T80_10 DP T80_10 T80_10 DP T80_10 T80_10 DP 
MMAD 
(m ± SD) 
2.64 ± 0.20 3.01 ± 0.18 3.22 ± 0.19 2.98 ± 0.26 3.17 ± 0.12 5.05 ± 0.40 
GSD 
(± SD) 2.68 ± 0.22 2.49 ± 0.074 2.41 ± 0.030 2.35 ± 0.020 2.34 ± 0.094 2.18 ± 0.012 
FPF* 
(% ±SD) 
49.0 ± 7.1 27.5 ± 3.9 53.6 ± 0.81 37.4 ± 1.5 30.1 ± 7.8 24.2 ± 2.7 
RF* 
(% ±SD) 
76.1 ± 4.7 74.8 ± 3.6 73.6 ± 9.0 79.8 ± 5.4 79.2 ± 9.0 79.3 ± 3.1 
*FPF was calculated on the nominal NCL dose, whereas the RF refers to the emitted dose of NCL. 
 
The deposition pattern of NCL throughout the NGI cups upon nebulization of 
T80_10 formulations showed a peak at 3.3 µm with 25-35% of the emitted dose 
recovered from Cup 4 independent of the nebulizer system (Figure 2.11B). In each 
case, less than 2.5% of the emitted NCL dose was deposited in the throat. Of note, 
55-60% of the particles were < 3.3 µm, and 75-80% of the particles were < 5.39 µm. 
Again, no significant difference in the deposition pattern was observed when 
T80_10 DP dry powder for inhalation solution was nebulized (Figure 2.11B). When 
calculated on the actual amount of NCL deposited on NGI cups with a cut-off 
diameter of less than 5.39 m (cups 3-7), FPF values of T80_10 nanosuspensions 
ranged from 30.1 to 53.6% (Table 2.3). The lowest value was achieved upon particle 
aerosolization through the eFlow® rapid system, whereas similar FPF (≈50%) were 
calculated for PARI TurboBOY® and Aeroneb® Go. In each case, the FPF values 
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decreased for T80_10 DP compared to the T80_10 fresh nanosuspension with a 
maximum value of 37.4% when using the Aeroneb® Go device. The differences in 
the FPF values were reflected by a different percent of NCL remaining inside the 
device chamber upon aerosolization. The amount of NCL remaining inside the 
nebulizer upon delivery through the NGI was quantitatively recovered and 
determined by dissolution in 2 ml of methanol (Figure 2.13). 
 
Figure 2.13. Amount of NCL remaining inside the nebulizer upon delivery through the NGI. 
Data are presented as percent of NCL total amount loaded inside nebulizer chamber ± 
standard deviation (n=3). 
2.3.5 QS inhibitory activity in Pseudomonas aeruginosa 
The ability of the NCL formulations T80_10 and T80_10 DP and of the NCL raw 
powder dissolved in DMSO to inhibit 3OC12-HSL-dependent QS in P. aeruginosa 
was compared by using the whole cell biosensor PA14-R3. This biosensor is a P. 
aeruginosa engineered strain that emits bioluminescence in response to 3OC12-HSL-
dependent QS signaling
27
. A preliminary control experiment was carried out in order 
to test the effect of increasing concentrations of DMSO, T80 and T80 plus mannitol 
on the PA14-R3 response. The results showed that PA14-R3 bioluminescence 
emission was not affected by these substances at the concentrations used in our 
experimental setting (data not shown).  
In accordance with previous studies
13
, 1.25 µM NCL in DMSO was able to inhibit 
the biosensor response at approximately 60% with respect to the untreated control. 
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Interestingly, the QS inhibitory effect of the NCL formulated as T80_10 was 
comparable to that of NCL at any concentration tested. However, the NCL 
formulated as T80_10 DP was less active than the other NCL formulations, showing 
inhibitory activity similar to T80_10, and unformulated NCL showed inhibitory 
activity at concentrations in the range of 2.5 - 10 µM (Fig. 2.14).  
 
Figure 2.14. QS inhibitory activity of NCL formulations. The NCL-dependent inhibition of 
the P. aeruginosa QS response was measured as inhibition of luminescence emission by the 
PA14-R3 biosensor. Black bars, NCL in DMSO; dark grey bars, T80_10; light grey bars, 
T80_10 DP. Bioluminescence was normalized to the cell density of the bacterial culture 
(relative bioluminescence, LCPS/A600) and expressed as a percentage relative to controls 
(indicated as C), corresponding to DMSO for the raw powder, T80for T80_10, and T80 plus 
mannitol for T80_10 DP at the same concentrations as in the samples containing 10 µM NCL. 
Values are the mean (± standard deviation) of three independent experiments. Asterisks 
indicate statistically significant differences (p< 0.01; ANOVA) with respect to the 
corresponding controls. 
2.3.6 Cytotoxicity to CF bronchial epithelial cells 
The cytotoxicity of the different NCL formulations against a CF bronchial epithelial 
cell line (CFBE41o) was assessed using the MTT assay. As shown in Figure 10, 
NCL did not significantly affect cell viability at any concentration tested (1-1000 
µM), although slight toxicity was observed at 1000 µM. However, the reduction in 
cell viability was comparable to that obtained for the corresponding control (5% 
DMSO), thus hampering the evaluation of NCL cytotoxicity at very high 
concentrations. On the other hand, NCL nanosuspensions showed significant 
reductions of CFBE41o viability at concentrations corresponding to 100 µM 
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(T80_10) and 1000 µM NCL (both formulations), while the corresponding controls 
did not cause significant toxicity (Fig. 2.15).  
 
Figure 2.15. Cytotoxicity of NCL formulations to CFBE cells. Cell viability was assessed 
after 3-h incubation in the presence of NCL dissolved in DMSO, T80_10 or T80_10 DP at 1, 
10, 100 or 1000 µM NCL concentrations (grey histograms) or their relative vehicles at the 
corresponding concentrations (black histograms; only the highest and lowest concentrations 
of each vehicle are indicated in the figure). Results are expressed as percentage of cell 
viability with respect to untreated controls (100%). Data are the mean ± standard deviation of 
3 experiments performed in duplicate. Asterisks indicate statistically significant reduction in 
cell viability with respect to untreated controls (*, p< 0.05; **, p< 0.01; ***, p< 0.001) . 
Abbreviations: T80, Tween 80; MAN, mannitol. 
 
Of note, the toxic concentration at 50% (TC50) was only reached for T80_10DP 
(corresponding to 600 µM; data not shown), suggesting that the overall toxicity of 
NCL is quite low. Moreover, this assay clearly demonstrated that, at 
microbiologically-active concentrations (≤ 10 µM, see Fig. 2.14), NCL and its 
formulations do not significantly affect the viability of CF bronchial epithelial cells 
in vitro. 
2.3.7 Lung acute toxicity in rats 
Acute toxicity and pulmonary injury in rats at 24 h after intra-tracheal administration 
of NCL T80_10 DP were evaluated. To this end, the cellular infiltrate into rat 
airways after treatment was investigated. There was no significant difference in the 
volume of BALF recovered from each animal and within each treated group (data 
not shown). In addition, lung accumulation of macrophages (A) and neutrophils (B) 
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are reported in Figure 11. Of note, NCL doses of 10 and 30 µg/rat contained in 
T80_10DP did not cause differences in lung accumulation of both cells when 
compared to sham operated animals. On the other hand, a significant increase of cell 
number at 24 h (p<0.001) was observed with the NCL dose of 100 µg/rat compared 
to sham group (Fig. 2.16A and B). Total protein amount measured in each BALF, 
evaluated as an index of lung damage, revealed no significant differences in the 
samples from rats treated with the formulation at the equivalent NCL dose of 100 
g/rat (Fig. 2.17 A). To evaluate tissue injury and toxicity of NCL-loaded T80_10 
DP, we also measured iNOS and COX-2 enzyme expression in lung homogenates at 
24 h; these are considered to be markers of the inflammatory process. No iNOS 
expression was observed in lung homogenates from all animals of each group (data 
not shown). As reported in Fig. 2.17 (panel B), no significant difference was 
observed in COX-2 protein expression 24 h after treatment at all doses used. 
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Figure 
2.16. A. Macrophage in BAL 24 h after treatments. Sham (PBS 50 µL) and NCL T80_10 DP 
(10, 30 or 100 µg/50 µL/rat). B. Neutrophils in BAL 24 h after treatments. Sham (PBS 50 µL) 
and NCL T80_10 DP (10, 30 or 100 µg/50 µL/rat). The results are expressed as mean ± 
S.E.M. (n = 4 rats per group at each dose). **p< 0.01 and ***p< 0.001 versus SHAM/PBS 
group. 
 
 
Figure 2.17. (A) Protein evaluation in BALF 24 h after treatment with PBS (50 μL) or NCL 
T80_10 DP (10, 30, or 100 μg/50 μL/rat). (B) COX-2 Western blot analysis reported as 
optical densitometric (O.D.) evaluation in lung homogenate 24 h after treatment with PBS (50 
μL) or NCL T80_10 DP (10, 30, or 100 μg/50 μL/rat). Densitometric data are normalized to 
GAPDH and expressed as the mean ± standard error of the mean of three experiments. 
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2.4. DISCUSSION 
Repurposing commercially available drugs for new therapeutic applications is an 
approach that has been used frequently in recent years. Approximately one out of 
four drugs/biologics that were approved in 2014 consisted of new formulations, new 
combinations or new therapeutic applications of existing drugs.
35
 Nevertheless, the 
success of drug repositioning depends not only on the existing knowledge but also 
on available information from specific drug- and disease-oriented studies allowing 
for the selection and determination of the most appropriate repurposing 
approach.
33,34
 Along these lines, in this work, nanocrystal-embedded dry powders 
generated into inhalable nanosuspensions by dilution in saline are proposed for 
repositioning of the poorly soluble anthelmintic drug NCL as an inhaled anti-
virulence agent against P. aeruginosa, the dominant pathogen in the airways of CF 
patients.  
NCL nanocrystals were produced through high-pressure homogenization, an 
industrially scalable process. To formulate NCL nanosuspensions for lung delivery, 
polysorbate 20 and polysorbate 80, two excipients already employed in marketed 
inhaled drugs
36
, were chosen as stabilizers of the dispersion and tested at different 
concentrations. Preliminary technological studies were crucial to assess optimal 
HPH processing parameters, with particular regard to the number of homogenization 
cycles required to achieve consistent nanocrystal size distributions, a key parameter 
that drives the performance of nanosuspensions.
20
 In accordance with the Noyes-
Whitney theory, the greater surface to volume ratio of NCL nanocrystals compared 
to the micronized material is expected to increase the dissolution rate of the active 
ingredient by raising its saturation solubility and dissolution rate.
19
 In fact, the 
dissolution profile of NCL in simulated lung fluids was strongly influenced by 
nanosizing with T80_10 nanosuspensions showing a significantly increased 
dissolution velocity compared to micronized NCL.  
Because nanosizing results in the creation of new interfaces and in a positive Gibbs 
free energy change, nanosuspensions are also thermodynamically unstable systems 
with a tendency toward crystal growth or agglomeration.
37
 Particle size growth is 
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largely responsible for agglomeration, and this was particularly evident upon storage 
of the nanosuspensions at 25°C. Since lower levels of nanoparticles agglomeration 
are expected upon decreasing the temperature (i.e., lower kinetic energy) of the 
system
37
, suspension stability was expected to be improved at lower temperatures; 
however, aggregation and nanocrystal growth was observed after 3 months of 
storage at 4°C. Many reports have indicated that an increase in the intrinsic 
solubility of a drug mediated by a surfactant, including polysorbate 80, would lead 
to Ostwald ripening, when small crystals dissolve and redeposit onto larger 
crystals.
37
 This effect typically results in an increase in the length of needle-shaped 
nanocrystals achieved by HPH during storage. On the other hand, a solution-
mediated transformation of NCL nanocrystals upon exposure to water, with 
consequent transformation to round needles typical of NCL monohydrate, could not 
be excluded on the basis of DSC analysis
32,38
. Of note, this phenomenon is regarded 
as the greatest challenge in formulating physically stable and pharmaceutically 
acceptable NCL suspensions, since it generates a cement-like sediment during 
storage.
32,39
 
In light of the observed suspension instability, NCL nanosuspensions were further 
processed to achieve a dry powder with long-term stability that could be 
reconstituted before use. The attention was focused on the T80_10 formulation, 
which not only showed the best solubility profile but also a lower amount of 
surfactant compared to T80_20. In principle, a nanosuspension can be processed 
into a solid dosage form using a well-established unit operation, such as freeze 
drying.
40
 Nevertheless, polysorbate 80 is a liquid at room temperature, and therefore, 
nanocrystal adhesion and aggregation is very likely during drying
41
 and could not be 
prevented using mannitol. As a viable alternative, nanocrystal-embedded dry 
powders were produced by spray drying in mannitol. This can be regarded as a 
“multifunctional” excipient, since it may prevent particle agglomeration in the dried 
state
42
, improve the solubility profile of drug nanocrystals
43
 and loosen CF mucus
44
, 
potentially enhancing drug penetration.
45
 Indeed, release data highlighted how NCL 
dissolution may be strongly reduced in a mucin-rich environment that more closely 
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resembles in vivo conditions, while the formulation facilitated diffusion of NCL 
through artificial CF mucus. 
In each case, the aerodynamic assessment of fine particles upon delivery from 
several nebulizers that are among the most widely employed in clinical practice 
confirmed that the developed formulation has a great potential to improve the lung 
deposition of NCL. Higher FPF and lower MMAD values were achieved compared 
to commercial liquid suspensions for inhalation tested in similar conditions.
23
 The 
best performances were achieved with the PARI
® TurboBOY™, a conventional 
system relying on a compressor combined with a jet nebulizer, and the Aeroneb® 
Pro, which is a VMT nebulizer. As recently reported for inhalable itraconazole 
nanosuspensions
46
, the ParieFlow® Rapid vibrating mesh nebulizer maybe less 
suited for nanosuspension aerosolization because higher amounts of residual dose 
within the nebulizer reservoir were observed for this device compared to the other 
devices tested. This is a well-established limitation of some VMT-based nebulizer 
systems, which may be overcome by modifying the priming dose of medication 
used.
24
 
Assuming that the inhaled formulation successfully lands in the lung and cross the 
extracellular barriers, NCL has still to inhibit the 3OC12-HSL-dependent QS 
signaling system of P. aeruginosa to be effective. Our results demonstrate that the 
QS inhibitory activity of NCL formulated as T80_10 or T80_10 DPis was equivalent 
to that of the unformulated NCL pre-dissolved in DMSO. NCL formulations showed 
maximum anti-QS activity at NCL concentrations ≥ 5 µM, corresponding to ca. 80% 
inhibition of the P. aeruginosa QS response, although significant effects were also 
observed at 1-2.5 µM concentrations. These concentrations are 40-400-fold lower 
than the NCL concentrations that show toxicity to CF bronchial epithelial cells, 
suggesting that there is a wide therapeutic range that can be explored for 
repurposing NCL as an anti-P. aeruginosa drug in CF therapy. Notably, it has 
recently been shown that NCL also displays promising anticancer activities, and the 
potential of this drug as an anticancer agent has been demonstrated in several animal 
models (reviewed in
47
) Reports suggest that NCL had no significant toxicity to non-
tumor cells in vitro and no obvious side effects in NCL-treated mice.
47
 Moreover, 
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toxicity studies in different mammalian models suggested that NCL has no 
mutagenic, oncogenic or embryotoxic activity, even after long-term treatment 
(reviewed in
48
). In the present study, in vivo toxicity studies in rodents support the 
safety of NCL upon local pulmonary administration because no toxicity was 
observed after intratracheal administration of a single dose of 30 µg, roughly 100 
times the maximum concentration that showed in vitro anti-QS activity. Local 
toxicity/inflammatory activity, such as lung accumulation of 
macrophages/neutrophils not related to COX-2 and iNOS expression, was observed 
only after intratracheal administration of a single dose of 100 µg of NCL, which is 
approximately 400-fold higher than the anti-QS activity concentrations. 
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2.5. CONCLUSION 
In this work, NCL nanocrystals formulated as a dry powder for reconstitution using 
excipients approved for lung delivery in order to be delivered as a nebulized aerosol 
from a liquid dispersion were successfully produced through a 2-step process 
involving industrially scalable techniques (i.e., high-pressure homogenization and 
spray drying). The use of appropriate surfactant types and concentrations allowed 
the production of nanocrystals with suitable properties for pulmonary delivery. NCL 
nanoparticles were successfully spray dried and suspended in a solution containing 
mannitol. NCL nanosuspensions, prepared from reconstitutions of spray-dried 
particles in saline solution, were effectively delivered through nebulizers commonly 
used to deliver antibiotics to CF patients. The ability of nanosuspensions to inhibit 
P. aeruginosa QS at NCL concentrations that do not significantly affect the viability 
of CF bronchial epithelial cells was demonstrated in vitro. Finally, in vivo data 
confirmed the absence of acute toxicity effects of NCL nanosuspensions at the 
proposed therapeutic doses. 
Overall, the presented experimental evidence provides the rationale for further 
development of NCL, an anti-virulence drug, as an alternative CF therapy and 
prompts the investigation of the anti-P. aeruginosa activity of the inhalable NCL 
formulations here developed in animal models of pulmonary infection. Repurposing 
a known drug, such as NCL, for inhalation to treat lung infections in CF patients 
may also result in considerable reduction in the cost of product development 
compared to developing new chemical entities. 
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ABSTRACT 
Flucytosine (5-fluorocytosine, 5-FC) is a fluorinated analogue of cytosine that is 
currently approved for the treatment of fungal infections and has been recently 
showed a very promising anti-virulence activity against Pseudomonas aeruginosa. 
In this work, we propose novel inhalable hyaluronic acid (HA)/mannitol composite 
dry powders for repositioning of 5-FC in the local treatment of CF lung infections. 
Dry powders were produced in one step by spray-drying. Formulation composition 
and process conditions were selected after in depth development studies aimed to 
achieve HA/mannitol particles loaded with 5-FC characterized by optimal properties 
for aerosolization and a convenient release profile in simulated lung fluids. The 
developed microparticles were effectively delivered from breath-activated dry 
powder inhalers (DPI) already available to CF patients, although the aerodynamic 
assessment of fine particles suggested that they well fit to a low-resistance DPI. The 
ability of optimised formulations to inhibit the growth of Candida Albicans and 
pyoverdine production in Pseudomonas aeruginosa at 5-FC concentrations (≥ 3.9 
µM and ≥ 1.2 µM, respectively) that do not affect the viability of bronchial 
epithelial cells, both normal and CF, was demonstrated in vitro. Finally, a 
pharmacokinetic comparison between the dry powder formulation here developed 
and 5-FC in solution after intra-tracheal delivery in rats was performed. In vivo 
results clearly demonstrated that, when formulated as HA/mannitol dry powders, 5-
FC is able to reach a significant concentration in both broncoalveolar fluid and lung 
tissue and it can be sustained over time as compared to 5-FC solution. Taken all 
together, our data demonstrate for the first time the feasibility to develop effective 5-
FC formulations for pulmonary delivery. Furthermore, results highlight that it is 
possible, by an appropriate formulation design, to modify the biodistribution of the 
drug at lung, where microorganisms, causing severe local infections and worsening 
the pathological status of the CF pulmonary disease, are located.  
Inhalable flucytosine dry powders Chapter 3 
 
110 
 
3.1. INTRODUCTION 
Flucytosine (5-fluorocytosine, 5-FC) is a fluorinated analogue of cytosine that is 
currently used for the treatment of fungal infections caused by Candida and 
Cryptococcus, mainly in combination with other antimycotic agents.
1
 Recently, a 
drug repurposing approach revealed that 5-FC is also able to reduce the virulence of 
the bacterium Pseudomonas aeruginosa
2
, one of the most dreaded opportunistic 
pathogens in hospitals and the main cause of chronic lung infection and mortality in 
individuals with cystic fibrosis (CF)
3
. Systemic administration of 5-FC almost 
completely prevented P. aeruginosa lethality in a mouse model of pulmonary 
infection
2
, highlighting the potential of this drug for antivirulence therapy of P. 
aeruginosa CF lung infections. On the other hand, although the prevalence and 
importance of fungi in the CF lung is still unclear, recent evidences suggest that 
chronic respiratory colonization of Candida albicans may be associated with 
worsening of CF lung disease.
4
  
Pulmonary administration represents an ideal way to locally treat lung infections and 
recent technological advances have fostered the development of inhaled CF 
antimicrobial therapies.
5,6
 In particular, novel particle engineering techniques, make 
portable and easily handled dry powder inhalers (DPIs) very appealing for drug 
inhalation in CF as demonstrated by recent approval of tobramycin and colistin 
DPIs.
7-9
 Nevertheless, the clinical outcomes strongly depend on the concentration 
and persistency of the drug at the lung target. The maximum therapeutic effect is 
achieved when the drug adequately deposits along the airways, remains in situ as 
long as possible and is able to overcome non-cellular (i.e., mucus, biofilm) and 
cellular (i.e., lung epithelia, bacteria) barriers imposed by CF lung.
10
 Thus, in order 
to translate the systemic treatment to an efficient inhalable administration approach 
in vivo, the old medication needs to be re-formulated taking into account its physico-
chemical properties and the peculiarities of CF patients.
10,11
  
Generating inhalable particles by spray-drying offers several advantages, the first of 
which relies in the possibility to produce dry powders of drug and carrier excipients 
in a one-step continuous particle processing operation.
12,13
 Furthermore, it is 
possible to select adequate process conditions so as to achieve particles with optimal 
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properties for aerosolization.
13-15
 Indeed, through the incorporation of selected 
excipients, it is possible to achieve spray-dried powders with enhanced 
dispersibility
15,16
, improved stability upon storage
17
 and modified drug release 
profile.
15
 Furthermore, tuning drug distribution at lung and its pharmacokinetic 
profile upon pulmonary delivery is feasible thorough appropriately engineered 
spray-dried powders.
18-20
 
Among materials currently under investigation for inhalation, an increasing 
knowledge has been acquired on the potential of hyaluronic acid (HA) not only as 
carrier but also as bioactive agent in the treatment of lung diseases.
21,22
 In particular, 
inhaled HA at high molecular weight (~1,000 KDa) has been proven to have anti-
inflammatory activity and to prevent bronchoconstriction induced in asthmatics by 
direct and indirect challenges.
21,22
 Indeed, aerosolized HA is currently employed in 
CF patients to improve tolerability of hypertonic saline.
23,24
 Nevertheless, only 
limited attempts have been made until now to produce HA-based spray-dried 
powders for inhalation.
25-27
 
The aim of this work was the development of HA-based dry powders for lung 
delivery of 5-FC to be used in the local treatment of lung infections. Formulation 
composition and process conditions were selected after in depth development studies 
aimed to achieve HA particles with optimal properties for aerosolization. Optimised 
HA/mannitol microparticles loaded with 5-FC were produced by spray drying and 
characterized for 5-FC release in simulated lung fluids as well as for in vitro 
aerosolization properties upon delivery from DPIs commonly used in CF patients. In 
vitro antifungal and antivirulence properties, as well as toxicity towards human 
bronchial epithelial cells, both normal and CF, were determined. Finally, a 
pharmacokinetic comparison between the dry powder formulation here developed 
and 5-FC in solution after intra-tracheal delivery in rats was performed, highlighting 
the potential of the developed formulation for in vivo delivery of 5-FC at lung..  
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3.2. MATERIALS AND METHODS 
3.2.1. Materials 
5-fluorocytosine (5-FC), hyaluronic acid sodium salt (HA; 0.6-1.1 MDa), egg yolk 
emulsion, RPMI amino acid solution, type II mucin from porcine stomach, gelatin 
from bovin skin type B, rhodamine B, calcium chloride dihydrate, cetyltrimethyl 
ammonium bromide (CTAB), magnesium chloride, potassium chloride, potassium 
phosphate dibasic, sodium acetate, sodium bicarbonate, sodium chloride, sodium 
citrate dihydrate, sodium phosphate dibasic, sodium sulfate, Triton™ X-100 solution 
(10%) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
were obtained from Sigma-Aldrich (Italy). Mannitol (Pearlitol®C160) was a kind 
gift of Roquette Italia S.p.a. (Italy). HPLC grade acetonitrile was supplied by Carlo 
Erba (Italy). Distilled water filtered through 0.22 m cellulose filters (Phenex® RC, 
Phenomenex, USA) was employed throughout the study.  
3.2.2. Hyaluronic acid analysis 
Hyaluronic acid (HA) was quantified by turbidimetric measurement upon 
complexation with CT.
28
 Briefly, 2 mg of HA were accurately weighted, transferred 
into a flask and dissolved under stirring at 37°C for 15 min in 10 ml of acetate buffer 
at pH 6.0 (0.2 M sodium acetate, 0.15 M sodium chloride; adjusted to pH 6.0 by 
acetic acid). This stock solution was stable for at least a week when stored at 4°C. 
Working standard solutions of HA were freshly prepared by further dilution in 
acetate buffer at pH 6.0. One milliliter of working standard solutions of HA was 
added to 2 ml of a 1 g/ml CTAB solution in 2% (w/v) aqueous sodium hydroxide. 
The absorbance of HA samples was measured at 350 nm using a Shimadzu 1204 
spectrophotometer (Shimadzu, Italy) fitted out with a 0.1-cm quartz cell (Hellma® 
Italia, Italy). All measurements were performed in triplicate at room temperature 
against a reagent blank. The linearity of the response was verified over the 
concentration range 4.0–200 g/ml (r2 ≥ 0.99).  
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3.2.3. 5-FC quantitative analysis 
The amount of 5-FC in solution was determined by UV-vis spectrophotometry. 
Briefly, the absorbance (ABS) of 5-FC samples was measured at the maximum 
absorption wavelength (275 or 285 nm) with a Shimadzu 1204 spectrophotometer 
(Shimadzu, Italy) fitted out with a 0.1-cm quartz cell (Hellma® Italia, Italy). 
Calibration curves were obtained by plotting ABS versus the concentration of 5-FC 
standard solutions in the different sample media, that is aqueous formic acid at pH 2 
(1 % v/v), phosphate buffer at pH 7.2 (PBS) and simulated interstitial lung fluids 
(SILF). In each case, the linearity of the response was verified over a concentration 
range of 0.2–20 μg/mL (r2= 0.999). The presence in the samples of interfering 
substances that could affect the UV-vis spectrum of 5-FC was accounted for with 
the appropriate blank. All blank media had negligible absorption at the maximum 5-
FC absorption wavelength. 
3.2.4. Production of microparticles 
Blank HA (Hya) or HA/mannitol (HyaMan) microparticles were produced by spray 
drying. Briefly, HA was dissolved in a water/ethanol mixture (80:20 v/v) at 0.1 or 
0.25 % w/v. When needed, mannitol was added to the mixture at theoretical 
HA:mannitol ratio of 1:1 or 1:2 w/w. Ammonium bicarbonate (AB) at 15 % (w/v) 
was also tested as porogen in blank formulations. Formulations were processed in a 
Mini Spray Dryer BüchiB290 (Flawil, Switzerland) equipped with a high-
performance cyclone for the recovery of small powder amounts. Different 
formulations were individually spray-dried with the following process parameters: 
feed rate 3 ml/min; aspirator setting 20; spray-flow 600 Nl/h; inlet temperature 
110°C (resulting outlet temperature = 75°C). A 0.5 mm nozzle was used throughout 
the experiments. Powders were collected and stored at 4°C until use.  
HA/mannitol microparticles at a 5-FC theoretical loading of 10 % (i.e., 10 mg of 5-
FC per 100 mg of dry powder) were produced in optimized formulation conditions. 
Briefly, HA concentration was fixed at 0.25 % w/v and mannitol was added to the 
water/ethanol mixture at a HA/mannitol ratio by weight of 1:2. Three different 
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formulations were produced by varying solvent composition (water/ethanol 80:20 or 
70:30 v/v) and the feed rate of the spray-drying (1.8 and 3 ml/min). 
3.2.5. Characterization of microparticles 
Particle morphology was analyzed by scanning electron microscopy (SEM) (Leica 
S440, Germany). The mean geometric diameter and size distribution of 
microparticles were determined by laser light scattering (Coulter LS 100Q, USA) on 
a particle suspension in methanol containing polysorbate 80 (10% w/v) as dispersing 
agent. Size is expressed as volume mean diameter ± standard deviation of values 
collected from three different batches.  
Powder tapped density was evaluated according to European Pharmacopoeia 8th 
Edition (Ph.Eur.).Briefly, a known weight of particles was transferred to a 10 
(±0.05) ml graduated cylinder and the initial volume recorded. The cylinder was 
then mechanically tapped 1250 times up to volume plateau by a tapped density tester 
(Mod. IG/4, Giuliani, Italy). The tapped density of the powder (ρwas expressed as 
the ratio between sample weight and the volume occupied after 1250 tappings (g/ml) 
± standard deviation of values collected from three different batches.  
The actual amount of HA per mg of HA/mannitol microparticles was also 
determined. Briefly, 5 mg of microparticles were dissolved in 10 ml of acetate 
buffer at pH 6.0 under stirring at 37°C and the HA content of the sample was 
determined by spectrophotometric analysis as reported above. Results are expressed 
as HA/Mannitol actual ratio by weight (HA/Man) ± standard deviation of values 
collected from three different batches. 
Actual 5-FC loading of HA/mannitol microparticles was determined by dissolving 2 
mg of dry powders under stirring in 1 ml of aqueous formic acid at pH 2 (1 % v/v). 
Aqueous samples were analyzed for 5-FC content by spectrophotometry as 
described above. Results are expressed as mg of 5-FC per mg of dry powders ± 
standard deviation of values collected from three different batches. 
Inhalable flucytosine dry powders Chapter 3 
 
115 
 
3.2.6. In vitro aerosolization properties 
The aerosolization properties of the dry powders were tested in vitro after delivery 
from breath-activated reusable DPIs working with single unit capsule containing the 
dry powder using a Next Generation Impactor (NGI) (Copley Scientific, UK) 
according to Ph.Eur. 8
th
 Ed. Depending on the dry powder, three devices with 
different resistances to the airflow were tested: the low-resistance DPI RS01 
(Plastiape, Italy); the medium-resistance DPI Turbospin® (PH&T Pharma, Italy); 
the high-resistance DPI HandiHaler® (Boehringer Ingheleim, Germany). For each 
test, a hard gelatin capsule (size 2, Capsugel, USA) was filled with about 20 mg of 
the powder and placed in the DPI. The capsule was then pierced and the liberated 
powder drawn through the NGI operated at 60 or 90 L/min. The emitted dose (ED) 
was calculated by accurately weighing the capsule before and after DPI actuation. 
The powder deposited on the seven NGI collection cups was quantitatively 
recovered by dissolution in an appropriate amount (2 or 8 ml for low-diameter or 
high-diameter collection cups, respectively) of aqueous solvent (acetate buffer at pH 
6 or formic acid at pH 2 for HA and 5-FC quantitation, respectively). The powder 
deposited in the induction port and in the micro-orifice collector was also recovered 
by washing with 10 ml of solvent. The experimental mass median aerodynamic 
diameter (MMADexp) and the geometric standard deviation (GSD) were calculated 
according to Ph.Eur. deriving a plot of cumulative mass of powder retained in each 
collection cup (expressed as percent of total mass recovered in the impactor) versus 
cut-off diameter of the respective stage. The FPF was calculated by interpolation 
from the plot as the percentage of powder emitted from the inhaler with an 
aerodynamic diameter less than 5 μm. The MMADexp of the particles was 
determined from the same graph as the particle size at which the line crosses the 
50% mark and the GSD was defined as  
 
GSD = (Size X/Size Y)
1/2
 
where size X was the particle size at which the line crosses the 84% mark and size Y 
the size at which it crosses the 16% mark. 
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3.2.7.  In vitro assessment of fluorescent particle interactions with simulated 
CF mucus 
Fluorescent HA/mannitol microparticles containing 0.1 % of rhodamine B 
(Rhod/HyaMan2) were produced by spray-drying in the same formulation 
conditions selected for 5-FC loading to assess particle behavior in an artificial CF 
mucus model as previously reported
29
. Artificial mucus (AM) was prepared by 
adding 250 μL of sterile egg yolk emulsion, 250 mg of mucin, 0.295 mg DTPA, 250 
mg NaCl, 110 mg KCl and 1 mL of RPMI to 50 mL of water. The dispersion was 
stirred until a homogenous mixture was obtained. For the experiment, 1 ml of a 
gelatin solution in hot water (10% w/v)was placed in each well of a 24-well plate, 
hardened at room temperature and stored at 4°C until use. Before use, 1 ml of AM 
was placed on the hardened gelatin gel. Then, 3 mg of microparticles were 
uniformly distributed on the AM layer and maintained at room temperature. At 
regular time frames, the well plate was visually inspected and the microparticle-
containing AM was withdrawn, centrifuged at 6,000 rcf and 4°C for 15 min 
(MIKRO 120, Hettich Zentrifugen, Germany) and the amount of rhodamine 
dissolved in mucus was evaluated by spectrofluorimetric analysis at ex/em 553/577 
nm (RF 1501 Spectrofluorometer, Shimadzu, Italy). Results are reported as 
percentage of rhodamine penetrated through AM (total amount of rhodamine in 
microparticles-amount of rhodamine in AM/total amount of rhodamine in 
microparticles x 100) ± standard deviation of values collected from three different 
batches. 
3.2.8.  In vitro 5-FC release in simulated lung fluids 
The release of 5-FC from optimized HyaMan_FC microparticles was followed in 
vitro by membrane dialysis in AM and simulated interstitial lung fluid (SILF) as 
previously reported.
17
 SILF was prepared following the preparation instructions 
dictated by Marques et al.
30
. Briefly, 1 L of SILF contains 0.095 g magnesium 
chloride, 6.019 g of sodium chloride, 0.298 g of potassium chloride, 0.126 g of 
sodium phosphate dibasic, 0.063 g of sodium sulfate, 0.368 g calcium chloride 
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dihydrate, 0.574 g of sodium acetate, 2.604 g of sodium bicarbonate and 0.097 g of 
sodium citrate dihydrate. 
HyaMan_FC dry powders (2 mg) were added to 0.3 mL of donor medium (artificial 
mucus or PBS) and placed in a dialysis membrane bag (MWCO: 5000 Da, 
Spectra/Por®). The membrane was dropped into 5 mL of SILF and kept at 37°C. At 
scheduled time intervals, 1 mL of SILF was withdrawn and analyzed for 5-FC 
content by spectrophotometric analysis as described above. The medium was 
replaced by the same amount of fresh medium. At the end of each release 
experiment, the amount of residual 5-FCin the dialysis bag was assessed upon 
dissolution in 5 ml of aqueous formic acid at pH 2 (1 % v/v). Experiments were run 
in triplicate for each time point of release kinetics. 
3.2.9.  In vitro antifungal activity 
For biological studies in vitro (§ 2.9, 2.10 and 2.11), stock solutions of 
HyaMan_FC#3 in sterile water was prepared at 6.33 mg/ml concentration 
(corresponding to 5 mM 5-FC). The minimum inhibitory concentration (MIC) of the 
5-FC formulation for Candida albicans (ATCC 60193) was first determined using 
the broth microdilution method as previously described.
31
 Briefly, about 10
4
 C. 
albicans cells were inoculated in RPMI 1640 medium supplemented with 2 mM L-
glutamine and buffered with 165 mM MOPS (pH 7.2) in the presence or absence of 
increasing concentrations of HyaMan_FC#3 or the same amount of 5-FC in saline 
and blank HyaMan as control, in 96-well tissue culture plates (200 µl final volume 
in each well). After 24 h of growth at 35°C under static conditions, ABS at 600 nm 
(A600) was measured in a Victor plate reader (Wallac), and the 5-FC MICs were 
calculated as the lowest concentration of each formulation causing at least 50% 
reduction in A600 with respect to untreated controls.
32
  
3.2.10. In vitro pyoverdine inhibitory activity 
The anti-pyoverdine activity of different 5-FC formulations was assessed as 
previously described
2
. Briefly, the P. aeruginosa reference strain PAO1 (ATCC 
15692) was cultured for 10 h at 37°C in the iron-depleted trypticase soy broth 
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dialysate medium (TSBD
33
 supplemented with 50 µM FeCl3, and then refreshed 
1:1000 in fresh TSBD in the presence or absence of increasing concentrations of 5-
FC in saline, HyaMan_FC#3 or HyaMan as control. After 14 h of growth, 
pyoverdine production was quantified by normalizing the ABS at 405 nm (A405) in 
cell-free culture supernatants appropriately diluted in 100 mM Tris-HCl (pH 8) by 
the cell density of the corresponding bacterial cultures, determined as A600.
34
 
3.2.11.  Cytotoxicity assay 
16HBE14o- (wt/wt CFTR; normal human bronchial epithelial cells) and CFBE41o- 
(F508del/F508del; cystic fibrosis bronchial epithelial cells, homozygous for the 
ΔF508 mutation) cells35 were maintained in MEM medium with 20 mM L-
glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin and 10% fetal bovine 
serum (FBS). When confluent, cells were trypsinized and seeded in 96-well 
microtiter plates at 30,000 cells per well (in 200 μL final volume). Twenty-four h 
after seeding, cells were washed three times with culture medium without any 
additive (FBS or antibiotics), and 200 μL of culture medium with or without 
different amounts of 5-FC formulations, or their corresponding controls, were added 
to each well. After 3 or 24 h of incubation at 37°C, cell culture medium was 
discarded and each well was washed with 200 μL of Hanks balanced buffer solution 
(HBSS). Cells were then incubated for 3 h at 37°C in the presence of 200 μL of 0.5 
mg/mL MTT in HBSS. MTT solution was then discarded, 100 μL of DMSO were 
added to each well, and ABS at 570 nm (A570) was read using an ELISA microtiter 
plate reader.
36
 
3.2.12.  In vivo biodistribution studies  
3.2.12.1. Animals 
Male Wistar rats (200-220 g; Charles River, Lecco, Italy) were used. All the 
experimental procedures were performed following the specific guidelines of the 
Italian and the European Council law for animal care. These procedures were also 
approved by the Animal Ethics Committee of the University of Naples “Federico II” 
(Italy).  
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3.2.12.2. Experimental procedures 
Rats were anesthetized using ketamine (80-100mg/kg, i.p.) and xilazine (10mg/kg, 
i.p.) and the depth of anesthesia was continuously controlled. The animals were 
divided into different groups and treated with PBS (100 µL, SHAM group), 
HyaMan_FC#3 dry powders(2.5 mg/rat) or an aqueous solution containing an 
equivalent amount of 5-FC (200µg/100µl). The formulations were intra-tracheally 
administered by using a mini DPI (Model DP-4, Penncentury, USA)or a 
Microsprayer
®
 (Model 1A-1B, PennCentury, USA), for dry powder and solution 
respectively. The cannula of the tracheal dispositive was inserted directly into the 
trachea through the mouth. At 5, 30 or 180 min after treatment and under anesthesia, 
the carotid artery was cannulated for blood collection. Thus after euthanization, 
bronchoalveolar lavage (BAL) and lungs were obtained. Briefly, the trachea was 
cannulated with a polyethylene tube (1 mm inner diameter) to perform BAL as 
previously reported.
17
 Lungs were washed (three times) by flashing sterile ice cold 
PBS. The BAL was centrifuged to separate cells (BALC) from fluid (BALF), while 
blood was withdrawn in glass tube and left for 24h at 4°C to obtain serum. BALC 
and lungs were homogenized in PBS containing Triton 0.1%. 
3.2.12.3. Sample treatment and analysis 
BALC, BALF, lung homogenate and serum were processed for 5-FC quantitation by 
RP-HPLC. Briefly, biological samples were incubated 1 h under stirring with 
acetonitrile (1:1 v/v for BALC and BALF, 1:2 v/v for homogenates and serum) for 
protein precipitation. The resulting dispersion was centrifuged at 18,000 rcf for 5 
min(MIKRO 120, HettichZentrifugen, Germany) and the surnatant filtered through 
0.45 mm cellulose filters (Phenex®, Phenomenex, USA) for RP-HPLC analysis. 
The same biological matrices were also analysed to assess the presence of 5-FU, the 
active metabolite of the 5-FC. In each case, the presence in the samples of 
interfering substances was accounted for with the analysis of biological samples 
derived from the SHAM group. 
A SHAM group was also used to determine the recovery yield of the extraction 
procedure. After spiking with known amounts of 5-FC or 5-FU (0.020-1.0 g), the 
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biological samples from SHAM animals underwent the same extraction procedure 
used for BALC, BALF, lung homogenates and serum derived from treated groups 
and were successively analyzed by RP-HPLC. In each case, data were corrected for 
recovery yields, which were always higher than 80%. 
The amount of 5-FC and its metabolite 5-FU in biological samples was determined 
by reverse-phase High-Performance Liquid Chromatography (RP-HPLC). The 
HPLC system consisted of a LC-10ADvp liquid chromatograph, a SIL-10ADvp 
auto-injector, a SPD-10Avp UV–Vis detector and a C-R6 integrator from Shimadzu 
(Japan). The quantitative analysis was performed by RP-HPLC on a Synergy Hydro 
column (250 × 4.6 mm, 100 Å) (Phenomenex, USA). The mobile phase was 
aqueous formic acid (1% v/v). The flow rate was 1 ml/min and the detection 
wavelength 285 nm. In these conditions the retention times of 5-FC and its 
metabolite 5-FU were 3.5 min and 6.5 min, respectively. Calibration curves were 
obtained by plotting peak area versus the concentration of 5-FC or 5-FU standard 
solutions in water. The linearity of the response was verified over the 5-FC 
concentration range of 0.2-20 g/ml and 5-FU concentration range 0.25-25g/ml (r2 
≥ 0.99). 
The limit of detection (LOD) (estimated as 3 times the background noise) of 5-FC 
and 5-FU were 0.067 and 0.14 μg/ml, respectively. The limit of quantitation (QOD) 
of 5-FC and 5-FU (estimated as 10 times the background noise) were 0.22 and 0.45 
μg/ml, respectively.  
3.2.13.  Statistical analysis 
The significance of differences was determined with the software GraphPad InStat 
using one-way ANOVA followed by the Tukey−Kramer multiple comparison test. 
A p value < 0.05 was considered significant.  
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3.3. RESULTS  
3.3.1. Design and development of 5-FC HA/mannitol dry powders for 
inhalation 
In depth formulation studies were devoted to the development of HA-mannitol dry 
powders for inhalation. As first step, several HA formulations, differing for the 
concentration of HA, presence and concentration of AB as porogen agent, were 
individually spray dried and fully characterized (Hya formulations in Table 3.1).  
Table 3.1. Composition of unloaded Hya and HyaMan spray-dried formulations. 
Formulation1 
HA 
(% w/v) 
AB 
(% w/v)  
HA/mannitol theoretical 
ratio (w/w)  
Hya0.1 0.1 - - 
Hya0.1AB15 0.1 15 - 
Hya0.1AB50 0.1 50 - 
Hya 0.25 - - 
HyaAB15 0.25 15 - 
HyaAB50 0.25 50 - 
HyaMan1 0.25 - 1:1 
HyaMan1AB15 0.25 15 1:2 
HyaMan2 0.25 - 1:1 
HyaMan2AB15 0.25 15 1:2 
1. The acronyms used are composed by character strings indicating: presence and 
concentration of HA (Hya 0.1 or Hya), presence of mannitol and its weight ratio with HA 
(Man1 or Man2), presence and concentration of AB (AB15 or AB50) within the 
formulation.  
 
As shown in Fig. 3.1, HA concentration in the spray-drying feeding solvent affected 
the morphology of the particles, which were less cohesive and collapsed when 0.25 
% (w/v) HA was spray-dried. This effect was particularly evident when AB was 
added to the formulation as porogen. 
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Figure 3.1. SEM micrographs of HA-based microparticles produced in different formulation 
conditions. Field is representative of the formulation. 
 
Increasing the concentration of HA from 0.1% (w/v) to 0.25% (w/v) caused an 
increase of the production yield from 17% to 25%. Nevertheless, the percentage of 
dry powders delivered from a mini-DPI was always very low, ranging from 9% to 
20%, suggesting very poor aerosolization properties for dry powders merely based 
on HA. 
In order to improve particle properties of the HA dry powders achieved by spray-
drying 0.25% (w/v) HA in water/ethanol 80:20 (v/v), mannitol was tested as second 
component. Different HA/mannitol formulations were spray-dried and fully 
characterized (HyaMan; Table 3.1). SEM images of HyaMan dry powders are 
reported in Fig.3.2.  
While mannitol crystals are still evident on HyaMan1 and HyaManAB15 surface, 
more regular microparticles were achieved at a HA/mannitol ratio by weight of 1:2. 
Bulk and flow properties of the formulations are reported in Table 3.2.  
 
Hyalu0.1
Hyalu
Hyalu0.1AB15
HyaluAB15
Hyalu0.1AB50
HyaluAB50
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Figure 3.2. SEM micrographs of HA/mannitol microparticles. Field is representative of the 
formulation. 
 
Table 3.2. Overall properties of blank HyaMan dry powders. 
Formulation 
Mean 
yield 
(%) 
Actaul 
HA/Man 
ratio 
(w/w) 
Volume mean 
diameter (d)1 
(m ± SD2) 
Tapped density 
() 
(g/ml ± SD2) 
Emitted 
dose3 
(%± SD2) 
Hya 
 - 20.8 ± 2.0 0.045 ± 0.006 22.2 ± 5.3  
HyaMan1 44.6 1.2  ± 0.19 19.4 ± 1.0 0.074 ± 0.008 85.3 ± 7.4 
HyaMan1AB15 
48.9  1.7  ± 0.38 21.7± 6.2 0.050 ± 0.008 96.6 ± 2.3 
HyaMan2 47.0 0.54  ± 0.10 18.7 ± 3.5 0.100 ± 0.009 100.2 ± 6.4 
HyaMan2AB15 
47.6 0.53 ± 0.04 15.4± 5.7 0.097 ± 0.008 90.0 ± 1.5 
1. Mean geometric diameter as determined by laser diffraction. 
2. Standard deviation of values calculated on three different batches. 
3. Percentage of dry powder delivered from a breath-activated medium-resistance DPI 
(Turbospin) operated at 60 L/min. 
 
As expected, the production yield significantly increased, up to 45-49%. Despite 
their high geometric diameter, always around 20 m, all particle formulations 
displayed very low tapped density values, ranging between 0.045 and 0.1 g/ml, 
suggesting a hollow structure, suitable for lung delivery. In each case, the theoretical 
HA/mannitol ratio by weight was maintained after spray-drying. Nevertheless, 
 
HyaMan1 HyaMan1AB15 
HyaMan2 HyaMan2AB15 
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differences were apparent in particle aerosol performance upon delivery from a 
medium-resistance breath-activated, reusable DPI, that is Turbospin® (PH&T 
Pharma, Milano, Italy). Results confirmed very poor aerosolization properties of HA 
particles, with an emitted dose (ED) as low as 22.2 ± 5.3 % of the initial amount 
loaded into the DPI (Table 2). The addition of mannitol to the formulation resulted 
in a significant increase of ED, with a maximum value, around 100%, for HyaMan2 
microparticles. No actual advantage was observed when AB was added to the initial 
formulation (Table 3.2). On the basis of these encouraging in vitro aerosolization 
properties, HyaMan2 formulation was selected as carrier for 5-FC. 
5-FC was added to the formulation before spray drying at a theoretical loading of 
10% by weight and the effect of the solvent and spray-drying conditions on the 
overall properties of dry powders was investigated. In each case, microparticles with 
a tapped density value around 0.3 g/ml and an actual 5-FC loading close to the 
theoretical one were achieved with good yields (≥ 40%). Differences were apparent 
among volume mean diameters, strictly depending on the formulation conditions 
(Table 3.3). 
The aerosolization properties of dry powders containing 5-FC were tested in vitro 
after delivery from Turbospin® DPI with a Next Generation Impactor (NGI) 
(Copley Scientific, UK) according to Ph.Eur. 8th Ed. The calculated values of fine 
particle fraction (FPF) (i.e., fraction of particles with an aerodynamic diameter lower 
than 5 m) and experimental mass mean aerodyanamic diameter (MMADexp) are 
reported in Fig. 3.3. Of note, 5-FC loaded HA/Mannitol microparticles achieved by 
spray drying at lower flow rates (HyaMan_FC#3) showed the lowest MMADexp 
value and the highest FPF. HyaMan_FC#3 dry powder was thus selected to 
investigate the in vitro and in vivo potential of the system for local antimicrobial 
therapy in CF. 
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Table 3.3. Composition, bulk and flow properties of HyaMan dry powders loaded with 5-
FC.1 
  HyaMan_FC#1 HyaMan_FC#2 HyaMan_FC#3 
Feedrate2 (ml/min) 3.0 3.0 1.8 
Feed solvent 
(water/ethanol, v/v) 
80:20 70:30 80:20 
Volume mean 
diameter  
(m ± SD) 
10.3 ± 5.0 21.3 ± 4.4 15.1 ± 3.8 
Tapped density 
(g/ml ± SD) 
0.273 ± 0.023 0.295 ± 0.016 0.302 ± 0.015 
Actualloading3  
(mg ± SD) 
0.095 ± 0.035 0.102 ± 0.005 0.108 ± 0.007 
1. All formulations were prepared at 0.25 % w/v of HA and 0.5 % w/v of  mannitol in the feed solvent. 
2. Corresponding to a pump rate of 10% and 6% when using a standard silicone tubing of 2/4. 
3. Milligrams of 5-FC per mg of  dry powder. The theoretical loading is 0.1 mg per 1 mg of dry 
powders.   
 
 
Figure 3.3. Effect of spray-drying conditions on the aerosolization properties of HA/mannitol 
microparticles loaded with 5-FC upon delivery from a medium-resistance DPI (Turbospin®). 
FPF = Fine particle fraction; MMADexp = experimental mass mean aerodynamic diameter. 
Data are the mean ± SD of values calculated on three different batches. 
Inhalable flucytosine dry powders Chapter 3 
 
126 
 
3.3.2.  In vitro aerosolization and release properties of optimized HyaMan_FC 
dry powders  
The aerosol performance of HyaMan_FC#3 upon delivery from a low-resistance 
DPI [namely, RS01 (Plastiape, Italy)] was also investigated and results compared 
with those achieved with Turbospin®. As can be seen in Fig. 3.4, the NGI 
deposition pattern of HyaMan_FC#3 dry powder varied as a function of the flow 
rate (i.e., 60 and 90 L/min) and of the DPI resistance. At 60 L/min flow rate, less 
than 20% of the emitted 5-FC dose was deposited from cup 3 to MOC (i.e., 
MMAD<4.46 m) with both DPIs tested. The remaining drug fraction was almost 
totally recovered in the throat/cup 1 when using Turbospin®, while it was found 
mostly in cup 1 (i.e., MMAD>8.06 m) when using RS01(Fig. 3.4A).  
At 90 L/min flow rate (Fig. 3.4B), the amount of 5-FC found in the throat when 
using both Turbospin® and RS01 lowered down to the benefit of cup 1 (>65 % of 
the emitted dose for Turbospin®). Nevertheless, a percentage as low as 15 % of the 
emitted dose was recovered from cup 2 to MOC (i.e., MMAD<6.48 m) after 
delivery from Turbospin®. Furthermore, results achieved with Turbospin® were 
much less reproducible, making difficult to determine the actual values of MMAD 
and GSD. 
The overall deposition pattern of the dry powder significantly improved when using 
RS01 at 90 L/min flow rate (Fig. 3.4B). The dry powder was delivered from RS01 at 
90 L/min with maximum efficiency and homogeneously distributed thorough the 
seven stage down to MOC ,with more than 40 % of the emitted dose depositing from 
cup 2 to MOC (i.e., MMAD<6.48 m) and about 25 % from cup 3 to MOC (i.e., 
MMAD<3.61 m). The FPF at 90 L/min was 2-fold higher than that calculated at 60 
L/min and MMADexp was reduced by half accordingly (Fig. 3.4C).  
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60 L/min 90 L/min 
Turbospin RS01 Turbospin RS01 
MMADexp 
(m ± SD) 
9.5 ± 0.55 13.8 ± 0.86 >20 6.9 ± 1.1 
GSD 
(± SD) 
2.1 ± 0.04 2.2 ± 0.06 ND 2.2 ± 0.03 
Figure 3.4. NGI deposition pattern of optimized HyaMan_FC dry powder (HyaMan_FC #3). 
The formulation was delivered at 60 (A) and 90 (B) L/min through the low-resistance DPI 
RS01  or the medium-resistance DPI Turbospin®. The corresponding values of MMADexp 
and GSD are reported in panel C. Data are the mean ± SD of values calculated on three 
different batches  
A 
B 
C 
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3.3.3 In vitro behavior of optimized HA/mannitol dry powders in simulated lung fluids 
In vitro release of 5-FC from HyaMan_FC #3 dry powder was assessed in simulated 
interstitial lung fluids (SILF). As shown in Fig. 3.5, 5-FC was rapidly released from 
HA microparticles even if the release profile was slightly affected by the presence of 
simulated CF mucus, which slowed down 5-FC release in SILF. 
 
Figure 3.5. Release profile of 5-FC from optimized HyaMan_FC dry powder 
(HyaMan_FC#3) evaluated by membrane dialysis from either PBS at pH 7.2 or artificial CF 
mucus to simulated interstitial lung fluid (SILF). Data are presented as mean ± standard 
deviation (n=3). 
The effect of mucus on HA/mannitol microparticles dissolution and drug diffusion 
was further investigated in vitro on an artificial CF mucus model. As can be seen in 
Fig. 3.6, fluorescent Rhod/HyaMan2 microparticles did not dissolve instantaneously 
in simulated CF mucus, and the released rhodamine B slowly diffused inside it 
within 24 h with the same kinetics observed for 5-FC.  
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Figure 3.6. Visual inspection of fluorescent Rhod/HyaMan2 dry powder behaviour in an 
artificial mucus layer and corresponding percent amount of rhodamine permeated in the 
gelatin layer during time. Data are presented as mean ± standard deviation (n=3). 
3.3.4.  Antifungal, antivirulence and cytotoxic properties of HyaMan_FC#3 
dry powders 
Taking into account that 5-FC is currently employed in the clinic as antifungal 
agent, we first tested in vitro activity of HyaMan_FC#3 dry powders against C. 
albicans. Of note, 5-FC in saline and HyaMan_FC#3 had comparable antifungal 
activity, with a MIC value of 3.9 µM 5-FC (corresponding to 0.5 µg/ml). HyaMan 
did not inhibit C. albicans growth even at the highest concentration tested (635 
µg/ml; data not shown). 
5-FC was previously reported to reduce the virulence of P. aeruginosa by inhibiting 
the production of the siderophore pyoverdine, without affecting bacterial cells 
viability [3]. Thus, the anti-pyoverdine activities of 5-FC in saline and 
HyaMan_FC#3 on P. aeruginosa cells were compared. As shown in Figure 3.7, both 
HyaMan_FC#3 and 5-FC in saline inhibited pyoverdine production in P. aeruginosa 
at comparable levels (5-FC concentrations ≥ 1.2 µM). Conversely, the HyaMan 
vehicle without 5-FC had no effect on pyoverdine production. 
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Figure 3.7. Pyoverdine production by P. aeruginosa PAO1 after 14-h growth in the iron-poor 
medium TSBD in the presence of increasing concentrations of 5-FC in saline (5-FC solution), 
5-FC dry powders (HyaMan_FC#3), or the corresponding concentrations of blank HyaMan 
dry powders. Values are the mean (±SD) of three independent experiments. Asterisks indicate 
statistically significant differences with respect to the untreated control (* p<0.05, *** 
p<0.01; ANOVA) . 
 
Finally, the cytotoxicity of the different 5-FC formulations was assessed on normal 
and CF bronchial epithelial cell lines (16HBE14o- and CFBE41o-, respectively), 
after 3- and 24-h treatments. After 3 h, 5-FC did not show any effect on viability of 
both cell lines, irrespective of the formulation or the concentration tested (Fig. 
3.8A). After a 24-h treatment, a significant reduction in cell viability of 16HBE14o- 
cells and, to a lesser extent, of CFBE41o- cells was only observed for 
HyaMan_FC#3 at the highest concentration tested (corresponding to 1 mM 5-FC), 
and for the corresponding concentration of the HyaMan vehicle alone (Fig. 3.8B). In 
contrast, 5-FC in saline did not show any toxicity on both cell lines even at 1 mM 
(Fig. 3.8B), strongly suggesting that the in vitro cytotoxicity of HyaMan_FC#3 at 
the highest dosage after 24-h treatment is related to the very high amount of HA and 
mannitol excipients in the cell culture medium (1.27 mg/ml). 
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Figure 3.8. Cytotoxicity of 5-FC formulations to 16HBE16o- and CFBE41o- cells. Cell 
viability was assessed after (A) 3-h or (B) 24-h incubation in the presence of 5-FC in saline 
(5-FC solution), 5-FC dry powders (HyaMan_FC#3), or the corresponding concentrations of 
blank HyaMan dry powders. Results are expressed as percentage of cell viability with respect 
to untreated controls (100%) (blue bar), and represent the average (±SD) of three independent 
experiments performed in duplicate. Asterisks indicate statistically significant differences 
with respect to untreated controls (* p < 0.05, *** p < 0.001; ANOVA). 
 
3.3.5. In vivo 5-FC biodistribution upon intratracheal insufflation of 
HyaMan_FC 
The fate of 5-FC upon intra-tracheal insufflation of HyaMan_FC#3 dry powder in 
rats was investigated over time and results compared with those achieved upon intra-
tracheal aerosolization of a 5-FC solution at the equivalent dose loaded in the dry 
powder formulation. The amount of 5-FC was determined in BALC, BALF, lung 
homogenates and serum by solvent extraction and subsequent RP-HPLC analysis. 
To determine the recovery yield of the extraction procedure, biological samples 
deriving from SHAM group spiked with known amounts of 5-FC or 5-FU were also 
analyzed. 
As shown in Fig. 3.9A, the concentration of 5-FC in BALF was 2-fold higher in case 
of HyaMan_FC#3 dry powder as compared to 5-FC solution (11.3 ± 0.68 g/ml and 
5.81 ± 0.44 g/ml for HyaMan_FC and 5-FC solution, respectively; p<0.001). 
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Furthermore, 30 min after the administration of HyaMan_FC #3, a 12-fold higher 
amount of 5-FC was found in BALF as compared to 5-FC solution (14.1 ± 0.59 
g/ml and 1.16 ± 0.04 g/ml for HyaMan_FC#3 and 5-FC solution, respectively; 
p<0.001). Indeed, at 30 min the concentration of 5-FC after administration of the 
solution significantly dropped if compared to that at 5 min (p<0.005). A detectable 
and higher amount of 5-FC was still observed after 180 min after HyaMan_FC#3 
administration as compared to 5-FC solution (Fig. 3.9A).  
A different profile was observed in the lung homogenate immediately after the 
administration compared to the BALF data (Fig. 3.9B). In fact, after 5 min from 
HyaMan_FC#3 dry powder administration, 5-FC values were significantly lower 
compared to 5-FC solution (p<0.01); meanwhile, a major accumulation of the drug 
in the lung was observed at 30 min by using HyaMan_FC #3 formulation compared 
to the 5-FC solution (p<0.01). In fact 5-FC concentration was 4.44 ± 0.49 g/g, a 
value more than 2-fold higher than that obtained with the 5-FC solution (1.91 ± 0.60 
g/g). A detectable but low amount of 5-FC in the lung was still observed 180 min 
after the administration of both HyaMan_FC#3 dry powder and 5-FC solution (Fig. 
3.9B). Of note, the different distribution at lung did not significantly affected the 
blood concentration profile of 5-FC (Fig. 3.9C). In fact, no significant variation in 5-
FC serum concentration between 5-FC solution and HyaMan_FC#3 dry powder was 
observed at any time interval (5, 30 or 180 min) from administration. In both cases, 
the amount of 5-FC in serum was significantly reduced after 180 min (p<0.001). 
Finally, no significantly different amounts of 5-FC were found in BALC 5 min after 
administration of 5-FC solution and HyaMan_FC#3 dry powder (0.26 ± 0.079 and 
0.20 ± 0.076 g, respectively), while 5-FC was not detected in BALC samples at 
longer time intervals (30 and 180 min; data not shown).  
In each case, we evaluated the possibility that an amount of 5-FC could be converted 
into 5-FU in the lung. Of note, after treatment with both HyaMan_FC#3 dry powder 
and 5-FC solution, no detectable amounts 5-FU was found in BALF, BALC, lung 
and serum samples (i.e., 5-FU<0.14 g/ml). 
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Figura 3.9. 5-FC amounts in rat BALF (A), lung (B) and serum (C) at different time intervals 
after intra-tracheal administration of HyaMan_FC#3 dry powder and of 5-FC solution by 
means of a low-scale DPI for rats. The results are expressed as mean ± S.E.M. (n=3). 
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3.4. DISCUSSION 
Nowadays, pulmonary drug delivery is at cutting edge for local treatment of severe 
lung disease, such as CF. Particular research efforts have been directed towards 
development of dry powders for inhalation, due to a number of advantages over 
conventional liquid formulations.
8,10
 Nevertheless, the development of inhalable dry 
powders runs into the need of safe materials for inhalation, which are currently very 
limited in number, and adequate engineering techniques, which should ensure 
effective deposition of the drug at the desired region of the lung and for the proper 
time interval.
37
 Inspired by the recent encouraging findings on HA and mannitol for 
inhalation
21,24,38
, in this work we have designed and developed novel inhalable 
composite HA/mannitol dry powders for local delivery of the antimycotic and 
antivirulence drug 5-FC in the treatment of lung infections. 
Despite the huge number of engineering techniques currently under investigation to 
develop inhalable formulations, spray-drying remains an easy and scalable approach 
to produce more or less complex drug delivery systems.
12,13,39
 Nevertheless, 
producing inhalable dry powders is straightforward in principle but complex in 
reality. Throughout the formulation studies, we run up into special difficulties to 
achieve pure HA aerosol particles within the respirable range. When used alone, the 
forces generated within the DPI were insufficient to aerosolize HA microparticles, 
with an emitted dose as low as 22%, likely as a result of poor HA particle flow 
properties. This issue is generally solved through the addition of a coarse material to 
produce free-flowing polymer particles/carrier blends.
40
 Here, we decided to 
incorporate the excipient, that is mannitol, inside the spray-dried formulation, thus 
producing HA/mannitol composite microparticles with enhanced dispersibility, 
which could be delivered by a medium-resistance DPI with 100% efficiency.  
In optimized formulation conditions, HA/mannitol composite microparticles could 
load 5-FC with high efficiency. In line with literature data
15
, spray-drying offered 
the possibility to tune particle aerodynamic features through the selection of 
adequate processing conditions. In particular, two parameters were found to affect 
the properties of 5-FC-loaded HA/mannitol composite microparticles, that are feed 
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rate and feed solvent. Particles produced at the lowest feed rate and the highest 
percentage of ethanol inside the feeding solution, namely HyaMan_FC#3, displayed 
the lowest MMADexp and the highest FPF. These formulations were, thus, selected 
for further investigations. Conceiving HyaMan_FC#3 for lung delivery, our focus 
was the thoroughly investigation of the aerodynamic behavior of the particles and 
their interaction with lung lining fluids.  
For the successful development of any inhalation therapy based on DPIs, the correct 
drug–device combinations is crucial.41 Thus, we become interested in testing the 
aerosolization properties of the developed dry powders delivered from DPIs 
characterized by distinct intrinsic resistances at the inspiratory flow and comparing 
their performance at different flow rates. As expected, the performance of the 
medium-resistance DPI, namely Turbospin, worsened by increasing the flow rate, 
while RS01 performance worked better at 90 L/min, useful to draw 4.0 L of air at a 
pressure drop of 4 kPa through the inhaler according to Pharmacopoeia. The 
deposition profiles and the fine particle characteristics of HyaMan_FC#3 in the 
different experimental conditions strongly suggested that the developed dry powders 
well fit to a low-resistance DPI. In fact, a poorer deposition profile of 
HyaMan_FC#3 was observed when using a high-resistance DPI (i.e., Handihaler, 39 
L/min) as compared to both Turbospin and RS01 (data not shown). 
Once the inhaled particles will deposit in the lung, the delivered drug has still to 
interact with local bacteria/fungi to be effective. The experimental conditions 
realized in the in vitro release studies well reproduced those occurring in vivo, taking 
into account that the inhaled particle will impact in the mucus layer, where microbial 
colonization will take place. Furthermore, the behavior of HyaMan_FC#3 upon 
contact with mucus was examined closely by further diffusion studies in the 
artificial CF mucus model. Combined results demonstrated the ability of the carrier 
system to assist 5-FC diffusion through airway mucus. A similar effect was already 
reported for mannitol-based dry powders, likely as a consequence of its osmotic 
properties.
42
 At the same time, in vitro biological studies confirmed the activity of 5-
FC against both C. albicans and P. aeruginosa at similar concentrations, which were 
not cytotoxic in vitro towards both normal and CF human bronchial epithelial cells. 
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Despite promising in vitro results, the therapeutic efficacy of the inhaled drugs in 
vivo will be definitively determined by the total lung deposition as well as the ability 
to overcome clearance mechanisms operating in situ. Thus, it was very interesting to 
compare the biodistribution of HyaMan_FC#3 dry powder versus 5-FC saline 
solution over 3 h after intra-tracheal administration in rats. The results obtained in 
vivo clearly demonstrated that, when adequately formulated, 5-FC is able to reach a 
significant concentration in the lung and this concentration may be sustained over 
time. In particular, optimized HyaMan_FC #3 dry powder offers the possibility to 
control local 5-FC concentration, increasing the drug level not only in the lung 
lining fluids but also into the lungs along time. Indeed, the clearance rate from the 
lungs may exert a major influence on the pharmacokinetic profile of the 
administered drug and this can depend on the physicochemical properties of both the 
drug and the carrier.
43,44
 Of note, when the drug was administered as dry powder, a 
notable increase of 5-FC in the lung over time was observed, suggesting a slower 5-
FC clearance as compared to the liquid formulation. Meanwhile, the very limited 
amount of 5-FC (~0.1% of the administered dose) within the cellular fraction of the 
BAL (i.e., BALC) 5 minutes after administration likely demonstrate that locally 
resident macrophages, and possibly neutrophils, do not phagocytosize HA/mannitol 
microparticles of this size and composition suggesting different clearance 
mechanisms. 
It is well established that after pulmonary administration a molecule may quickly 
reach the circulation system (within few minutes) and, of course, this is tightly 
related to drug chemical/physical characteristics. After oral administration, 5-FC is 
well absorbed, easily penetrates into body tissues and is excreted mainly by the 
kidneys via glomerular filtration. The half-life of 5-FC is very short (1–2 h) in 
patients with normal renal function.
45
 For its pharmacokinetic characteristics, the 
pulmonary administration of 5-FC solution can be thus assimilated to the 
intravenous one. On the other hand, the developed HA/mannitol dry powder 
HyaMan_FC#3 significantly modifies the persistence of the drug in the lung and this 
may be useful to improve local treatment while limiting undesirable systemic side 
effects. Indeed, by an higher amount of 5-FC in the lung, no significant differences 
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in serum concentrations were observed between 5-FC solution and the dry powder 
formulation.  
The antifungal/antibacterial activity of 5-FC is due to its intracellular conversion 
into the cytotoxic compound 5-FU by fungal and bacterial enzymes that are not 
present in mammalian cells.
45,46
 However, the rat lungs are not bacteria-free, hence it 
is relevant that 5-FU was not detected in biological matrices after treatment with 
both HyaMan_FC#3 dry powders and 5-FC solution.  
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3.5. CONCLUSIONS 
HA/mannitol composite dry powders for controlled release of 5-FC at lung have 
been successfully developed by spray-drying. The composition of the formulation 
along with processing conditions played a pivotal role in determining particle 
aerosolization profile. The aerodynamic behavior of optimized formulation could be 
further controlled by a correct device choice. Indeed, the developed dry powders 
were efficiently delivered from a low-resistance DPI already available to CF patients 
and assisted 5-FC dissolution in simulated CF lung mucus. In vitro studies 
confirmed the ability of released 5-FC to inhibit both the growth of C. albicans and 
the production of pyoverdine in P. aeruginosa, thus attenuating its pathogenicity. At 
bioactive concentrations, the developed formulations did not display any toxicity 
towards both normal and CF bronchial epithelial cells. Finally, a pharmacokinetic 
comparison between the dry powder formulation here developed and 5-FC in 
solution after intra-tracheal delivery in rats highlighted the potential of the 
developed formulation for local and controlled delivery of 5-FC.  
Taken all together, our data demonstrate for the first time the feasibility to develop 
effective 5-FC formulations for pulmonary delivery by inhalation. Furthermore, 
results clearly show that it is possible, by an appropriate formulation design, to force 
the concentration of the drug at lung, where the microorganisms causing severe local 
infections or worsening the pathological status of pulmonary diseases are located.  
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ABSTRACT 
We have recently demonstrated that the specific inhibition of nuclear factor-B by a 
decoy oligonucleotide (dec-ODN) delivered through inhalable large porous particles 
(LPP) made of poly(lactic-co-glycolic acid) (PLGA) may be highly beneficial for 
long-term treatment of lung inflammation. Nevertheless, besides chronic 
inflammation, multi-functional systems aimed to control also infection are required 
in chronic lung diseases, such as cystic fibrosis (CF). In this work, we tested the 
hypothesis that engineering PLGA-based LPP with branched poly(ethylenimine) 
(PEI) may improve LPP properties for pulmonary delivery of dec-ODN, with 
particular regard to the treatment of Pseudomonas aeruginosa lung infections. After 
getting insight into the role of PEI on the technological properties of PLGA-based 
LPP for delivery of dec-ODN, the putative synergistic effect of PEI free or PEI 
released from LPP on in vitro antimicrobial activity of tobramycin (Tb) and 
aztreonam (AZT) against P. aeruginosa was elucidated. Meanwhile, cytotoxicity 
studies on A549 cells were carried out. Results clearly demonstrate that the dry 
powders have promising aerosolization properties and afford a prolonged in vitro 
release of both dec-ODN and PEI. The encapsulation of PEI into LPP results in a 2-
fold reduction of the minimum inhibitory concentration of AZT, while reducing the 
cytotoxic effect of PEI. Of note, the developed ODN/PLGA/PEI LPP persisted at 
lung at least for 14 days after intratracheal administration in rats where they can 
provide sustained and combined release of dec-ODN and PEI. dec-ODN will likely 
act as an anti-inflammatory drug, while PEI may enhance the therapeutic activity of 
inhaled antibiotics, which are commonly employed for the treatment of concomitant 
lung infections. 
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4.1. INTRODUCTION 
Innovative oligonucleotide (ON)-based therapies are rather recent in the respiratory 
field but very intriguing in the light of their proved in vitro and in vivo potential, 
also in humans.
1-3
 Different formulation approaches have been recently pursued to 
fulfil the requirements dictated by translation of ON-based inhalation therapy in 
humans.
3,4
 Amid them, poly(lactic-co-glycolic) acid (PLGA) particles have 
generated considerable research interest due to their biodegradability and excellent 
biocompatibility
5
. Infact, ON encapsulation within PLGA microparticles can be 
regarded as a powerful mean to achieve its sustained release for long time-frames 
and to effectively protect the labile macromolecule from in vivo degradation 
occurring at the administration site.
6,7
 Furthermore, PLGA microparticles may be 
engineered through the addition of specific excipients to proper deposit at lungs, to 
transport ONs in lung lining fluids and to enhance ON internalization in lung 
epithelial cells, where the target is located.
8
 
Among excipients investigated to engineer PLGA microparticles for inhalation, 
those playing a dual role in the formulation should be preferred, especially if one of 
their effects is to widen and/or to enhance the biological activity of the inhaled 
drug.
8,9
 This is the case of poly(ethylenimine) (PEI), which has been used as non-
viral gene transfer agent since 90’s10
-12
 and has recently shown promise also for 
pulmonary delivery of ONs
13-15
. Due to high cationic charge density, PEI very 
efficiently condenses negatively-charged nucleic acid molecules into nanosized 
complexes, which provide escape from the harsh endosomal/lysosomal environment 
after internalization and allow a highly efficient transgene expression.
10-12
 
We have recently tested PEI in the formulation of inhalable large porous particles 
(LPP) of PLGA for sustained delivery of a decoy oligonucleotide against NF-B 
(dec-ODN) in cystic fibrosis (CF).
16
 Indeed, PLGA-based LPP were demonstrated: 
i) to display promising aerodynamic properties for delivery from breath-actuated dry 
powder inhalers (DPI); ii) to exert a temporal control over dec-ODN released 
amount, while preserving its integrity; iii) to cause a persistent inhibition of the 
expression of important pro-inflammatory mediators as compared to naked dec-
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ODN
16,17
, also in vivo.
7
 Nevertheless, engineering of PLGA-based LPP with PEI 
was demonstrated crucial to control mucin gene expression in mucoepidermoid lung 
epithelial cells, suggesting a potential active role of PEI in CF treatment.
16
 Actually, 
besides chronic inflammation, multi-functional systems aimed to control also 
overproduction of the viscous airway mucus and lung infections is highly desirable  
in CF treatment.  
Chronic Pseudomonas aeruginosa airway infections remain among the primary 
cause of mortality and morbidity in the CF population. Despite aggressive antibiotic 
therapy, P. aeruginosa is rarely eradicated owing to its level of intrinsic resistance to 
many drugs.
18
 A major cause of resistance is the outer membrane of Gram-negative 
bacteria, which consists of an asymmetric double layer of polyanionic 
lipopolysaccharide (LPS) molecules (outer leaflet) and glycerophospholipids (inner 
leaflet). LPS molecules are electrostatically linked by bivalent cations (e.g. Mg 
2+
 
and Ca 
2+
), forming a strong structure that acts as an effective permeability barrier 
against hydrophobic antibiotics, detergent, dyes and macromolecules.
19
 PEI may act 
as an effective permeabilizer of Gram-negative bacteria
20
 and displays antibacterial 
properties ascribable to its polycationic structure, that comes from amino groups.
21,22
 
In fact, the bactericidal activity of PEI increases by increasing its polycationic 
character.
23
 In particular, Gibney et al.
24
 pointed out recently that it depends on both 
molecular weight and architecture of the macromolecule (i.e., linear or branched 
structure of polymer).  
In this work, we test the hypothesis that engineering PLGA-based LPP with 
branched PEI may improve their carrier properties for pulmonary delivery of ONs, 
with particular regard to CF treatment. After getting an insight into the role of PEI 
on the technological properties of PLGA-based LPP for delivery of ONs, the 
synergistic effect of PEI free and PEI released from LPP on in vitro antimicrobial 
activity of tobramycin (Tb) and aztreonam (AZT) against P. aeruginosa is 
elucidated. 
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4.2. MATERIALS AND METHODS 
4.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (50:50) (PLGA) (Resomer RG 504 H; Mw 41.9 kDa; 
inherent viscosity 0.5 dl/g) was purchased from Boehringer Ingelheim (Germany). 
Phosphorothioate oligodeoxynucleotide synthesis was performed by Tib Molbiol 
(Roche Diagnostics, Italy). Ammonium hydrogen carbonate, polyethylenimine (Mw 
25 KDa; branched, PEI), polysorbate 80, polyvinylalcohol (PVA, Mowiol
®
 40−88), 
aztreonam (AZT) and tobramycin (Tb) were obtained from Sigma-Aldrich (Italy). 
Analytical grade sodium chloride, potassium chloride, sodium phosphate dibasic 
anhydrous, sodium bicarbonate, methylene chloride, were supplied by Carlo Erba 
(Italy). 
A plain double-stranded decoy oligodeoxynucleotide to nuclear factor-kB (dec-
ODN) was prepared by annealing sense and antisense phosphorothioate ONs in vitro 
in filtered water solution as previously reported 
16
. The wild-type NF-kB consensus 
sequence used (dec-ODN) was: 5’−GAT CGA GGG GAC TTT CCC TAG C−3’; 
3’−CTA GCT CCC CTG AAA GGG ATC G−5’. 
4.2.2 Preparation of PEI-engineered LPP 
PEI-engineered LPP were prepared in different formulation conditions by a 
modified double emulsion-solvent evaporation technique assisted by gas-foaming as 
previously reported.
16
 Briefly, 0.25 ml of water containing ammonium bicarbonate 
(AB) as porogen (10-18 % w/v) and dec-ODN (0.140 nmol per mg of LPP) were 
poured into 2.5 ml of methylene chloride containing PLGA (15% w/v) in the 
presence of PEI (PEI:PLGA ratio 1:100−1:200 w/w). Emulsification was achieved 
using a high-speed homogenizer (Ystral, Heidolph, Germany) operating at 755 xg 
(tool 6G) for 3 minutes. Afterwards, the emulsion was added to 25 ml of aqueous 
PVA solution (0.5−1.0 % w/v) and homogenised 676 xg (tool 10F) for 2 minutes to 
produce the multiple emulsion (w1/o/w2). Solvent evaporation and subsequent 
particle hardening was achieved under magnetic stirring (MR 3001K, Heidolph, 
Germany) at room temperature. After 3 h, particles were collected, washed three 
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times with distilled water by centrifugation (Hettich Zentrifugen, Universal 16R) 
and freezed at -80°C. Samples were then dried for 36 h by a Modulyo freeze-drier 
(Edwards, UK) operating at 0.01 atm and -60°C. 
LPP encapsulating dec-ODN at the theoretical loadings of 1.0 and 2.0 nmol per mg 
of LPP were also achieved by increasing PEI amount in the organic phase 
(PEI:PLGA ratio 1:50−1:100 w/w). LPP containing dec-ODN without PEI, blank 
LPP containing PEI (PEI:PLGA ratio 1:50, 1:100 or 1:200 w/w) without dec-ODN 
in the internal water phase were prepared as controls. Fluorescent LPP were 
prepared using Rhodamine-labeled PLGA (PLGA-Rhod) in the organic phase at 10 
% w/w with respect to the total PLGA amount. PLGA-Rhod was synthesized 
according to a previously reported procedure.
25
 
4.2.3 Characterization of PEI-engineered LPP 
Particle shape and morphology were analysed by Scanning Electron Microscopy 
(SEM) (Leica S440, Germany). The samples were stuck on a metal stub and coated 
with gold under vacuum for 90−120 seconds.  
The mean geometric diameter and size distribution of the particles were determined 
by laser light scattering (Coulter LS 100Q, USA) on a dispersion of freeze-dried 
particles in 0.2 % w/v aqueous PVA. Particle size is expressed as volume mean 
diameter ± standard deviation of values collected from three different batches.  
Powder density was estimated by tapped density measurements according to Ph. 
Eur. 8th Ed. A known weight of particles (100 mg) was transferred to a 10 (±0.05) 
ml graduated cylinder and the initial volume recorded. The cylinder was then 
mechanically tapped 1250 times up to volume plateau, by mean of a tapped density 
tester (Mod. IG/4, Giuliani, Italy). Tapped density of particles () was expressed as 
the ratio between sample weight (g) and the volume occupied after 1250 tappings 
(ml).  
To achieve information about LPP flow properties, the compressibility index or 
Carr’s Index was estimated through the relative percent difference between bulk and 
tapped density as stated by US Pharmacopoeia: 
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Carr’s Index = (i/)*100  (1) 
where and i are tapped and bulk density of the powder, respectively. On the basis 
of Carr’s Index value, powder flow ability is defined as: 5−12%, excellent; 12−18%, 
good; 18−21%, fair; 21−25%, poor, fluid; 25−32%, poor, cohesive; 32−38%, very 
poor; >40%, extremely poor. 
The theoretical mass mean aerodynamic diameter (MMADt) of the particles was 
also estimated on the basis of the definition:  
MMADt = d (/0X)
1/2
  (2) 
where d is the geometric mean diameter, 0 is a reference density of 1 g/ml and X is 
the dynamic shape factor, which is 1 for a sphere. In the case of porous particles of 
approximately spherical shape: 
 ≈ s(1-)  (3) 
where s is the skeletal mass density of the particle as measured by pycnometry,  is 
the particle porosity. An approximate bulk measure of as defined by equation (3) 
is provided by tapped density. 
Fluorescent LPP were further characterised by confocal laser scanning microscopy 
(CLSM) analysis carried out on a LSM 510 Zeiss confocal inverted microscope 
equipped with a Zeiss 20X/3 NA objective lens (Carl Zeiss, Germany). An argon 
laser (excitation = 541 nm; emission = 572 nm) was used.  
The amounts of dec-ODN and PEI encapsulated within LPP were determined after 
particle degradation in 0.5 N NaOH. For dec-ODN, 10 mg of LPP were dissolved in 
2 ml of 0.5 N NaOH under stirring at 37°C until a limpid solution was obtained. 
Dec-ODN content in the resulting solution was quantified by UV 
spectrophotometric analysis using a Shimadzu 1204 apparatus (Shimadzu, Milan, 
Italy) operating at 265 nm. The linearity of the response was verified over the 
concentration range 0.020–1.0 nmol/ml (r2 > 0.99). Blank LPP were used as control 
to verify that no particle component interfered with dec-ODN quantification. The 
amount of PEI in the solution was contemporary quantified by UV 
spectrophotometric analysis at 285 nm after complexation with cupper(II) as 
previously reported.
26
 Results are expressed as encapsulation efficiency (ratio of 
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actual and theoretical loadings × 100) ± standard deviation of values collected from 
three different batches. 
4.2.4 In vitro release of dec-ODN and PEI from ODN/PLGA/PEI LPP  
4.2.4.1 In vitro release of dec-ODN 
In vitro release of dec-ODN from optimised PLGA/PEI LPP (ODN/PLGA/PEI) was 
monitored by membrane dialysis in phosphate buffer (120 mM NaCl, 2.7 mM KCl, 
10 mM phosphate salts) (PBS) at 37°C. Prior to use, the pH was adjusted to 7.2 with 
0.01 M HCl to better resemble in vivo conditions.
27
 A known amount of dec-ODN-
loaded LPP (5 mg) was suspended in 0.35 ml of PBS and placed in a dialysis 
membrane bag (MWCO: 50000 Da, Spectra/Por®). The sample was dropped into 5 
ml of PBS (sink condition) and kept at 37°C. At scheduled time intervals, 1 ml of 
external medium was withdrawn and replaced by the same amount of fresh PBS. 
The withdrawn medium was analyzed for dec-ODN content by UV analysis as 
described above.  
4.2.4.2 In vitro release of PEI 
In vitro release of PEI from LPP was evaluated suspending a known amount of 
ODN/PLGA/PEI LPP (10 mg) in 1 ml of PBS at pH 7.2 and 37°C as described 
above for in vitro release of dec-ODN. The samples were incubated in a horizontal-
shaking water bath at 40 rpm and 37°C (ShakeTempSW 22, Julabo Italia, Italy). At 
scheduled time intervals, the samples were centrifuged at 5000 xg, 4°C for 15 min 
(Hettich Zentrifugen, Universal 16R), 1 ml of release medium was withdrawn and 
replaced by the same amount of fresh PBS. The withdrawn medium was analyzed 
for PEI content by UV analysis after complexation with cupper(II) as described 
above for actual loading. As control, PEI release profile from blank PLGA/PEI LPP 
prepared in the absence of dec-ODN was determined. 
Release kinetics are expressed as percentage of dec-ODN or PEI released versus 
time ± standard deviation of values collected from three different batches. 
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4.2.5 In vitro aerosolization properties of LPP 
The aerosolization properties of optimised ODN/PLGA/PEI LPP were tested in vitro 
after delivery from Turbospin® (PH&T Pharma, Milano, Italy), a breath-activated, 
reusable medium resistance DPI working with single unit gelatin capsule containing 
the dry powder. The deposition pattern of the powder was investigated using a Next 
Generation Impactor (NGI) (Copley Scientific, UK) according to Ph. Eur. 8th Ed.  
For each test, a hard gelatine capsule (size 2, Capsugel, USA) was filled with about 
20 mg of the powder and placed in the Turbospin®. The capsule was then pierced 
and the liberated powder drawn through the impactor operated at 60 L/min for 4 s. 
The powder deposited on the seven NGI collection cups was quantitatively 
recovered by dissolution in an appropriate amount of dichloromethane. The powder 
deposited in the induction port and in the micro-orifice collector (MOC) was also 
recovered by washing with 10 ml of dichloromethane. 
The emitted dose (ED) was calculated by accurately weighing the capsule before 
and after Turbospin® actuation. Upon emission, the experimental mass median 
aerodynamic diameter (MMADexp) and the geometric standard deviation (GSD) 
were calculated according to Ph.Eur. deriving a plot of cumulative mass of powder 
retained in each collection cup (expressed as percent of total mass recovered in the 
impactor) versus cut-off diameter of the respective stage. The MMADexp of the 
particles was determined from the same graph as the particle size at which the line 
crosses the 50% mark and the GSD was defined as  
GSD = (Size X/Size Y)
1/2
 
where size X was the particle size at which the line crosses the 84% mark and size Y 
the size at which it crosses the 16% mark. 
The fine particle fraction (FPF) was calculated taking into account the actual amount 
of LPP deposited on stage 3 through 7 (MMAD < 4.46 μm) as compared to the 
initial amount loaded into the nebulizer chamber, that is the nominal dose of NCL, 
according to the following equation: 
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LPP amount on cup 3 through 7
FPF  x 100
LPP amount loaded into the device
  
On the other hand, the respirable fraction (RF) was defined as: 
LPP amount on cup 3 through 7
RF  x 100
LPP total amount deposited in the NGI 

 
4.2.6 In vitro effect of PEI on antibiotic susceptibility of P. aeruginosa  
4.2.6.1 Minimum inhibitory concentration of free antibiotics 
The minimum inhibitory concentration (MIC) of free Tb and AZT was determined 
by the broth microdilution method in 96-well microplates (Falcon). The AZT- and 
Tb-sensitive P. aeruginosa strain used for the experiments was a clinical isolate at 
the Operating Unit Laboratory of Virology and Microbiology, Faculty of Medicine 
and Surgery, Second University of Naples (Italy). Briefly, P. aeruginosa was grown 
in Brain Heart Infusion (BHI) broth at 37 °C. The bacterial suspension to be used as 
the inoculum was diluted to yield an optical density (OD) around 1 at 600 nm 
(corresponding to about 1×10 
8 
CFU/ml). Afterwards, the bacterial cell suspension 
was further diluted 100-folds to produce a bacterial cell suspension of 10×10
 5
 
CFU/ml.  
Free AZT and Tb were serially diluted twofold in BHI broth to achieve final Tb 
concentrations ranging from 7.9 μg/ml to 0.95 μg/ml and AZT concentrations 
ranging from 32 to 0.25 μg/ml in a final volume of 200 μl (including 100 μl of 
bacterial suspension). The bacterial suspension alone was used as the positive 
control while the negative controls were the antibiotics at the highest concentrations 
and BHI broth alone. After 24 h of incubation the spectrophotometric absorbance 
was measured at 600 nm.  
The MIC is defined as the lowest concentration of the tested antibiotic that inhibited 
the visible growth of the inoculum. The MIC endpoints were determined by reading 
the optical density (OD) of the plate at 600 nm with a Biophotometer 860 (Bio-Rad 
laboratories s.r.l., Italy) and confirmed by visual inspection. The lowest 
concentration that yields OD≤0.1 is determined as the MIC.  
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Results are expressed as percentage of P. aeruginosa growth ± standard deviation of 
values collected from three separate experiments performed in triplicate (n=9). P. 
aeruginosa alone has been considered as 100%.  
4.2.6.2 Antibiotic susceptibility of P. aeruginosa in the presence of PEI 
To test the susceptibility of P. aeruginosa to Tb and AZT in presence of PEI, either 
free or released from LPP, two set of experiments were set up. 
Dose-response studies were first performed with free PEI in 96-well microplates. 
Briefly, 100 μl of free PEI were added to 100 μl of bacterial suspension (final P. 
aeruginosa concentration 5×10
5
 CFU/ml) so as to achieve final PEI concentrations 
in the wells ranging from 5.0 to 40 μg/ml. After 1 h of incubation at 37°C, either Tb 
or AZT at MIC and sub-MIC concentrations were added to pre-treated P. 
aeruginosa and then incubated for 24 h to verify the inhibition of P. aeruginosa 
growth. Vehicle and PEI alone were added as control. 
In case of released PEI, aqueous dispersions of blank PLGA/PEI LPP and 
ODN/PLGA/PEI LPP at 5 mg/ml were first incubated for 72 h at 37°C in PBS. The 
samples were then centrifuged at 3500 rpm for 15’ and the supernatants were used 
for the study. In 96-well microplates, 100 μl of PEI-containing supernatants were 
added to 100 μl of P. aeruginosa inoculum (final bacteria concentration 5×105 
CFU/ml). The inhibition of P. aeruginosa growth after further treatment with Tb and 
AZT was determined as described for free PEI. Blank PLGA LPP and ODN-loaded 
PLGA LPP (ODN/PLGA LPP), Tb (3.96 and 1.98 μg/ml), AZT (8 and 4 μg/ml) and 
P. aeruginosa alone were tested for comparison. 
The inhibitory effects of the treatments were determined by reading the OD of the 
plate at 600 nm with a Biophotometer 860 (Bio-Rad laboratories s.r.l., Italy) and 
confirmed by visual inspection . 
Results are expressed as percentage of P. aeruginosa growth ± standard deviation of 
values collected from three separate experiments performed in triplicate (n=9). P. 
aeruginosa alone has been considered as 100%.  
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4.2.7 Cytotoxicity studies on human alveolar basal epithelial cells 
4.2.7.1 Cell culture and treatments 
Human lung adenocarcinoma epithelial cells (A549) were grown in GIBCO™ F-12 
K cell-culture medium (Invitrogen s.r.l., Italy) supplemented with 10% FBS, 1% 
glutamine and 1% penicillin/streptomycin at 37 °C and incubated at 90% humidity 
and 5% CO2. The cells were allowed to grow until confluence and were trypsinized 
and seeded in plates (12 wells and/or 96 wells) for each experiment. Then, A549 
cells (1.5x10
5
 cells/well) were seeded in a final volume of 1 ml of DMEM 
supplemented with 10% FBS, 1% glutamine and 1% penicillin/ streptomycin at 37 
°C and incubated at 90% humidity and 5% CO2 for 24 h. Afterwards, the cells were 
treated for 24 h with different amounts of ODN/PLGA/PEI LPP (final concentration 
in the medium of 1.25, 2.5 and 5.0 mg/ml). Blank PLGA LPP, blank PLGA/PEI 
LPP and ODN-loaded PLGA LPP were used as control. Cytotoxicity of free PEI 
was tested in the concentration range 2.5 to 40 μg/ml. Tb and AZT have been also 
tested at the highest concentration employed on bacteria, respectively 7.9 and 32 
μg/ml.  
4.2.7.2 Trypan blue test 
After 24 h of treatment, the cells were harvested and pooled in 1 ml of cell culture 
medium. The suspensions of treated or non-treated cells were diluted 1:1 v/v with a 
0.4% sterile-filtered trypan blue solution (Sigma-Aldrich, Italy) for viable cell 
counting. Viable cells (uncoloured) compared to dead blue cells were counted on 10 
l of the trypan blue-cell suspension in four 1 x 1 mm squares of a Burker chamber 
under an optical microscope (Olympus CK40). The average number of cells per 
square was determined. For an accurate determination, the cell density was fixed 
between 20−50 cells/square overlying 1 mm2. Results are expressed as percentage of 
cell vitality reduction ± standard deviation of values collected from three separate 
experiments performed in triplicate (n=9). 
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4.2.7.3 LDH release test 
Lactate dehydrogenase (LDH) release in cell supernatants after 24 h of treatment 
was measured by a CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega, 
Italy) according to the manufacturer’s instruction. Briefly, released LDH was 
measured with a 30-min coupled enzymatic assay, which results in the conversion of 
a tetrazolium salt (iodonitrotetrazolium chloride − INT) into a red formazan product. 
The spectrophotometric absorbance was measured at 490 nm. Results are expressed 
as percent increase of OD at 490 nm as compared to control ± standard deviation of 
values collected from three separate experiments performed in triplicate (n=9).  
 
4.2.8 In vivo studies of LPP persistence at lung 
4.2.8.1 Animals  
Male Wistar rats (200−250 g, Charles River, Italy) were used for in vivo 
ODN/PLGA/PEI LPP persistence studies. Animals were housed in an environment 
with controlled temperature (21−24°C) and lighting (12:12 h light-darkness cycle). 
Standard chow and drinking water were provided ad libitum. A period of 7 days was 
allowed for acclimatisation of rats before any experimental manipulation was 
undertaken. Animals use was in accordance with the guidelines of Italian (N. 
116/1992) and European Council law (N.86/609/CEE) for animal care. The 
experimental procedures were also approved by the Animal Ethics Committee of the 
University of Naples Federico II (Italy). 
4.2.8.2 Lung administration of ODN/PLGA/PEI LPP 
Animals were anesthetized using ketamine (100 mg/kg, i.p.) and xylazine (5 mg/kg, 
i.p.), and the depth of anaesthesia was continuously controlled. Rats were then 
placed ventral side up on a surgical table provided with a temperature-controlled pad 
to maintain physiological temperature. To avoid breathing problems, rats were 
placed on a slanted board (30° from the vertical). Rats were divided into different 
groups (n=4−6, for each group) and intratracheally administered with air (3 mL, 
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SHAM group) or about 2 mg of ODN/PLGA/PEI LPP by the low-scale DPI Model 
DP-4 (Penn-Century, USA). The cannula of the DPI was inserted directly into the 
trachea through the mouth. At predetermined time intervals (0, 3, 7 and 14 days), the 
rats were anesthetized by urethane (25% i.p.; 10 mL/kg), and after euthanization, 
bronchoalveolar lavage (BAL) was obtained for Scanning Electron Microscopy 
(SEM) analysis. As an index of the healthy status of the treated animals, rat body 
weights were recorded throughout the experiment. 
4.2.8.3 SEM analysis of BAL 
After euthanization, the trachea of rats was cannulated with a polyethylene tube (1 
mm inner diameter) to perform BAL as previously reported.
28
 Briefly, the lungs 
were sequentially washed by flushing with 4 mL of sterile, ice-cold PBS three times 
for each animal. The first PBS recovery was immediately placed on ice and then 
centrifuged at 1000 xg for 15 min at 25°C. The resulting pellet was suspended in 0.5 
ml of aqueous formaldehyde (10% w/v). A small amount of each sample (20 l) was 
transferred in a 24-well plate containing coverslips coated with pre-fibrillated 
collagen (100 l of type I collagen per well were fibrillated at 37°C for 20 min). 
Samples were then dehydrated with 60%, 70%, 80% and 90% ethanol. Finally, 
coverslips were carefully taken out of the 24-well plates, dried overnight and coated 
with gold for SEM analysis (Leica S440 microscope, Germany) 
PEI-releasing Large Porous Particles Chapter 4 
 
 158 
4.3. RESULTS  
4.3.1 Effect of the formulation conditions on the overall properties of PEI-engineered 
LPP 
To investigate the role played by the excipients on the properties of LPP prepared by 
double emulsion (w1/o/w2) assisted by gas-foaming, preliminary formulation studies 
were carried out (table 4.1). In particular, three formulation variables were taken into 
account, that is the amount of AB in the internal aqueous phase (w1), the PEI/PLGA 
ratio in the organic phase (o) and the PVA concentration in the external aqueous 
phase (w2). Morphology, size and flow properties of the achieved formulations were 
compared with those of previously developed LPPPEI.
16
 
Table 4.1. Composition and overall properties of PLGA/PEI LPP containing dec-ODN1 
prepared by double emulsion (w1/o/w2) assisted by gas-foaming. 
 
LPPPEI
2 
LPPPEI200 LPPPEIPVA LPPPEI15AB 
AB in w1 (w/v) 10 % 10 % 10 % 15 % 
PEI/PLGA ratio 
(w/w) 
1:100 1:200 1:100 1:100 
PVA in w2 (w/v) 0.5 % 0.5 % 1 % 0.5 % 
Mean volume 
diameter3 
(m ± S.E.M.4) 
45.9 ± 3.3 34.6 ± 2.0 29.0 ± 2.5 43.4 ± 3.3 
Tapped density 
() 
(g/ml ± S.E.M.4) 
0.043 ± 0.004 0.011 ± 0.001 0.077 ± 0.001 0.029 ± 0.007 
MMADt6 
(m ± S.E.M.4) 
3.6 ± 1.5 3.6 ± 1.0 8.0 ± 0.5 5.1 ± 0.6 
Carr’s index7 33.5 ± 0.78 9.9 ± 1.2 38.5 ± 0.011 23.7 ± 4.1 
1. The theoretical loading was 0.140 nmoles of dec-ODN per mg of LPP. 
2. Data from Ungaro et al. 16 are reported for comparison. 
3. Mean geometric diameter as determined by laser diffraction. 
4. Standard error mean of values calculated on three different batches (n=6). 
5. Mass mean aerodynamic diameter estimated on the basis of the equation 2. 
6. Powder flowability estimated on the basis of the equation 1. 
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As shown in Fig. 4.1, both the amount of PEI in the organic phase and AB in w2 
play a crucial role in determining the morphology of LPP. The reduction of PEI 
amount inside the formulation determined breaking and collapsing of LPP (Fig. 4.1, 
A1-A2), while a homogeneous population of highly porous particles was achieved in 
case of LPPPEIPVA (Fig. 4.1, B1-B2) and LPPPEI15AB (Fig. 4.1, C1-C2). In 
particular, LPP produced in the presence of 15% of AB in w1 displayed numerous 
and regular pores homogeneously distributed through the particle surface (Fig. 4.1, 
B2).  
 
Figure 4.1. SEM micrographs at different magnification of dec-ODN loaded PEI-
engineered LPP produced in different formulation conditions: LPPPEI200 (A1-A2); 
LPPPEIPVA (B1-B2); LPPPEI15AB (C1-C2). Field is representative of the formulation. 
Nevertheless, a slight increase the amount of AB up to 18 % in w1 was detrimental 
for particle morphology (Fig. 4.2). 
 A1 
B1 
C1 
A2 
B2 
C2 
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Figure 4.2. SEM micrographs at different magnification of dec-ODN loaded PEI-engineered 
LPP (PEI/PLGA 1:100 w/w) produced in the presence of 18% AB in the internal water phase. 
Field is representative of the formulation. 
 
The developed LPP formulations displayed volume mean diameters falling 
approximately within the range 30−45 m. A reduction of particle size was observed 
either by reducing PEI amount in the organic phase or increasing PVA concentration 
in w2, with a minimum mean diameter value around 30 m for LPPPEIPVA (Table 
4.1). On the other hand, by the same amount of PEI in the organic phase, AB 
concentration in w did not affect significantly the mean geometric diameter of the 
particles (45.9 ± 3.3 and 43.4 ± 3.3 m for LPPPEI and LPPPEI15AB, respectively).  
Flow properties and entrapment efficiency of the developed LPP are relevant 
parameters to select the proper formulation conditions. As far as LPP aerodynamic 
diameter and, consequently, aerosolization properties, are concerned, the right 
combination of three main parameters, that is LPP shape, geometric diameter and 
mass density should occur. Despite their highly irregular shape and morphology, 
LPPPEI200 displayed the lowest values of tapped density and Carr’s index. 
Meanwhile, a lower tapped density and a higher flowability was shown by 
LPPPEI15AB as compared to their counterpart prepared at 10% AB in wi.e., 
LPPPEI) and those of LPPPEIPVA. Nevertheless, formulation conditions affected also 
entrapment efficiency of PEI and dec-ODN (Fig. 4.3).  
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Figure 4.3. Effect of formulation conditions on the entrapment efficiency of PEI-engineered 
LPP. Data on previously developed LPPPEI are reported for comparison
16. No-Detectable 
(ND) amount of PEI was found in LPPPEI200 particles. 
 
While the amount of dec-ODN entrapped within LPP increased by increasing PVA 
concentration in w2, PEI entrapment efficiency decreased as compared to both 
previously developed LPPPEI 
16
 and LPPPEI15AB. On the other hand, at the same 
amount of dec-ODN entrapped as compared to LPPPEI, LPPPEI15AB allowed a slight 
increase of PEI entrapment efficiency from 36 to 42%.  
Of note, no detectable amount of PEI was found in LPPPEI200, although this did not 
result in a lower dec-ODN entrapment efficiency. The effect of the amount of PEI in 
LPP on dec-ODN entrapment efficiency was better elucidated by increasing the 
amount of dec-ODN inside the formulation. Results demonstrated that only a 2-fold 
increase of PEI in the organic phase allowed to entrap amount of dec-ODN ranging 
between 0.8 to 1.5 nmol per mg of LPP with very good efficiency (≈65%) (Fig. 4.4).  
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Figure 4.4. Dec-ODN actual loading and entrapment efficiency ofPEI-engineered LPP as a 
function of PEI theoretical loading.  
4.3.2 Release features and aerosolization properties of optimized ODN/PLGA/PEI 
LPP 
On the basis of the promising flow properties and entrapment efficiency, 
LPPPEI15AB, from here on called ODN/PLGA/PEI LPP, were selected for further 
studies. In vitro release kinetics of dec-ODN and PEI from ODN/PLGA/PEI LPP 
were evaluated as described above. As reported in Fig. 4.5A, encapsulated dec-ODN 
was slowly released from LPP, with a typical two-stage release profile. After a burst 
effect around 30% in the first hours, LPP displayed a sustained release of the dec-
ODN lasting about 15 days, with an approximately zero-order release kinetics. A 
very similar release profile was observed for PEI, which was slowly released from 
ODN/PLGA/PEI LPP for 15 days as well (Fig. 3.5B). Of note, the release rate of 
PEI from blank PLGA/PEI LPP prepared in the absence of dec-ODN slowed down 
as compared to ODN/PLGA/PEI LPP (Fig. 3.5B).  
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Figure 4.5. In vitro release kinetics of dec-ODN (A) and PEI (B) from ODN/PLGA/PEI LPP 
in PBS at pH 7.2 and 37°C. The release profile of PEI from blank PLGA/PEI LPP prepared 
without dec-ODN is reported for comparison in panel B. 
 
In vitro aerosolization properties of ODN/PLGA/PEI LPP have been evaluated by 
NGI upon delivery from a low-resistance DPI. To this purpose, fluorescently-labeled 
ODN/PLGA/PEI LPP have been produced replacing 20% of the initial amount of 
PLGA with PLGA-Rhod. This allowed the achievement of fluorescent highly 
porous microparticles (Fig. 4.6A) characterized by the same properties of unlabeled 
ODN/PLGA/PEI LPP (data not shown). Of note, fluorescent ODN/PLGA/PEI LPP 
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distributed along all the NGI stages down to MOC. The dry powders displayed a 
MMADexp around 8 m, with a FPF and RF of 10.6 and 17.9 %, meaning that about 
20% of the emitted dose has a MMAD lower than 5 m (Fig. 4.6B). 
 
 
MMADexp 
(m ± SD) 
8.12 ± 0.404 
Geometrical Standard 
Deviation (GSD) (± SD) 1.24 ± 0.0472 
Fine particle fraction 
(FPF) (% ± SD) 10.6 ± 2.70 
Respirable Fraction (RF) 
(% ± SD) 17.9 ± 3.10 
 
Figure 4.6. Fluorescent ODN/PLGA/PEI LPP and their in vitro aerosolization properties: A) 
CLSM analysis (field is representative of the sample); B) Values of MMADexp, FPF 
(calculated on the nominal LPP dose) and RF (calculated on the emitted LPP dose) upon 
delivery from a medium-resistance DPI (Turbospin®). Standard deviation (SD) is calculated 
on two different batches (n=6). 
4.3.3 In vivo lung persistence of ODN/PLGA/PEI LPP 
To allow a proof of concept of the ability of the developed LPP to deposit and to 
persist at lung in vivo, the developed ODN/PLGA/PEI LPP were intra-tracheally 
delivered in healthy rats and their fate in the lung upon delivery followed during 
time. As shown in Fig. 4.7, BAL analysis suggest the presence of a huge amount of 
LPP in the lung just after administration (time 0). Nevertheless, detectable amounts 
of LPP were found in the rat BAL for at least two weeks. Furthermore, body weight 
changes were monitored as a sensitive indication of the general health status of the 
treated animals. Of note, no significant differences in the body weight were found 
A 
B 
A 
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between the treated and the sham group at each time interval (data not shown). 
Nevertheless, a significant increase in the body weight was observed at 7 and 14 
days (* p<0.05 and *** p<0.001, respectively) as compared to time 0, in both treated 
and sham groups. 
 
Figure 4.7. SEM micrographs of rat BAL samples collected at different time intervals upon 
intratracheal administration of ODN/PLGA/PEI LPP. Fields are representative of the sample. 
 
4.3.4 Effect of PEI on antibiotic susceptibility of P. aeruginosa 
Fig. 4.8 shows the effect of PEI alone and in association with either Tb or AZT on 
P. aeruginosa growth. In a preliminary set of experiments we tested Tb at 
concentrations ranging from 7.9 to 0.95 μg/ml and AZT concentrations ranging from 
32 to 0.25 μg/ml (data not shown). The resulting MIC of Tb and AZT were 3.9 
μg/ml and 8 g/ml, respectively. In Fig. 4.8A we show that free PEI (2.5−40 µg/ml) 
did not affect P. aeruginosa growth and did not show any effect on Tb antimicrobial 
activity, at all concentration tested (ranging from 20 to 2.5 μg/ml) and similar results 
were obtained by using AZT at the concentration of 8 µg/ml. On the other hand, 
concentrations of 5, 10 and 20 μg/ml of PEI were able to reduce the MIC of AZT 
from 8 to 4 μg/ml (Fig. 4.8.B). The same concentrations of PEI were not able to 
further reduce the value of MIC in association with AZT ranging from 2 to 0.25 
μg/ml (data not shown). 
0 3 days 7 days 14 days
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Figure 4.8. Effect of PEI (ranging from 40 to 2.5 g/ml) on  P. aeruginosa growth and on 
P.aeruginosa susceptibility vs Tb (3.96 and 1.98g/ml) (A) and vs AZT (8 and 4g/ml) (B). 
P. aeruginosa alone was used as control. The dotted lines represent the percentage of P. 
aeruginosa growth at MIC concentrations. Data are the mean values of three independent 
experiments, each performed in triplicates (n=9).   
 
B 
B 
A 
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A parallel set of experiments was performed on PEI released from ODN/PLGA/PEI 
LPP and blank PLGA/PEI/LPP after 72 h of incubation at 37°C in association with 
Tb or AZT (Fig. 4.9). Of note, PEI released from LPP (5 mg/ml) did not reduce the 
MIC of Tb (Fig. 4.9A), while it was able to reduce the value of MIC for AZT from 8 
μg/ml to 4 μg/ml (Fig. 4.9B). 
4.3.5 Cytotoxicity of ODN/PLGA/PEI LPP towards A549 cells 
The effect of ODN/PLGA/PEI LPP on A549 cells viability was investigated and 
compared with the same amount of free PEI. Blank PLGA LPP, blank PLGA/PEI 
LPP and PLGA LPP containing dec-ODN without PEI (ODN/PLGA) were also 
tested as controls. Fig. 4.10A shows the results of the trypan blue exclusion test. All 
the treatments performed with the LPP formulations did not significantly affect 
A549 cell viability, whereas free PEI at 10 g/ml and 20 g/ml determined a 
significant reduction in cell viability. On the other hand, no difference in cell 
viability was observed by using free PEI 5 µg/ml. The measurement of LDH activity 
confirmed the results showing a significant LDH release only in presence of free PEI 
concentrations (Fig. 4.10B). Tb and AZT did not show any cytotoxic effect on A549 
cells at the concentration used (data not shown).   
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Figure 4.9. Effect of PEI released at 72 h from blank PLGA/PEI and ODN/PLGA/PEI LPP 
on  P. aeruginosa growth and on P.aeruginosa susceptibility vs Tb (3.9 and 1.98g/ml) (A) 
and vs AZT (8 and 4g/ml) (B). P. aeruginosa alone was used as control. Data are the mean 
values of three independent experiments, each performed in triplicates (n=9). 
  
B 
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Figure 4.10. Cytotoxicity studies on A549 cells: A) percent reduction of cell viability upon 
24 h incubation with ODN/PLGA/PEI LPP as compared to untreated control cells (Ctr, 100% 
viability) as determined by Trypan Blue test; B) LDH release at 24 h expressed as percent 
increase of OD at 490 nm as compared to untreated control cells (Ctr, <1%). Data are the 
mean values of three independent experiments, each performed in triplicates (n=9). 
B 
A 
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4.4. DISCUSSION  
In order to limit inflammation and hyper-production of mucin in CF patients, a 
therapeutic strategy based on the specific inhibition of the nuclear transcription 
factor NF-ĸB by an oligonucleotide decoy, named dec-ODN, has been recently 
proposed.
29
 Nevertheless, the structural complexity of this macromolecule as 
compared to conventional drugs demands for an efficient delivery system to allow 
dec-ODN to easily access and to remain at the target site, i.e. at lung. With this idea 
in mind, we have recently developed dry powders for dec-ODN inhalation 
consisting in LPP made of a biodegradable sustained-release polymer, that is 
PLGA.
7,16,17
 This study tests the hypothesis that PEI could work as multifunctional 
excipient in PLGA-based LPP engineered for pulmonary drug delivery, from both a 
technological and a therapeutic point of view. On one hand, PEI could be of help in 
optimizing aerosolization properties due to its possible action on LPP porosity.
30,31
 
On the other hand, it may act as an adjuvant in the therapy of CF lung disease, due 
to its potential ability to permeabilize the membrane of Gram negative bacteria, such 
as P. aeruginosa.
20
 
Conceiving LPP for sustained delivery of dec-ODN in the lung, the effect of the 
formulation conditions on the most relevant properties of PEI-engineered LPP for 
inhalation was first elucidated. Among aerosol drug delivery technologies, we 
selected dry powders, which should allow to overcome stability and bioavailability 
issues associated with conventional modes of ON aerosolization. Nevertheless, the 
use of DPIs encompasses the need of adequately engineered particles, which should 
possess optimal size, density and flow properties to be delivered from the DPI and to 
effectively deposit at lung.
32
 Thus, the formulation studies were useful to select 
those LPP characterized by adequate bulk and flow properties for inhalation. 
Furthermore, the ability to entrap an adequate amount of dec-ODN and PEI was 
considered a key requisite. This was the case of LPP prepared at the highest 
PLGA/PEI ratio (i.e., 1:100) and porogen concentration (i.e., 15 % w/v).  
Optimised ODN/PLGA/PEI LPP displayed promising in vitro aerosolization 
properties. The dry powder was delivered from a medium-resistance breath-actuated 
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DPI with a maximum efficiency. Around 20% of the recovered dose of 
ODN/PLGA/PEI LPP displayed MMADexp lower than 5 m, likely depositing in 
deep lung. In fact, a widespread deposition along bronchi and bronchioles is 
expected on the basis of distribution in rat lungs found for similar LPP with a 
MMADexp lower than 10 m.
33
 
Once deposited in the lung, ODN/PLGA/PEI LPP are expected to serve as a local 
depot for the slow release of dec-ODN and PEI. To this purpose, two conditions 
should subsist: i) LPP persistence at lung; ii) sustained dual release of the entrapped 
dec-ODN and the antimicrobial polycation PEI. Concerning LPP clearance from the 
lung, although LPP are reported to escape uptake from pulmonary macrophages
34
, 
mucociliary clearance, designed by evolution to eliminate inhaled and possibly 
noxious material from the airways, may considerably limits the benefits of 
sustained-release inhalation therapy.
35
 Here, in vivo persistence studies performed 
after intratracheal administration of ODN/PLGA/PEI LPP clearly showed that the 
particles deposit at lung, by virtue of their aerosolization properties, and remain in 
situ at least for 2 weeks, supporting the ability of LPP to overcome macrophage-
mediated clearance. Furthermore, the developed LPP allowed a sustained in vitro 
release of both dec-ODN and PEI lasting two weeks.  
Of note, dec-ODN and PEI were released from LPP with very similar kinetics. In 
our previous papers, we demonstrated that it is possible to entrap ON and PEI in 
PLGA particles and release them in the form of complexes, thus improving ON 
uptake inside cells in vitro.
36,37
 Here, dec-ODN/PEI interactions cannot be excluded 
and, consequently, their release in the form of complexes as well. Thus, 
ODN/PLGA/PEI LPP may serve as carrier for the combined and sustained release of 
dec-ODN and PEI. The first will likely act as an anti-inflammatory drug
7,16,17
, the 
second could in principle enhance the therapeutic activity of inhaled antibiotics 
commonly employed for the treatment of concomitant P. aeruginosa lung infections.  
To prove this hypothesis, we tested antimicrobial activity of free PEI and its 
synergic effect with antibiotics commonly used in CF. Consensus guidelines 
recommend an early and aggressive treatment to eradicate acquired P. aeruginosa 
lung infections, although no specific protocol is preferred in CF patients. In the 
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setting of pulmonary exacerbation, the therapy frequently consists of -lactams, 
such as AZT, and/or an aminoglycoside, such as Tb. In recent years, the evidence 
that the use of AZT solution for inhalation is associated with an increase in quality-
adjusted life–years and improvement of clinical outcomes among patients with CF 
with extensive prior use of Tb solution for inhalation.
38,39
 Our data showed that free 
PEI itself up to 40 µg/ml did not affect or interfere with the growth of P. aeruginosa. 
Nevertheless, PEI showed a synergic effect with AZT and not with Tb, with a 
consequent two-fold reduction of AZT MIC from 8 to 4 g/ml. Similar results were 
achieved when PEI was released from LPP. It seems that PEI, similarly to other 
polyamines and polymyxin B nonapeptide, disorganizes the outer membrane of P. 
aeruginosa by intercalating in the LPS layer thus causing outer membrane 
permeabilization without significant liberation of LPS.
40,41
 Although being a potent 
permeabilizer, PEI did not inhibit bacterial growth but, by virtue of its permeability-
increasing properties, it may facilitate antibiotic delivery into cells, thus potentiating 
antibacterial effect. As previously reported, this synergic effect strictly depends on 
the chemical structure of the antibiotic and more benefits are expected for 
hydrophobic molecules, such as AZT, entering bacterial wall through passive 
diffusion.
19
 
Unfortunately, PEI may act as a permeabilizer on all types of membranes. Thus, a 
great attention should be paid to PEI potential cytotoxicity towards lung epithelial 
cells, strictly dependent on its molecular weight.
10,42
 It has been demonstrated that 
PEI exerts its cytotoxic effect by a two-phase mechanism.
43
 In a first phase, PEI 
molecules bind to the plasma membrane proteoglycans resulting in membrane 
destabilization. This was found to generate significant release of LDH within the 
first hours, which continued in a time-dependent manner. On the other hand, 
significant activation of caspase-3 occurs 24 h post-treatment with PEI, suggesting 
that apoptosis represents phase II cytotoxicity.
43
 LDH release test allowed us to 
confirm the destabilization of the cell membrane caused by PEI. On the other hand, 
trypan blue assay demonstrated that free PEI determines also late apoptosis/necrosis 
in A549 cells. Thus, cytotoxicity of free PEI would strongly hamper its use as 
synergic agent with antibiotics. Interestingly, PEI cytotoxicity was significantly 
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reduced once entrapped in the LPP developed here, presumably due to a slow and 
sustained PEI release. In perspective, LPP are expected to give synergic effects with 
specific antibiotic therapies without arising toxicity concerns. 
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4.5. CONCLUSIONS 
Sustained drug delivery to the lungs is nowadays regarded as an effective strategy 
for local treatment of chronic lung diseases, such as CF, to achieve long-term 
maintenance of therapeutic drug concentrations, to reduce doses and dosing 
frequency and, last but not least, to improve patient adherence to the therapy. In this 
work, by acting on crucial formulation parameters, PLGA-based LPP have been 
successfully engineered for deposition and long-term persistence at lung in form of 
dry powders. The developed system affords slow dual release of a decoy ON against 
NF-kB with a well-established anti-inflammatory activity and PEI, displaying a 
synergic effect with one of the inhaled antibiotic currently used in CF, that is AZT. 
Meanwhile, cytotoxicity studies demonstrate the feasibility of PEI-based 
antimicrobial therapy only when slowly released from LPP, which allow to avoid 
PEI mediated epithelial cell damage. Taken all together, our data pave the way to the 
use of biodegradable PLGA LPP as sustained-release carriers for combined anti-
inflammatory and antimicrobial therapy of CF lung disease. 
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ABSTRACT 
In the last years, the down-regulation of genes directly involved in the pathogenesis 
of severe lung diseases, such as cystic fibrosis (CF), through siRNA delivery to the 
lung has gained tremendous research interest. Nevertheless, adequately engineered 
inhalable siRNA formulations are required to translate this approach in vivo. Here, 
we propose novel hybrid lipid/polymer hybrid nanoparticles (hNPs) for pulmonary 
siRNA delivery consisting of a poly(lactic-co-glycolic) acid (PLGA) core 
surrounded by a dipalmitoyl phosphatidylcholine (DPPC) shell. A preliminary 
formulation study allowed to select optimized muco-inert PLGA/DPPC hNPs, 
comprising or not poly(ethylenimine) (PEI) as third component, which displayed 
mean hydrodynamic diameters around 150 nm, low polydispersity index (~0.1) and 
negative zeta potential (about -25 mV). Stable hNP-based dry powders were 
produced by freeze-drying with mannitol. A combination of siRNA against α and β 
subunits of the ENaC channel was entrapped with high efficiency (75-95 %) in 
optimised hNPs. The fate and the effects of hNPs upon in vitro deposition on a triple 
cell co-culture model (TCCC) mimicking human epithelial airway barrier were 
assessed. Transmission electron microscopy analysis before and after aerosolization 
demonstrated hNP stability towards nebulization. Cell uptake studies confirmed the 
ability of fluorescently labelled hNPs to be internalized inside the epithelial airway 
barrier. As measured by LDH release 24 h after treatment, PLGA/DPPC hNPs did 
not exert any cytotoxic effect towards TCCC. Furthermore, TCCC exposure to 
PLGA/DPPC hNPs did not result in a significant increase of TNF-alpha release after 
24 h, suggesting no acute pro-inflammatory effect. Overall, results demonstrate the 
great potential of PLGA/DPPC hNPs as carriers for siRNA delivery on the human 
epithelial airway barrier, prompting towards investigation of their therapeutic 
effectiveness in CF.  
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5.1. INTRODUCTION 
RNA interference refers to the inhibition of gene expression by small, double-
stranded RNA molecules (small interference RNA or siRNA) that direct the mRNA 
machinery to degrade a specific mRNA. siRNA therapeutics have many advantages 
in terms of clinical applications, the first of which is their virtual potential to 
specifically silence any gene underlying more or less complex pathologies.
1,2
 In 
particular, severe lung diseases, such as lung cancer and cystic fibrosis (CF), 
nowadays represent a very important area of application for siRNA-based therapies.
3
 
Nevertheless, to harness the full potential of the siRNA strategy for severe lung 
diseases, an appropriately designed delivery system is mandatory.
4,5
  
Naked siRNAs have a half-life of less than an hour in human plasma and are often 
unable to penetrate cellular membranes. In fact, cellular uptake and the escape from 
endo-lysosomes are critical steps before siRNA reaches the cytoplasm, where its 
target is located. Conceiving siRNA for local delivery by inhalation, the presence of 
high mucin, DNA and actin concentrations, making airway mucus a very complex 
barrier, should also be taken into account.
4,5
 Thus, optimal inhalable formulations 
are required to: i) enhance siRNA stability; ii) overcome lung cellular and non-
cellular barriers; iii) increase siRNA availability at the target level. Amid advanced 
drug delivery systems, the encapsulation of siRNA into colloidal carriers is 
considered a very promising formulation approach for inhaled treatment of severe 
lung diseases.
4,5
  
The most studied nanocarriers for the delivery of siRNA are based on lipids and 
comprise either the entrapment of siRNA into liposomal vescicles or, more often, its 
complexation with positively charged lipids (i.e., lipoplexes).
4,6
 Thanks to their 
ability to enhance cell uptake and their good tolerance in the pulmonary tract, these 
carriers gained tremendous interest for pulmonary delivery, both in the scientific and 
industrial environment.
7
 Nevertheless, the application of lipid-based carriers is 
strongly limited by the low loading efficiencies, especially for hydrophilic drugs 
and, depending on their composition, by poor stability and drug release control in 
vitro/in vivo.
7,8
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Biodegradable polymeric nanoparticles (NPs) represent a viable alternative for 
pulmonary delivery of nucleic acid therapeutics,
9
 since they may overcome most of 
the lipid carrier limitations. Among the polymers of interest for lung delivery of 
siRNA, poly(lactic-co-glycolic) acid (PLGA) seems very promising.
5,9
 In fact, 
PLGA-based NPs may provide protection of the therapeutic cargo from enzymatic 
degradation, prolonged release (i.e., decreased number of administrations) and 
improved retention in the lungs.
10,11
  
In the attempt to combine the most valuable properties of both lipid and polymeric 
nanocarriers, hybrid lipid–polymer nanoparticles (hNPs) are under investigation.12
,13
 
Along these lines, our aim was to design and optimize core-shell hNPs consisting of 
a PLGA core surrounded by a dipalmitoylphosphatidylcholine (DPPC) shell. hNPs 
have been further engineered with poly(ethylenimine) (PEI), introduced as a third 
component to assist siRNA entrapment in the hNPs and its cell uptake.
14
 A 
preliminary formulation study allowed to select optimized muco-inert PLGA/DPPC 
hNPs containing or not PEI. To allow a proof of principle of their potential for 
siRNA delivery to the lung, selected formulations were loaded with therapeutic 
siRNA of interest for CF therapy, that is a combination of siRNA against α and β 
subunits of the sodium transepithelial channel (ENaC).
15,16
 Finally, a thorough in 
vitro study allowed to assess the fate and the effect of hNPs upon aerosolization on a 
triple cell co-culture model (TCCC) grown at air-liquid interface (ALI) mimicking 
the human airway epithelial barrier.
17
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5.2. MATERIALS AND METHODS 
5.2.1. Materials 
Resomer® RG 502H (uncapped PLGA 50:50, inherent viscosity 0.16 - 0.24 dl/g) 
was purchased from Boehringer Ingelheim (Ingelheim, Germany). siRNA 
(siGENOME Human SCNN1A and SCNN1B) was purchased from Dharmacon (GE 
Healthcare). Rhodamine-labeled PLGA was synthesized as previously described
18
. 
1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DPPC) was a kind gift of Lipoid 
GmbH (Cam, Switzerland). Ph.Eur. grade lactose was used (NEW.FA.DEM., Italy) 
and mannitol (Pearlitol® C160) was kindly gifted by Roquette Italia S.p.a. (Italy). 
Egg yolk emulsion, phosphate buffer salts, polyvinyl alcohol (PVA, Mowiol
®
 40–
88), porcin mucin, branched polyethylenimine (PEI; 25 KDa), potassium chloride, 
rhodamine B (Rhod-B), RPMI amino acid solution, type II mucin from porcin 
stomach, sodium chloride were purchased from Sigma Aldrich (USA). Methylene 
chloride and ethanol were supplied by Carlo Erba (Italy). All other reagents were of 
analytical grade or better. 
5.2.2. Preparation of PLGA/DPPC hybrid nanoparticles 
PLGA/DPPC hNPs were prepared by a modified emulsion/solvent diffusion 
technique. Briefly, a water in oil emulsion (w/o) was achieved adding 100 l of 
water to 1 ml of methylene chloride solution containing PLGA (1% w/v) and DPPC 
at different DPPC/PLGA ratios (1:10; 1/20; 1:50; 1:100; 1:150), under vortex 
mixing (2400 min
-1
, Heidolph, Germany). When needed, PEI was added to the 
internal water phase at the theoretical loading of 0.016 % (0.016 mg per 100 mg of 
hNPs). Just after mixing, the w/o emulsion was added to 12.5 ml of ethanol 96° 
under moderate magnetic stirring, leading to immediate precipitation of the polymer 
blend in the form of hNPs. The formulation was diluted with 12.5 ml of Milli-Q 
water under stirring for 10 min. Afterwards, residue organic solvent was removed by 
rotary evaporation under vacuum at 30ºC (Rotavapor®, Heidolph VV 2000, 
Germany). hNP colloidal dispersion was collected and adjusted to a final volume of 
5 ml. Finally, hNPs were isolated by centrifugation at 7000 rcf for 20 minutes at 4°C 
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(Hettich Zentrifugen, Germany) and dispersed in ultrapure water. A table 
summarizing all blank PLGA/DPPC hNP formulations produced is reported (Table 
1). 
Table 5.1 Composition of blank PLGA/DPPC hNPs prepared by 
emulsion/solvent diffusion in the presence or not of PEI.  
Formulation 
PEI theoretical 
loading 
(mg/100 mg of hNP) 
DPPC/PLGA 
ratio (w/w) 
DPPC10 - 1/10 
DPPC20 - 1/20 
DPPC50 - 1/50 
DPPC100 - 1/100 
DPPC150 - 1/150 
PEI/DPPC10 0.016 1/10 
PEI/DPPC20 0.016 1/20 
PEI/DPPC50 0.016 1/50 
PEI/DPPC100 0.016 1/100 
PEI/DPPC150 0.016 1/150 
 
Fluorescently-labelled hNPs (DPPCRhod and PEI/DPPCRhod) were prepared using 
rhodamine-labelled PLGA (PLGA-Rhod) in the organic phase at 10% w/w with 
respect to the total PLGA amount. siRNA-loaded hNPs were prepared at a 
theoretical loading of 1 nmol/100 mg of PLGA (N/P theoretical ratio of 10 in PEI-
modified hNPs) by adding siRNA to the internal water phase.  
Just after production, the hydrodynamic diameter, the polydispersity index (PI) and 
the zeta potential ( potential) of hNPs were determined by photon correlation 
spectroscopy (PCS) with a Malvern Zetasizer Nano ZS (Malvern Instruments, UK). 
Results are expressed as mean value ± standard deviation of triplicate measurements 
on different batches. 
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5.2.3. Freeze-drying studies 
Optimized blank PLGA/DPPC hNPs (i.e., DPPC20 and PEI/DPPC20) underwent 
freeze-drying in the presence or not of appropriate cryoprotectants. In particular, a 
freeze-drying study was carried out on a 2 mg/ml aqueous dispersion of hNPs 
employing different types and concentrations of cryoprotectants (Table 2).  
 
Table 5.2 Types and amounts of cryoprotectant used for the freeze-drying studies. 
hNP 
formulation 
Cryoprotectant 
Cryoprotectant 
concentrantion 
(mg/ml) 
hNP/Cryoprotectant 
ratio (w/w) 
DPPC20 Trehalose 50 1/25 
100 1/50 
Lactose 50 1/25 
100 1/50 
Mannitol 50 1/25 
100 1/50 
Lactose/Mannitol 
blend (1:1 w/w) 
50 1/25 
100 1/50 
PEI/DPPC20 Trehalose 50 1/25 
100 1/50 
Lactose 50 1/25 
100 1/50 
Mannitol 50 1/25 
100 1/50 
Lactose/Mannitol 
blend (1:1 w/w) 
50 1/25 
100 1/50 
 
The obtained hNP dispersion was frozen at -80°C and freeze-dried for 24 h by a 
Modulyo freeze-drier (Edwards, UK) operating at 0.01 atm and -60°C. The dried 
particles were reconstituted with 1 ml of ultrapure water and the samples were 
analysed by PCS, as described above, in order to evaluate the particle size and PI 
after the freeze-drying process. Results were compared with those achieved on 
freshly prepared hNPs and hNPs freeze-dried in the absence of cryoprotectant. 
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Results are expressed as mean values ± standard deviation of triplicate 
measurements on different batches. 
The effect of the cryoprotectant in the aqueous solution on hNP size and PI was 
excluded by the appropriate control. 
5.2.4. In vitro assessment of hNP interactions with mucus 
The mucoadhesive tendency of PLGA/DPPC hNPs was assessed by turbidimetric 
measurement of mucin/particle interactions as previously described.
19,20
 Briefly, a 
saturated solution of type II mucin was prepared by centrifugation at 6000 rcf for 20 
min of a 0.08% (w/v) mucin dispersion in water stirred overnight. For turbidimetric 
analysis, hNPs were dispersed in the mucin solution at a concentration of 1 mg/ml 
by vortexing for 1 min. The turbidity of the mucin/hNPs mixtures was measured by 
spectrophotometric analysis at 650 nm at time 0 and after incubation for 30 or 60 
minutes at room temperature. Reference ABS of mucin and 1 mg/ml hNP 
dispersions in water were also evaluated. Experiments were run in triplicate and 
results are expressed as ABS at 650 nm ± standard deviation over time. 
5.2.5. siRNA loading inside hNPs 
siRNA actual loading was measured indirectly by quantitation of non-encapsulated 
siRNA. Briefly, just after production hNPs were collected by centrifugation (7000 
rcf for 20 minutes at 4°C) and the supernatant was analysed for siRNA content by 
spectrofluorimetry (EnVision® Multilabel Plate Readers, PerkinElmer Inc., USA) 
using Quant-IT RiboGreen® reagent (Thermo Fisher Scientific) according to the 
manufacturer’s instructions.  
Results were reported as actual loading (nmol of encapsulated siRNA per mg of 
hNPs) and encapsulation efficiency (actual siRNA nmol/theoretical siRNA x 100) ± 
standard deviation of values collected from three different batches. 
5.2.6. In vitro exposure of airway triple cell co-cultures to nanoparticles  
All in vitro exposure experiments were conducted with a three dimensional triple 
cell co-culture model of the human epithelial airway barrier comprising human 
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bronchial epithelial cells (16HBE14o-), human blood monocyte-derived 
macrophages (MDM) and dendritic cells (MDDC).
17
 
5.2.6.1. 16HBE14o- cell cultures 
16HBE14o- cells were kindly provided by Dieter Gruenert (passage number P2.54; 
University California, San Francisco, CA, USA). Cells were maintained in minimum 
essential media (MEM) 1X medium (with Earle’s Salts, 25 mM HEPES and without 
L-glutamine; Gibco BRL), supplemented with 1 % L-glutamine, 1 % 
penicillin/streptomycin and 10 % foetal calf serum. For experimental cultures, cells 
were seeded at a density of 0.5 x 106 cells/insert on transparent BD Falcon cell 
culture inserts (surface area of 0.9 cm2, pores with 3.0 μm diameter, PET 
membranes for 12-well plates). The cell culture inserts were pre-treated with 150 μL 
of a fibronectin coating solution containing 0.1 mg/mL bovine serum albumin 
(Sigma-Aldrich), 1 % Type I bovine collagen (BD Biosciences) and 1 % human 
fibronectin (BD Biosciences) in LHC Basal Medium (Sigma-Aldrich). Inserts were 
placed in BD Falcon tissue culture plates (12-well plates) with 1 mL medium in the 
upper and 2 mL in the lower chamber. The cells were kept at 37 °C in 5 % CO2 
humidified atmosphere for 7 days (medium changed after 3–4 days). 
5.2.6.2. Triple cells co-culture (TCCC) system 
To produce the TCCC in vitro model, 16HBE14o- cells cultures were supplemented 
on the apical side with MDM and on the baso-lateral side with MDDC derived from 
human blood as previously reported.
17,21
 Briefly, 16HBE14o-  were cultured as 
described above. At 7 days, the medium was removed from the upper and lower 
chamber, the inserts turned upside down and the bottom was abraded carefully with 
a cell scraper. The inserts were then incubated with 65 μL medium containing 83 x 
10
4
 MDDC/mL on the basal side for two hours. Afterwards, the non-adherent cells 
were removed, the inserts turned around again and placed in BD FalconTM tissue 
culture plates (12-well plates). In the lower chamber 1.5 mL of medium and at the 
apical side of the TCCC 500 μL medium containing 2.5 x 104 MDM/mL was added. 
Once again the systems were incubated for two hours to allow the macrophages to 
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attach, before non-adherent cells were washed away. The complete TCCC systems 
were kept with 1.5 mL of medium in the lower chamber and 0.5 mL in the upper 
chamber at 37 °C in 5 % CO2 humidified atmosphere for 24 h.  
To establish the air-liquid interface (ALI), the medium in the upper chamber of the 
TCCC systems was removed 24 h prior to exposure in the Vitrocell® Cloud, while 
the medium in the lower chamber was replaced by 0.6 mL of fresh medium. 
5.2.6.3. In vitro TCCC exposure to aerosolized nanoparticles 
Cell exposure to hNPs at ALI was carried out with the Vitrocell® Cloud system 
(Vitrocell Systems GmbH, Germany). Briefly, the Vitrocell® Cloud consists of 
three main components: a droplet generator (nebulizer), an exposure chamber and a 
flow system with an incubation chamber providing temperature and humidity 
conditions suitable for cell cultivation. The aerosol  is generated into the exposure 
chamber by a perforated vibrating membrane nebuliser (Aeroneb
®
Pro with a larger 
span of 2.5 to 6.0 μm VMD). Before each experiment, freeze-dried NPs were 
dispersed in 0.5 μM sodium chloride. For TCCC exposure to low hNP 
concentrations, 200 L of a 0.5 mg/mL hNP dispersion were aerosolized 
(corresponding to a total hNP amount of 0.1 mg). In case of high hNP 
concentrations, TCCC were exposed to further 400 L (2 x 200 L) of a 0.9 mg/mL 
hNP dispersion (corresponding to a total hNP amount of 0.5 mg). TCCC exposed to 
sodium chloride and mannitol aqueous solutions in the absence of hNPs were used as 
control. Following the exposure in the chamber (for about 10 or 30 minutes, 
depending on the concentration of nebulized hNPs), the inserts were immediately 
placed in new BD Falcon tissue culture plates (12- well plates), with 0.6 ml of fresh 
medium in the bottom for cell uptake studies, cytotoxicity assay and evaluation of 
tumor necrosis factor α release. 
5.2.7. Stability of hNPs upon aerosolization  
In order to evaluate the stability of hNPs after nebulisation, transmission electron 
microscopy (TEM) analysis was performed on hNP samples before and after 
nebulization. To this purpose, TEM copper grid (Plano, Germany) were exposed in the 
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Vitrocell® Cloud system to different amounts of aerosolized blank DPPC, blank 
PEI/DPPC, siRNA/DPPC and siRNA-PEI/DPPC hNPs. After air drying, 
representative images of both the stock dispersions of hNPs before nebulization and 
the deposited samples were captured using a Tecnai F20 transmission electron 
microscope (FEI, Eindhoven, The Netherlands) equipped with an Ultra- Scan 1000XP 
2 k CCD camera (Gatan Inc., Pleasanton, CA, USA). 
5.2.8. Cell uptake studies 
For cell uptake studies, the TCCC system was exposed to different concentrations of 
rhodamine-labeled hNPs, that is DPPCRhod and PEI/DPPCRhod. After the post-
incubation of 24 h, TCCC were fixed for 15 min with 3% paraformaldehyde in 
phosphate buffered saline (PBS) at room temperature. To permeabilise the cell 
membrane, cells were washed three times in PBS and subsequently treated with 0.2% 
Triton X-100 in PBS for 15 min. The actin cytoskeleton and the DNA of all cells 
were stained with phalloidin ALEXA (Molecular Probes, Life Technologies Europe 
B.V., Switzerland) in a 1:100 dilution and 4′,6- diamidin-2-phenylindol (DAPI) at 1 
μg/mL in 0.3% Triton X-100 in PBS, respectively. For microscopy, membranes were 
embedded in Glycergel (DAKO Schweiz AG, Baar, Switzerland). Visualisation of 
the samples was conducted with an inverted Zeiss confocal laser scanning 
microscope 710 (LSM, Axio Observer.Z1). Representative images (z-stacks) were 
recorded at 5 independent fields of view for each sample.  
Image processing was achieved with LAS AF Lite version (Leica software).  
5.2.9. Cytotoxicity assay 
To evaluate hNP cytotoxicity, the TCCC was exposed to different amounts of 
aerosolized siRNA/DPPC and siRNA-PEI/DPPC hNPs and corresponding blank 
hNPs. To exclude any effect of the cryoprotectant on cell viability, TCCC were also 
exposed to aqueous solutions of mannitol at the same concentrations of hNP 
dispersions.  
After exposure, the release of the intracellular enzyme lactate dehydrogenase (LDH) 
by the TCCC, indicative of cell membrane damage, was assessed by the LDH 
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cytotoxicity detection kit (Roche Applied Science, Mannheim, Germany) according to 
the manufacturer’s guidelines. The test was performed in triplicates and evaluated in 
comparison to the negative control, that is TCCC exposed to sodium chloride. As a 
positive control, co-cultures were treated with 100 μl of 0.2% Triton X-100 in H2O on 
the apical side and incubated for 24 h at 37°C, 5% CO2. 
5.2.10.  Tumor necrosis factor α release 
The potential hNP-mediated pro-inflammatory response was investigated by 
quantifying the release of the mediator tumor necrosis factor α (TNF-α). Again, the 
TCCC was exposed to different amounts of aerosolized siRNA/DPPC and siRNA-
PEI/DPPC hNPs and corresponding blank hNPs. To exclude any effect of the 
cryoprotectant on cell viability, TCCC were also exposed to aqueous solutions of 
mannitol at the same concentrations of hNP dispersions. After exposure, TNF-α 
release in the medium was quantified by an ELISA kit (R&D Systems) according to 
the manufacturer’s protocol. 
5.2.11.  Data analysis 
Results are expressed as mean value ± standard error mean (S.E.M.) (n=3). The 
significance of differences was determined with the software Kaleidagraph using One-
Way Analysis of Variance (ANOVA) followed by Bonferroni post-hoc test. A p value < 
0.05 was considered significant. 
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5.3. RESULTS 
5.3.1 Development of siRNA-loaded PLGA/DPPC hNPs 
PLGA/DPPC hNPs were prepared by a modified emulsion/solvent diffusion 
technique, adding to the organic phase DPPC as surface-engineering excipient. 
Conceiving these systems for siRNA delivery, PEI, a well-established transfection 
agent for nucleic acid therapeutics, was added to the internal water phase as third 
component. An in depth formulation study was performed on blank hNPs to 
establish the optimal ratio between the three selected components, that are PLGA, 
DPPC and PEI. Overall properties of the developed blank hNPs are reported in 
Table 3.  
Table 5.3 Overall properties of hNPs prepared by emulsion/ solvent diffusion technique at 
different DPPC/PLGA ratios.  
Formulation Hydrodinamic 
diameter (DH)  
(nm ± SD) 
Polydispersity index 
(PI)  
(mean ± SD) 
Zeta Potential 
(mV ± SD) 
DPPC10 151.3 ± 21.3 0.127 ± 0.079 -25.3 ± 0.5 
DPPC20 149.7 ± 2.1 0.083 ± 0.006 -23.2 ± 2.4 
DPPC50 135.4 ± 17.2 0.088 ± 0.008 -24.3 ±6.0 
DPPC100 158.9 ± 7.1 0.082 ± 0.004 -28.4± 2.9 
DPPC150 168.6 ± 7.1 0.124 ± 0.094 -15.7 ± 1.3 
PEI/DPPC10 166.5 ± 13.9 0.128 ± 0.093 -26.1 ± 0.5 
PEI/DPPC20 165.4 ± 9.1 0.102 ± 0.006 -31.7 ± 1.2 
PEI/DPPC50 162.3 ± 13.9 0.124 ±0.041 -28.0 ± 0.7 
PEI/DPPC100 150.9 ± 30.4 0.106 ± 0.027 -28.0 ± 0.3 
PEI/DPPC150 146.4 ± 0.3 0.123 ± 0.027 -22.2 ± 2.7 
 
Independent of the amount of lipid added to the organic phase and the presence of 
PEI in the internal water phase, the adopted formulation conditions lead to the 
formation of hNPs with a hydrodynamic diameter between 135 and 170 nm, 
monodisperse particle population (PI lower than 0.130) and negative ζ potentials 
(between -22 and -30 mV). Nevertheless, in each case a flocculation of the 
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exceeding amount of the lipid component was apparent after rotary evaporation of 
the diffusion solvent under vacuum. This phenomenon was particularly evident 
when high amounts of DPPC were added to the formulation, while it was limited up 
to DPPC/PLGA 1:20 ratio (w/w). These formulations, from here on named DPPC 
and PEI/DPPC, were thus selected for further studies. 
Mucoadhesion studies were performed by measuring the turbidity at 650 nm (ABS) 
of DPPC and PEI/DPPC hNPs in mucin over time (Fig. 5.1). While the ABS of the 
reference mucin dispersion did not significantly deviate from zero (being within the 
range 0.040–0.045 arbitrary units), higher values of ABS were observed at each 
time-point upon addition of hNP dispersions. Nevertheless, no significant 
differences were observed between ABS of hNPs dispersed in water or in mucin 
(Fig. 5.1).  
 
Figure 5.1. In vitro assessment of mucin interactions with optimized blank DPPC/PLGA 
hNPs. Data are expressed as turbidimetry (ABS at λ 650 nm) over time. 
Both the formulations were chosen for the encapsulation of siRNA against ENaC at 
a theoretical loading of 1 nmol/100 mg of hNPs. The resulting siRNA-loaded hNPs 
were fully characterized in terms of hydrodynamic diameter, PI and ζ potential. As 
can be seen in Table 4, the addition of siRNA inside the formulation did not result in 
significant changes of hNP size and PI as compared to blank hNPs (DPPC20 and 
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PEI/DPPC20 in Table 5.3). siRNA-loaded hNPs with a hydrodynamic diameter 
around 140 nm and a low PI were produced with good yields (around 50%). siRNA 
was effectively entrapped inside PLGA/DPPC hNPs with a mean entrapment 
efficiency of 74.8%. Nevertheless, the addition of PEI inside the formulation 
allowed to increase siRNA actual loading from 1.35 nmol per mg of DPPC hNPs to 
1.74 nmol per mg of PEI/DPPC hNPs.  
Table 5.4. Overall properties of siRNA-loaded PLGA/DPPC hNPs prepared by emulsion/ 
solvent diffusion technique.  
 siRNA-DPPC siRNA-PEI/DPPC 
Hydrodinamic diameter (nm 
± SD) 
141.4 ± 0.50 141.7 ± 1.8 
PI (mean ± SD) 0.120 ± 0.018 0.114 ± 0.0050 
 Potential  
(mV ± SD) 
-29.1 ± 1.6 -29.9 ± 1.4 
Yield of production  
(% ± SD) 
52.0 ± 8.9 53.4 ± 2.5 
siRNA actual loading a  
(% ± SD) 
1.35 ± 0.02 1.74 ± 0.04 
Entrapment efficiency  
(% ± SD) 
74.8 ± 1.5 95.9 ± 2.2 
anmol of encapsulated siRNA per 100 mg of hNPs. The siRNA theoretical loading was 1 
nmol/100 mg of hNPs. 
 
5.3.2 Production of stable hNP-containing dry powders 
To achieve long-term stable PLGA/DPPC hNP formulations, dry powders 
containing hNPs were produced by freeze-drying in the presence of a cryoprotectant. 
Different cryoprotectant types were tested and employed at different ratios by 
weight to the hNPs (Table 5.2). As can be seen in Fig. 5.2, the lowest variation in 
particle size and PI with respect to the control is observed for hNPs freeze-dried in 
presence of either trehalose or mannitol. No differences were observed changing the 
cryoprotectant amount used.  
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Figure 5.2. Size and PI of DPPC (A) and PEI/DPPC (B) hNPs after freeze-drying in the 
presence of different cryoprotectants. Measurements were performed after redispersion in 
water. Each cryoprotectant system (cryo) was employed at two different ratio by weight to 
hNPs. 
 
Nevertheless, mannitol based dry powder were chosen for further experiments 
because of its approval for pulmonary delivery (i.e., Bronchitol) and the proved 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0
100
200
300
400
500
600
700
800
DPPC hNPs
Ctr
Trehalose Mannitol Lactose Lactose &
Mannitol
P
I
Si
ze
 (n
m
)
NP/cryo ratio 1/25
NP/cryo ratio 1/50
no freeze drying
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0
100
200
300
400
500
600
700
800
PEI/DPPC
hNPs Ctr
Trehalose Mannitol Lactose Lactose &
Mannitol
P
I
Si
ze
 (n
m
)
NP/cryo ratio 1/25
NP/cryo ratio 1/50
no freeze drying
A 
B 
Hybrid nanoparticles for siRNA delivery Chapter 5 
 
 196 
osmotic beneficial properties on mucus viscosity in CF patients. All the in vitro 
experiments on TCCC were, thus, performed on freeze-dried hNPs, in presence of 
mannitol, after reconstitution in water at the appropriate concentration.  
5.3.3 In vitro aerosolization of nanoparticles on TCCC  
Optimized freeze-dried formulations underwent interaction studies with TCCC.  
The stability of hNPs during the nebulisation process was confirmed by TEM analysis 
of freeze-dried hNPs in the presence of mannitol (1:25 NP/mannitol ratio) before and 
after nebulization in the Vitrocell® Cloud system (Fig. 5.3). From TEM images it is 
apparent that hNPs, according to data reported in literature,
22,23
 display a typical core-
shell structure characterized by a hydrophobic PLGA core and a DPPC shell. Of note, 
the core-shell structure of the hNPs was retained after the nebulization process, that 
did not cause any apparent modification of the hNP structure nor hNP aggregation 
(Fig. 5.3) at none of the tested concentrations (data not shown) 
Figure 5.3. TEM images of reconstituted freeze-dried DPPC hNPs before (A) and after 
nebulization (B). Field is representative of the sample. 
 
Morphological analysis was carried out by TEM also on optimised siRNA-loaded 
hNPs freeze-dried in the presence of mannitol (1:25 w/w NP/mannitol ratio) and 
results confirmed the core-shell structure observed in blank hNPs (Fig. 5.4). 
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Figure 5.4. TEM images of reconstituted freeze-dried siRNA-loaded hNPs (siRNA-
DPPC and siRNA-PEI/DPPC) before and after nebulization. Field is representative of 
the sample. 
5.3.4 Uptake of aerosolized nanoparticles in TCCC 
In order to run cell uptake studies, fluorescently labelled DPPCRhod and 
PEI/DPPCRhod hNPs were produced using PLGA-Rhod. Of note, the addition to the 
formulation of 10 % w/w PLGA-Rhod with respect to the total PLGA amount did 
not affected hNP properties as compared to non-fluorescent hNPs (data not shown). 
After 24 h of incubation in the presence of deposited DPPCRhod and PEI/DPPCRhod, 
CLSM analysis of treated TCCC were performed (Figure 5). Results indicate that both 
DPPCRhod and PEI/DPPCRhod hNPs (labelled in red) can effectively penetrate into cells 
and are localized intracellularly (labelled in blue). 
 
Before nebulization After nebulization 
siRNA-DPPC 
siRNA-PEI/DPPC 
Hybrid nanoparticles for siRNA delivery Chapter 5 
 
 198 
 
 
Figure 5.5. CLSM images of TCCC incubated at 37°C in the presence of fluorescently-
labelled DPPCRhod (A) and PEI/DPPCRhod (B)  hNPs deposited after aerosolization. The 
arrows show hNPs engulfed by the cells.  
A 
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5.3.5 Effects of aerosolized hNPs on TCCC  
At the tested concentrations, the developed hNPs displayed no significant cytotoxicity 
as compared to both sodium chloride and mannitol solutions aerosolized at the same 
concentrations of the samples (p>0.5). On the other hand, a significant cytotoxic effect 
as compared to TCCC exposed to both low and high hNP concentrations (p<0.001) 
was observed when the co-cultures were challenged with LPS from P. aeruginosa as 
positive control.  
 
Figure 5.6. LDH release in TCCC upon incubation for 24 h at 37°C after exposure to different 
amounts (low and high in the graph) of blank and siRNA-loaded PLGA/DPPC hNPs. Triton 
0.2.% (w/v) in PBS was used as positive control. Sodium chloride was used as negative 
control. Mannitol aqueous solutions at the same volume and concentrations used for the hNP 
samples were also aerosolized. Data are presented as mean OD values ± S.E.M. of samples 
diluted 1:10 v/v in cell culture medium (n=3) (**p<0.001).  
These findings were confirmed by CLSM analysis of all treated samples, since no 
alteration to cell morphology occurred after TCCC exposure  to hNPs as compared 
to the negative control (data not shown).  
The potential pro-inflammatory effect of aerosolized blank and siRNA-loaded hNPs 
on TCCC was also investigated by evaluating the amount of TNF- released as 
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compared to the negative control (i.e., sodium chloride). As can be seen in Fig. 5.7, 
at all tested concentrations, TCCC exposure to mannitol solutions determined a less 
than 1-fold increase (0.839 ± 0.116 and 0.530 ± 0.223 for low and high samples, 
respectively) of TNF-release  relative to the negative control. When exposed to 
hNPs, a slight increase of TNF-release was observed as compared to sodium 
chloride, being more pronounced in case of  siRNA-loaded hNPs. Nevertheless, no 
significant differences in the fold increase of TNF-release relative to the negative 
control was observed between hNPs and the mannitol control, at all concentration 
tested. 
 
Figure 5.7. TNF- release in TCCC upon incubation for 24 h at 37°C after exposure to 
different amounts with blank and siRNA-loaded hybrid PLGA/DPPC hNPs. Mannitol aqueous 
solutions at the same volume and concentrations used for the hNP samples were also 
aerosolized as controls. Data are presented as the fold increase relative to the negative control 
(i.e., sodium chloride) ± S.E.M. of samples. 
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5.4. DISCUSSION 
In the last years, the therapeutic approach based on down-regulation of genes 
directly involved in the disease pathogenesis (e.g., siRNA administration) has 
gained tremendous interest to counteract the dehydration, and consequent chronic 
inflammation and recurrent infections, of CF airways.
16,24,25
 Nonetheless, the clinical 
application of siRNA-based therapies is seriously hindered by siRNA short half-life 
in vivo and its low capability to penetrate cell membranes.
4,5
 Furthermore, the 
typical CF lung environment, i.e thick and viscous mucus layer, may seriously 
hinder drug interaction with its target at lung, i.e the cells.
11
 To overcome these 
issues, in this work we have designed novel PLGA/DPPC hNPs suitable for 
pulmonary delivery of siRNA.  
The importance of extracellular and cellular barriers imposed by the CF lung in 
determining the therapeutic efficacy of inhaled drugs is nowadays acknowledged.
11
 
A current paradigm suggests that only NPs with appropriate size and surface 
properties may overcome the complex mucus airway barrier and assist NP 
interactions with human airway epithelial cells.
26,27
 This aspect is particularly crucial 
for siRNA-based therapeutics. The developed PLGA/DPPC hNPs showed a typical 
core-shell structure,
12
 which suggest the presence of a PLGA core surrounded by a 
lipid shell made by DPPC, independent of the presence of PEI. As demonstrated by 
mucoadhesion studies, this results in non-mucoadhesive or “muco-inert” hNPs, 
likely able to easily penetrate across the airway mucus layer.
19,20,26
 Furthermore, the 
adopted formulation conditions allowed the production of hNPs with a 
hydrodynamic diameter around 150 nm, which are expected to easily diffuse 
through the gel-like structure of the mucus.
28,29
  
Aiming to local delivery of siRNA at lung, another important concern that has been 
addressed is the transformation of the aqueous hNP dispersion into a solid long-term 
stable product. Indeed, after optimization of PLGA/DPPC hNP formulation, the 
most appropriate freeze-drying variables were selected in order to obtain a 
lyophilizate with good quality, which could be re-dispersed in saline before use 
without affecting the peculiar NP properties. To avoid common hNP aggregation in 
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a collapsed cake,
30
 different cryoprotectants were added to the aqueous dispersion. 
Among the most promising, mannitol was selected owing to its established 
beneficial properties on mucus fluidity in CF
31
. At least in principle, mannitol could 
work synergistically with DPPC to facilitate hNP transport, and in so doing siRNA 
diffusion, through mucus. 
If DPPC, that is the principal component of the lung lining fluids, is expected to tune 
hNP interactions with the lung environment, the addition of PEI can play a crucial 
role for siRNA entrapment inside PLGA/DPPC hNPs. This hypothesis was 
confirmed by encapsulation studies performed on two siRNA sequences, for α and β 
ENaC subunits. Indeed, these have been shown to produce a long term reduction of 
trans-epithelial Na+ currents and of fluid absorption 
15
, and that the combination of 
the two siRNA can expand the lung fluid volume in vitro.
16
 Of note, siRNA was 
entrapped inside selected hNPs with high efficiency, particularly when PEI was co-
encapsulated. This effect could be likely ascribed to the formation of a complex 
between PEI, employed at the theoretical N/P ratio of 10, and siRNA.  
Although an increasing knowledge supports the use of modified PLGA NPs for lung 
delivery, comprehensive characterization of their biocompatibility and efficacy is a 
complex task that has not been fulfilled yet. To fill this gap and look to the 
formulation in a translational perspective, the behaviour of the developed 
PLGA/DPPC hNPs after deposition on triple cell co-cultures, which realistically 
mimick human airway epithelium environment, was investigated. Indeed, when 
primary human bronchial epithelial cells (16HBE14o-) are grown on porous 
supports at ALI they undergo mucociliary differentiation, reproducing both the in 
vivo morphology and key physiologic processes, sometimes including tight 
junctions, cilia, basal and mucus cells.
21,32
 Furthermore, direct deposition of the 
aerosolized drug to the apical compartment of the cell culture can be envisaged 
through systems especially designed for dose-controlled and spatially uniform 
deposition of liquid aerosols on cells,
33,34
 such as the Vitrocell
®
 Cloud here 
employed. 
To attain maximum siRNA availability at lung epithelial cells, where its target is 
located, the hNPs should: i) deposit on the airway epithelium in their stable form; ii) 
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penetrate inside the mucus barrier; iii) interact with the lung epithelium, without 
compromising cell availability. The adopted model was crucial to draw key 
information on all these points and to establish a priori target formulation 
parameters for siRNA delivery to human airway epithelium (e.g., size, surface 
modification). Indeed, results demonstrated that the adopted formulation conditions 
allowed to tune hNP size and surface properties, so as to be aerosolized on lung 
epithelial cells in their integer form, to penetrate inside extracellular lung lining 
fluids, to be taken up by lung epithelial cells without exerting neither a cytotoxic 
effect or a pro-inflammatory response on the treated lung epithelium model. 
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5.5. CONCLUSION 
In this work, we have successfully designed and developed novel PLGA/DPPC 
hNPs with size and surface properties optimized for siRNA transport and delivery at 
lung. Stable hNP-based dry powders were produced by freeze-drying with mannitol, 
an osmotic agent of interest for CF treatment. Optimised formulations allowed 
entrapment of a combination of siRNA against α and β subunits of the ENaC sodium 
transepithelial channel with high efficiency, which could be optimized by the 
addition of PEI inside the formulation. The fate and the effects of hNPs upon in vitro 
deposition on a triple cell co-culture model of the human airway epithelium was 
thoroughly investigated. Transmission electron microscopy analysis before and after 
aerosolization demonstrated NP stability towards nebulization on cells. Cell uptake 
studies confirmed the ability of fluorescently labelled hNPs to be internalized inside 
the airway epithelial barrier. Finally, hNP hazard assessment demonstrated that the 
developed system do not exert neither cytotoxic nor acute pro-inflammatory effect 
towards none of the cell components of the co-culture model. Overall, results 
demonstrate the great potential of PLGA/DPPC hNPs as carriers for siRNA delivery 
on the epithelial airway barrier, prompting towards investigation of its therapeutic 
effectiveness in CF. 
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